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Abstract
Surveilling the Distinctive Vascular and Metabolic Features of Tumor Progression
and Response to Therapy
John James Walsh
2021

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults.
Despite maximal treatment with surgical resection, radiotherapy and temozolomide
chemotherapy, prognosis is dismal with median survival around 15 months. GBMs are highly
infiltrative tumors that invade into surrounding brain tissue, which makes defining the
extent of tumor spread difficult and recurrence common. Radiological identification of GBMs
with magnetic resonance imaging (MRI), using transvers (T2) or longitudinal (T1) relaxation
contrasts, is a mainstay in the initial diagnosis as well as tracking therapeutic response in
GBM. However, there is extreme variability in the structural appearance, size, metabolism,
and genetic landscape of GBMs, making imaging characteristics highly heterogeneous and
hard to define with tumor progression. Although T2-weighted and contrast-enhanced T1weighted MRI provides anatomical details of the tumor architecture, these methods can be
confounded by pseudoprogression and pseudoresponse in the context of therapy.
The GBM microenvironment is characterized by immature vasculature and
extracellular acidification due to a metabolic shift towards aerobic glycolysis (Warburg
effect). The reduced extracellular pH (pHe) has been associated with promoting angiogenesis
and invasion as well as creating an immunosuppressive environment. Given the important
contribution of vascular changes and extracellular acidosis to shaping the tumor
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microenvironment, advanced MRI techniques are needed to better characterize the tumor
microenvironment to provide more specific readouts of tumor progression and therapeutic
response.
Biosensor Imaging of Redundant Deviation in Shifts (BIRDS) is a magnetic resonance
spectroscopic imaging (MRSI) technique that utilizes the temperature and pH-dependent
hyperfine shifts of paramagnetic agents (e.g., TmDOTP5-) for high resolution, threedimensional, quantitative temperature and pHe mapping. BIRDS has been used to
demonstrate the acidic pH in preclinical models of GBM, where the intratumoral space is
highly acidified (pH<6.8) in comparison to healthy brain tissue (pH~7.2) and acidic pH
spread beyond the anatomically defined tumor core relates to the invasiveness of the
tumors. However, a limitation of the BIRDS technique is the necessity of detectable (>1 mM)
levels of contrast agent, which are cleared rapidly by the kidney. To obviate need for surgical
intervention (e.g., renal ligation) to stop rapid agent clearance, here we demonstrate that
pharmacological inhibition of renal clearance of these agents using probenecid allows for
longitudinal imaging of pHe throughout tumor progression and show that acidosis develops
early in tumor progression in human-derived GBM tumors (U87 and U251).
Since other tomographic pHe mapping methods are non-quantitative and directly
altering pHe in a specific tissue is difficult to implement, we looked to assess the ability of
BIRDS-based temperature measurements to evaluate a localized cooling system that induces
hypothermia in sheep brain to levels suggested to be neuroprotective in hypoxic states.
Quantitative temperature mapping using BIRDS showed significantly decreased cerebral
temperatures with cooling over all defined brain regions and was in agreement with
thermocouple measurements.
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While pHe is a useful metric, tumor vascularity also shapes tumor metabolism and the
microenvironment. BIRDS can be combined with other imaging modalities such as dynamic
contrast enhanced (DCE) MRI, which allows quantification of vascular parameters (e.g.,
permeability) through modeling the dynamic uptake of Gd3+-based contrast agents.
Multiparametric characterization of the spatiotemporal changes in cellularity, vascularity
and acidosis of U87 and U251 tumors throughout progression showed unique patterns that
could be used to identify tumor features and differentiate between tumor types.
Finally, pHe readouts have potential as a biomarker of therapeutic response. After
finding an increase in pHe after treatment with temozolomide in U251 tumors, we used
BIRDS longitudinally to demonstrate normalization of pHe in U87 tumors treated with
sorafenib, a nonselective tyrosine kinase inhibitor. Both treatments slowed tumor
progression and led to increases of pHe which establishes a role for pHe imaging as an early
and sensitive marker of evaluating therapeutic response prior to observable changes in the
tumor appearance on standard MRI.
The potential of BIRDS is vast and not limited to GBM, or cancer in general. Additional
work has demonstrated that an acidic pHe is not limited to preclinical tumor models, but is
also found in patient-derived xenograft (PDX) models of metastatic melanoma in the brain.
BIRDS can also be utilized in evaluating tumors in any organ, as BIRDS has also shown acidic
pHe in models of liver cancer. In summary, this work further expands BIRDS into a broadly
applicable longitudinal platform for characterization of the tumor microenvironment and
may aid in evaluation of many targeted therapeutic strategies.
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Chapter 1: Introduction to the Vascular and Metabolic Features of the
Tumor Microenvironment in Glioblastoma

1.1 Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults.
GBMs exhibit unique genetic and metabolic alterations, as well as a characteristic tumor
microenvironment that is shaped by the properties of surrounding brain tissue. Like other
solid tumors, GBMs exhibit several of the hallmarks of cancer including altered cellular
metabolism and disorganized vasculature. Hypoxia, as well as metabolic dysregulation,
promotes a switch to glycolysis even in the presence of oxygen, termed aerobic glycolysis or
the Warburg effect. Upregulated glycolysis results in extracellular acidosis, where the pH of
the extracellular space (pHe) becomes significantly lower than that found in normal tissues.
Further, acidosis is not only linked to tumor growth, but may be regulated independently to
promote more invasive and metastatic tumors. Extracellular acidosis results in remodeling
of the extracellular matrix and shaping the tumor microenvironment as well as impacting
both angiogenesis, the development of new vasculature in the tumor, and the tumor immune
response. In this chapter, the role of metabolic and vascular changes in shaping the tumor
microenvironment will be explored, with a particular focus in the context of glioblastoma
(GBM).
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1.2 Introduction
Cancer is the second leading cause of death in the United States. Glioblastoma (GBM)
is the most common primary central nervous system (CNS) tumor in adults with
approximately 10,000 new cases each year in the United States.1 GBMs exhibit characteristic
genetic and metabolic alterations and, like other solid tumors, maintain a tumor
microenvironment that favors proliferation and invasion into surrounding tissue. Many
connections between tumor metabolism and the microenvironment have been explored,
including how genetic changes in cellular metabolism impact the local vasculature and
microenvironment.
Alterations in cellular metabolism are a hallmark of cancer.2 This dysregulation
promotes a switch to glycolysis even in the presence of oxygen, termed aerobic glycolysis by
Otto Warburg or otherwise known as the Warburg effect.3 However, a clear link also exists
between hypoxia and acidosis. With this switch comes an overproduction of lactate and
protons that first accumulate in the intracellular compartment and are then extruded from
the cell into the extracellular space, resulting in extracellular acidosis (Figure 1.1). To
accomplish this, cells upregulate many transporters including the proton-sodium exchanger
(NHE1) as well as monocarboxylate transporters (MCT4) to transport lactate out of the cell.4
The pH of the extracellular space becomes significantly lower than that found in normal
tissues. Further, acidosis may be regulated independently to promote more invasive and
metastatic cancers as well as driving tumor growth.5,6 Extracellular acidosis results in
remodeling of the extracellular matrix and shaping the tumor microenvironment as well as
impacting both angiogenesis, the development of new vasculature in the tumor, and the
tumor immune response.7,8 Before discussing the metabolic and vascular changes that occur
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in solid tumors, a brief introduction to GBM is presented along with rodent models that can
be used as representative GBM models in preclinical work.

3

Figure 1.1. Tumor cell metabolism. Blood delivers both glucose and oxygen to the cell.
Glucose is taken up by glucose transporters (GLUTs). Glucose then enters the glycolytic
pathway where it is converted to pyruvate. Pyruvate is then either converted to lactate or
enters the oxidative phosphorylation pathway. The ratio in the rate of glycolytic metabolism
(CMRglc) to the rate of oxidative phosphorylation (CMRO2) is altered in tumor cells. To
prevent acidification of the intracellular environment, lactate is extruded from the cell
through monocarboxylate transporters (MCT) and protons through the sodium-proton
exchanger (Na+-H+ exchanger). Adapted with permission.9
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1.3 Glioblastoma
Glioblastomas are the most prevalent malignant CNS tumors in adults and carry a
poor prognosis.10,11 Gliomas are solid tumors that form in the brain parenchyma and are
composed of glial cells and astrocytes. Gliomas as a more general class of tumors are divided
into four grades, with grade 4 being glioblastoma. There is no clear association with risk
factors for developing CNS tumors; however, the general characteristics of the patient
population tend to skew older with a higher incidence in men.12 Tumor classification
schemes have been developed by the World Health Organization (WHO) and are primarily
based on histological characteristics with the prognosis and survival becoming shorter with
increasing tumor grade.12 Lower grade gliomas can progress into the more malignant GBMs.
Another common feature of gliomas is that they tend to recur even after maximal treatment
and recurrence nearly always occurs at the initial primary site. The overall survival without
therapy is less than one year.
Glioblastomas are initially diagnosed with imaging modalities, such as computed
tomography (CT) and magnetic resonance imaging (MRI).13 However, due to the infrequency
of the tumors, screening is not usually performed. Therefore, diagnosis is either incidental,
or much more frequently only after the onset of symptoms. This lack of early detection
means that the tumors are large enough (or affecting more critical brain structures) before
diagnosis is made; tumors are often greater than 1 cm in size. As tumors grow, they increase
intracranial pressure often resulting in compression of brain tissue that can lead to
neurologic symptoms. Official diagnosis still requires histology, either from biopsy, or more
commonly at the time of surgical resection.14 Further, glioblastomas are highly aggressive
and infiltrative tumors and tumor growth usually progresses rapidly. Gliomas do not
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metastasize to other parts of the body, and rarely even metastasize to a secondary location
within the CNS.
Treatment for glioblastoma includes surgery, radiotherapy, and adjuvant
chemotherapy. Despite maximal medical and surgical interventions, the prognosis for
glioblastoma only improves to 15 months. The five-year survival for glioblastoma is less than
5%, however younger patients on average tend to have slightly higher 5-year survival rates.
The poor prognosis for glioblastoma can be attributed to many factors. One key feature of
glioblastoma is its ability to invade into surrounding brain tissue, making complete surgical
resection exceptionally difficult. Further, these regions of invading tumor cells are located
behind an intact blood brain barrier, which limits the delivery of therapeutic agents.
However, the blood brain barrier within the solid tumor is highly disrupted. Further, gliomas
are often characterized by extensive edema surrounding the primary tumor site.
In the treatment course, the first and most important step is surgical resection with a
goal of removing as much tumor burden as possible while maintaining as much neurological
function as possible.15 Surgical resection is often palliative as recurrence is common due to
the inability to remove infiltrating tumor cells. A critical goal of presurgical planning is to be
able to clearly delineate tumor margins which is again challenging.16 Nearly all recurrence is
at the initial primary tumor site or in the surrounding surgical resection cavity. Another goal
of surgery is for decompression, removing pressure on critical brain structures that may be
driving neurological symptoms. Thus, determination of tumor margins as well as regions of
infiltrating tumor cells is currently an unmet diagnostic imaging need. Following surgical
resection of the tumor, secondary treatments include radiotherapy.17 Radiotherapy can
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either be focal or whole brain. Finally, a course of adjuvant temozolomide, an alkylating
agent, completes the standard treatment course for newly diagnosed GBM.18,19

1.4 Rodent Models of GBM
Although many studies have been conducted on characterizing human GBM samples,
manipulation of the tumor microenvironment, testing different chemotherapy strategies,
and directly probing the acidity and hypoxia that develops in tumors requires the use of
preclinical animal models of GBM. From patient samples, it has been appreciated that many
tumors have different driving mutations, morphology, and metabolic profiles, making
predicting therapeutic efficacy and forming a cohesive representation of the tumor
microenvironment difficult. Therefore, preclinical models of GBM that recapitulate human
GBM are needed.
Preclinical models of GBM have focused on a few key rodent cell lines as well as
patient-derived cell lines, which are used in immunosuppressed rodents. Rat glioma models
include the C6, 9L, RG2, and CNS-1 gliomas 20 and in mice, the GL-261 glioma model. There
are several models of GBM in rats (RG2, U87, U251) that have been used for in vitro
characterization and in vivo tumor monitoring. These tumor models reproduce
histopathological and imaging characteristics found in human GBM and are useful for tumor
characterization and development of imaging modalities. However, the use of stable glioma
cell lines has limitations (similar to other tumor models) in that no disease model involving
the direct injection of cells fully recapitulates exactly the human condition.
Syngeneic models of GBM in rats include the RG2 cell line, which allows for the tumors
to grow in immunocompetent animals. The RG2 tumor was initially generated by the
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administration of ethylnitrosurea to a pregnant Fisher rat, which resulted in tumor
development in offspring that could be collected and maintained in vitro.21 RG2 tumors
exhibit invasive growth patterns and are non-immunogenic in Fisher rats. In terms of
genetics, RG2 has wild-type p53 and has increased expression of several genes including Ras,
cyclin D2, PDGFß, IGF-1, and Erb3/HER3.22 RG2 cells develop reproducible solid tumors
when injected in vivo and develop minor necrotic regions independent of tumor size.5
Minimal signs of inflammation or gliosis outside of the tumor can be identified. RG2 tumors
induce disruption of the blood brain barrier and produce edema surrounding the tumor.21
There is a role of pericytes in RG2 tumors for promoting angiogenesis and leading to
increased permeability of the tumor vasculature.23 Many metabolic studies were performed
on C6 cells. The C6 model has been widely used because it has similar genetic changes to
those seen in human gliomas; however, it is immunogenic and cannot be used in
immunocompetent rats or used to test immunotherapy. It forms pleomorphic cells with
variable nuclear sizes and it does invade into surrounding brain. The 9L gliosarcoma is
another model used in Fisher rats and is the most widely used glioma model. The 9L tumor
is immunogenic and in some cases can be completely eliminated by robust anti-tumor
immune responses. However, the tumors formed are well circumscribed and do not
demonstrate invasion into surrounding tissue and are not representation of this property of
human GBMs. Conversely, the RG2 glioma has a highly infiltrative pattern of growth;
however, it is not immunogenic when used in Fischer rats and therefore cannot be used to
study immune response or immunotherapy. Human GBMs are generally considered to be
weakly immunogenic and this must, to an extent, be replicated in rodents for more
representative tumor models. The F98 glioma model is very similar to RG2 except it is
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weakly immunogenic making it useful for studying immunotherapy. The F98 tumor is also
highly invasive and tumor cells are found beyond the tumor core. Finally, the CNS-1 glioma
is also highly infiltrative and develops pseudopalisading pattern, a characteristic of human
GBM. Further, the tumor becomes infiltrated with macrophages and T cells, as it is highly
immunogenic. Similarly, in mice the GL261 tumor can be used for its invasive features and
immunogenic response.
Xenograft models include the U251 and U87 cells implanted in athymic/nude rats.
Both the U251 and U87 cell lines were derived from patients with pleomorphic gliomas.24
However, because of the immunosuppressed nature of the animals in these models, they do
not allow for studying anti-tumor immune responses or immunotherapies. However, they
can be useful for studying tumor characteristics such as invasion, angiogenesis, or the
therapeutic response to non-immune mediated therapies. Both U251 and U87 are
hypercellular, induce inflammation, and exhibit nuclear atypia.2 U251 tumors are more
invasive than U87 tumors and tumor cells infiltrate to a greater extent and a farther distance
from the primary tumor.25 U251 exhibits greater necrosis and greater expression of hypoxia
inducible factor (HIF-1a), suggestive of hypoxia, and greater expression of Ki67, suggestive
of higher rates of cellular proliferation.26 U251 tumors are positive for GFAP and vimentin.
They develop pseudopalisading necrosis and exhibit neovascularization and angiogenesis.
U87 tumors are positive for vimentin and do not develop necrosis; however, they do exhibit
significant angiogenesis. Neither U87 or U251 exhibit endothelial proliferation, a common
hallmark of human GBM.25
Together, these glioma models have attempted to replicate the genetic changes and
morphology of human GBM and recapitulate the tumor microenvironment. Further, in
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immunogenic models, the anti-tumor immune responses have also been able to be studied
and have demonstrated a response to a variety of different therapies as well as
characteristics of the tumor microenvironment. However, for eventual translation to clinical
care, noninvasive methods to examine the tumor microenvironment need to be developed,
which has led to the realm of different translational imaging technologies. Of usefulness in
imaging research is the faster translatability of preclinical animal imaging to human studies.

1.5 Tumor Microenvironment
The tumor microenvironment is composed of both tumor cells, the extracellular
matrix or stroma, blood vessels and a variety of host cells.27 The tumor microenvironment is
also composed of immune and inflammatory cell,28 and is understood in the context of a state
of chronic inflammation. There also exist direct links between tumor metabolism and the
tumor microenvironment.29 This can be understood because of regions of hypoxia, edema,
angiogenesis, and tissue remodeling develop throughout the tumor. The tumor
microenvironment in gliomas in the brain has many unique features.27,30 The extracellular
matrix found in the brain, and in gliomas, includes many glycoproteins and proteoglycans.31
Glioma cells have migratory capacity, suggesting an even more pronounced role of the tumor
microenvironment in promoting tumor progression. Specifically, some key features
including the presence of tenascin-C, fibronectin, laminin, and collagen lead to tumor cell
invasion into surrounding tissue.32 There also may be a role of cancer stem cells in promoting
tumorigenesis as well as tumor progression.33 The unique composition of the
microenvironment makes gliomas more difficult to treat.34 Additionally, features of the
microenvironment are useful for characterizing tumors using imaging methods.35
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1.6 Angiogenesis
All cells and tissues rely on the vascular system for the delivery of both oxygen and
nutrients for cellular metabolism. Capillaries are where gas exchange and nutrient delivery
occurs. Additionally, the vasculature is responsible for clearing waste products. In tumors,
cells proliferate at a high rate without an initial change in the vasculature, resulting in tumor
cells becoming located farther away from the vasculature. This results in regions of the
tumor becoming hypoxic. However, tumor cells adapt to this changing landscape by
upregulating key molecules resulting in angiogenesis, or the production of new blood
vessels. The newly formed vessels are immature, tortuous, and leaky and this characteristic
vascular architecture is typically found within tumors.36 Angiogenesis primarily relies on the
production of new blood vessels from existing vessels. Angiogenesis is tightly regulated by
both pro- and anti-angiogenic factors; however, of primary importance is vascular
endothelial growth factor (VEGF). VEGF induces both angiogenesis and increases the
vascular permeability, resulting in leaky vasculature. Without angiogenesis, tumors cannot
grow beyond a critical size from which these hypoxic regions develop that will ultimately
lead to necrosis.37 Therefore, angiogenic processes are necessary for sustained tumor
growth. Given that the vasculature is present outside of the tumor and this is where
angiogenesis occurs, blood vessels tend to be located near the tumor periphery, rather than
in the tumor core, which is also why necrosis tends to develop in deeper regions of tumors.
From a therapeutic standpoint, the disrupted vasculature is also critical for
understanding the delivery of therapeutic agents to tumors. In GBMs there is an additional
consideration that the brain is located behind the BBB, which makes delivery of these agents
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even more difficult. The BBB is composed of endothelial cells connected by tight junctions,
which provide a barrier to nearly all non-selective transport, including both endogenous
molecules and exogenous agents.21 The endothelial cells are associated with astrocytes and
together provide for selective transport of glucose and other nutrients as well as allow
oxygen diffusion.
The highly abnormal and non-uniform nature of the vasculature results in vessels of
varying sizes due to differences in the thickness of the capillary walls and endothelial layer.
This abnormal vasculature results in an increase blood volume, but blood flow may be
reduced because of the tortuous network. Even regions of tumors that exhibit high
vascularity may show a reduction in perfusion with perfusion rates in some tumors being
greatly decreased. However, there is a corresponding increase in the permeability of the
vasculature such that the driving force for delivery may be reduced. However, the leakiness
of the vasculature may allow for greater delivery of drugs or contrast agents to the tumor
versus surrounding healthy tissue. There is also a decrease in the ability of tumors to clear
waste products. This can be due both to the poor vascularization as well as a less developed
lymphatic system in the brain.38 Anti-angiogenic therapies have attempted to target
normalizing the vasculature of tumors.39

1.7 Hypoxia
Hypoxia, a reduction in tissue oxygenation, is a hallmark of the tumor
microenvironment that results from a decreased vascular supply.40 Prominent changes in
the vascularization of tumors occur as tumors become larger in size and angiogenesis occurs;
however, angiogenesis also occurs early in cancer development and is not entirely mediated
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by hypoxia. Although premalignant lesions are vascularized, the tumor cells are surrounded
and separated by a basement membrane. Therefore, tumors initially develop in avascular
environments requiring the diffusion of both glucose and oxygen across the basement
membrane. As cancer cells proliferate and the tumor increases in size, the necessary
diffusion distance increases resulting in only the outermost cells receiving levels of nutrients
suitable for sustained growth. Hypoxia develops near the diffusion limit of nutrients, as
oxygen does not diffuse as far as glucose, promoting the switch to anaerobic metabolism.
Levels of hypoxia within tumors vary with time and can be influenced both by altered blood
flow and angiogenesis (promoted by VEGF) once the basement membrane is breached and
the tumor becomes vascularized.
The glycolytic switch occurs before the angiogenic switch as lactic acid increases
precede changes in vessel permeability.41 Hypoxia also may not be chronic, but rather
fluctuate and vary spatially throughout the tumor. Along with deficiencies in delivering
oxygen, the decreased perfusion also leads to a decreased supply of nutrients and an inability
to remove metabolic waste products. Cancer cells have a high proliferative rate, which
necessitate energy production and synthesis of biomolecules. Although glycolysis may be
necessary due to hypoxia, it is an inefficient means of energy production. From these
observations, tumor growth and metabolism are tightly regulated to the growth of the
vasculature. Further, as the tumor core becomes more hypoxic, necrosis forms and that area
of the tumor becomes dormant due to the decreased proliferation. The process of
angiogenesis results in expansion of endothelial cells, as well as underlying pericytes;23
however, the interactions between the endothelial cells and the pericytes is not as strong as
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in normal vasculature since the vasculature is highly irregular and disorganized resulting in
vessels with high permeability.
Hypoxia triggers genetic changes such that signal transducer and activator of
transcription 3 (STAT3), an immunosuppressive molecule, is upregulated. STAT3 induces
expression of hypoxia inducible factor (HIF-1α), which subsequently increases VEGF.
Activation of oncogenes such as epidermal growth factor receptor (EGFR) and loss of tumor
suppressor genes such as p53 can both lead to HIF-1α expression.40 Interestingly, these same
mutations also drive many of the metabolic alterations seen in GBM and upregulation of HIF1α directly upregulates many glycolytic enzymes and downregulates enzymes that target
pyruvate for oxidative phosphorylation.42 HIF-1α also promotes tumor invasion by
activating cathepsins, matrix metalloproteinases (MMPs), and transforming growth factor β
(TGFβ). In GBM, HIF-1α is expressed at the leading edge of the tumor and corresponds to
tumor grade. Fatty acid biosynthesis, required for cellular proliferation, is also upregulated
by hypoxia in cancer cells. Hypoxia also induces macrophages to become tumor associated
macrophages, also mediated through the STAT3 pathway, and ultimately leads to
angiogenesis and invasion. Based on the importance of HIF-1α and VEGF, inhibitors of both
molecules are being studied intensely as possible therapeutic targets with most success to
date being in anti-VEGF therapies. Interestingly, interactions between anti-VEGF treatments
and radiotherapy indicate that hypoxia may decrease the sensitivity of both therapies and
further, there is some evidence that when used in combination there is actually an increase
in the oxygen tension in the tumor.43 Areas of hypoxia are thought to trigger genetic changes
in tumor cells leading to both increased tumor aggressiveness and heterogeneous cell
populations within the tumor. Therefore, even if oxygen levels are restored by angiogenesis,
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these cells remain more invasive and the decreased sensitivity to both radiotherapy and
chemotherapy may remain.

1.8 Acidosis
Cancer exhibits unregulated cell growth and altered metabolism that is shifted
towards aerobic glycolysis.41 In normal tissue, glucose and oxygen are delivered by the
vasculature and taken up by cells. Glucose enters the glycolytic pathway and is converted to
pyruvate, producing 2 ATP in the process. In the presence of oxygen, pyruvate (the end
product of glycolysis) is converted to acetyl-CoA to enter the TCA cycle and fuel oxidative
phosphorylation in the mitochondria, producing an additional 30-34 ATP. However, the
metabolic phenotype of cancer is one of upregulated glycolysis and reduced oxidative
phosphorylation.44 Although this initial metabolic switch occurs early in cancer
development, the driving force behind the metabolic dysregulation is not well understood.
The upregulation of glycolysis, as the first metabolic pathway of glucose utilization in cells,
necessitates increased glucose consumption to support increased biosynthetic needs. As
tumors grow in size, areas of hypoxia develop prior to the development of new vasculature
in the tumor (angiogenesis). In the absence of oxygen, pyruvate is converted to the
byproduct lactate, in the process reforming NAD+ to be reused in the glycolytic pathway.
Although glycolysis produces NADH from NAD+, the TCA cycle is the primary producer of
NADH to fuel oxidative phosphorylation and together these two pathways are essential for
maintaining energy production over a range of oxygen tensions. Glycolysis is normally
inhibited by oxygen since oxidative phosphorylation is a more efficient means of energy
production, termed the Pasteur effect. Unique to tumors, glycolysis is upregulated even in
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the presence of oxygen (aerobic glycolysis), termed the Warburg effect. However, as hypoxia
develops, metabolism becomes further reliant on glycolysis, exacerbating already altered
tumor metabolism. The glycolytic switch precedes the development of hypoxia in the tumor
and is therefore thought to be more than just a reaction to the hypoxic conditions; however,
a key regulator of the glycolytic response is HIF-1α, which induces increased expression of
glucose transporters, VEGF to promote angiogenesis, and the glycolytic enzyme hexokinase.
Genetic mutations in p53, KRAS, and MYC (found in many cancers) accompany some
of these metabolic changes and act as a direct link between cancer genetics and
metabolism.42,45,46 In some cancers, the capacity to undergo oxidative phosphorylation is
reduced such that if glycolysis is downregulated, the cells are no longer able to compensate
in energy production,47 indicating that genetic changes at the cellular level reduce metabolic
fitness. However, altered metabolism allows cancer cells to be better suited for proliferation,
a hallmark of cancer, rather than energy production as several signaling pathways are
involved in both proliferation and metabolism. Proliferating cancer cells exhibit anabolic
metabolism and add to the tumor mass by incorporating nutrients into nucleotides, amino
acids, and lipids. Although uncontrolled proliferation is normally prevented by growth factor
regulation, cancer cells overcome the regulatory mechanisms by constitutively activating
pathways leading to nutrient uptake. However, resistance to therapies that reduce the
proliferative and replicative potential of tumors may be due to acquired mutations that
change the metabolic phenotype to relying on mitochondrial function to a greater extent.48
Oxidative phosphorylation is accomplished in mitochondria by the flow of electrons through
complexes anchored in the mitochondrial membrane. As oxidative phosphorylation
decreases, the reduced function of the electron transport chain allows reactive oxygen
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species (ROS) to form, which maintains the cancer cell phenotype and leads to further
genetic instability, altered metabolism, and increased tumor invasion. Although
mitochondrial function is not directly impaired, the metabolic decoupling from oxidative
phosphorylation necessitates increased glycolysis. Further, the ROS generated are toxic to
cells and would seem to contradict the replicative advantage seen in cancer; however, the
upregulation of glycolysis also produces reducing equivalents to handle the oxidative stress
associated with increased ROS production.3
Additionally, with the upregulation of glycolysis and decreased oxidative
phosphorylation, there is both a generation of protons and increased lactate production that
result in an acidic intracellular environment (Figure 1.1). As acidity is toxic to cells,
expression of Na+/H+ cotransporters and vacuolar H+-ATPases is increased to neutralize the
intracellular pH and shift the acidic conditions to the extracellular environment. However,
exposure to acidic conditions in the extracellular environment promotes necrosis and
apoptosis. Since carcinogenesis is accomplished by the selection of specific cell populations
with the greatest growth advantage, selected cancer cell phenotypes become resistant to
acid induced cell toxicity. The glycolytic phenotype (including extracellular acidosis) may
offer a selective advantage to tumor cells because the acidic conditions are toxic to
surrounding cells (not adapted to survive in acidic conditions). Further, the low pH increases
degradation of the extracellular matrix (ECM) by upregulating metalloproteinases and
cathepsins, increasing invasiveness, again a hallmark of cancer. In total, the metabolic
changes seen in cancer are a fundamental property of the genetic mutations and altered
enzyme expression that lead to a proliferative and replicative advantage.
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Lactate is found in the highest concentration in the most hypoxic tumor regions.49,50
Lactate can also serve as an additional fuel for other cells that are able to capture lactate and
utilize it as a metabolic fuel. However, maintaining a near neutral intracellular pH is critical
for maintaining the fluxes needed for lactate transport. There are also changes in lipid
metabolism, mainly in the carboxylation of alpha-ketoglutarate, that are specifically seen
with isocitrate dehydrogenase (IDH) mutations in GBM.
Acidosis in the tumor microenvironment has been associated with many features of
cancer progression including remodeling of the extracellular matrix, tumor invasion and
metastatic spread.7,8 Acidosis leads to activation of proteases that disrupts or alters adhesion
proteins between cells and between cells and the matrix. Further, proteases found in
lysosomes are most active under acidic conditions. Lysosomes may also be involved in
removing excess protons from the cytosol if upregulation of transporters was not able to
sufficiently remove the amount of generated protons. Tumor regions with the greatest
acidity (lowest pH) are areas where the tumor is likely to invade. Acidosis also results in
increased angiogenesis due to the release of pro-angiogenic molecules normally found in the
extracellular matrix and triggers cells to have more stem-cell like properties. The acidic pHe
(and corresponding alkaline pHi) contribute to many features of the tumor
microenvironment (Figure 2.2) and several key impacts of the acidic microenvironment will
be discussed individually.

18

Figure 1.2. Effects of pH changes on the hallmarks of cancer. Dysregulated metabolism leads
to a decrease in the extracellular pH (pHe) along with an increase in the intracellular pH
(pHi). The decrease in pHe leads to tumor invasion into surrounding tissue, an upregulation
of angiogenesis leading to increased vascularization, and aids in creating an
immunosuppressive environment resulting in immune escape. The increase in pHi results in
an increased rate of cellular proliferation and a resistance to undergoing apoptosis.
Reproduced with permission.51
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1.9 Acidosis results in tumor invasion
Altered metabolism does not only respond to the tumor microenvironment (hypoxia)
but also helps shape it (lactate and proton production and extracellular acidosis). Although
hypoxia and acidosis are prominent features of the tumor microenvironment, in GBM the
tumor microenvironment is complex and optimal for cancer cell survival, invasion, and
metastasis. A unique element of the GBM environment is the presence of tight junctions on
the foot processes of astrocytes that forms the foundation of the BBB. Similar genetic
alterations that lead to changes in tumor metabolism also play a role in the remodeling of
the extracellular matrix (ECM).
The tumor microenvironment is composed of stromal, endothelial, and immune cells
in addition to tumor cells. Of emerging importance in the GBM microenvironment is the role
of cancer stem cells, which are characterized by expression of CD133 and exhibit a specific
phenotype of self-renewal and proliferative advantage.33 Although a small population of the
heterogeneous collection of cells within the tumor, these cells are capable of maintaining the
tumor and are surrounded by ECM composed of collagen, glycoproteins, and proteoglycans,
which supports tumor cells and creates a specific niche.31 Integrins located on the cell
membranes of stem cells interact with the ECM, triggering cytoskeleton remodeling,
proliferation, and gene transcription. Therefore, changes in the ECM can have direct impacts
on cellular signaling, cancer cell survival, and invasion into surrounding tissue.
A critical element of tumor development is angiogenesis as a tumor vascular supply
is critical for the delivery of oxygen and nutrients. The angiogenic switch occurs later than
the glycolytic switch, but is driven by both hypoxia and oncogene activation, primarily
through VEGF.41,52 Further, the stem cell niche is tightly coupled to vascular areas of the
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tumor. However, the vessels produced through angiogenesis are immature with excessive
branching leading to increased vessel permeability and micro-hemorrhages. Finally, there is
a role for proteases, such as matrix metalloproteinases (MMPs), that degrade the ECM and
lead to local invasion. Although some cancer cells may directly secrete MMPs, other cancer
types secrete chemokines that attract protease-secreting proinflammatory cells. In general,
however, the tumor microenvironment is immunosuppressive and immune evasion is
increasingly becoming evident as a hallmark of cancer.53
Solid tumors maintain an acidic extracellular environment with extracellular pH
values of 6.2-7.0 being reported (normal tissues have a pH of 7.2-7.5).54 The altered
metabolism in tumors, described previously, results from both genetic changes as well as
changes in the tumor microenvironment, such as hypoxia.42 Acidosis, much like hypoxia, can
also vary spatially within tumors.44 The dysregulation of metabolism results in extracellular
acidosis and is directly connected to changes in the tumor microenvironment. For example,
mutations in certain oncogenes, such as those found in GBM, upregulate lactate
dehydrogenase, glucose transporters and glycolytic enzyme activity, all of which are
necessary for regulating tumor cell metabolism. However, acidosis also activates the tumor
suppressor p53, which may reactivate oxidative phosphorylation and might aid in alleviating
oxidative stress from ROS. Ultimately, loss of function mutations in p53 with chronic acidosis
limit this alternate pathway, fully shifting tumor cell metabolism to the predominately
glycolytic phenotype. Although the early shift in metabolism is not entirely understood, it
results in the selection of cell populations resistant to acid-induced toxicity. In addition to
lactate production, protons are also generated by the hydrolysis of ATP and carbonic
anhydrase activity. The end result is that protons and lactate accumulate in the interstitial
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environment.42 Further, the deregulated pH results in tumor growth and cancer
progression.55 Specifically, an acidic extracellular pH increases proliferation, angiogenesis,
and invasion. In gliomas, the decreased extracellular pH can increase the invasiveness by
increasing the expression of extracellular degrading proteases which disrupts the basement
membranes of the extracellular matrix, promoting tissue invasion.56
Although the acidic extracellular pH originates from within the tumor habitat, it is
also thought to drive local invasion.57 The direction of tumor infiltration directly follows the
areas with the lowest extracellular pH. The altered pH results in the genetic upregulation of
ionic transporters. Specifically, there is an upregulation of the Na+/H+ cotransporter to
remove protons from the intracellular environment and monocarboxylate transporters
(MCTs) to remove lactate, shifting the acidity to the extracellular environment.58
Additionally, low extracellular pH also promotes angiogenesis through interleukin 8 (IL-8)
and VEGF.51 As metastasis is the process where migratory cells invade the basement
membrane, enter the bloodstream, and then spread to distant sites, cells grown in acidic
conditions showed greater motility and invasion and may be better enabled to extravasate
through fenestrae in blood vessels leading to metastasis.

1.10 Acidosis hinders therapeutic response
Due to the effects of acidosis on promoting a favorable environment for continued
tumor growth, the acidic extracellular pH has been proposed as a target for cancer
treatment.59,60 Alkalinizing the extracellular environment can lead to increased sensitivity to
some chemotherapy agents and decrease the rate of metastasis.60 Further, because certain
chemotherapy agents have ionizable functional groups with characteristic acid dissociation
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constants (pKa), there can be improved response to some therapies with normalization of
the tumor pH.61-63 Low pH decreases sensitivity of radiation therapy, but can also be
exploited to enhance delivery of weak-acid chemotherapy agents.56 Further, the acidic
extracellular pH has been exploited to deliver chemotherapy agents in an acidosisdependent manner such as with the use of low pH insertion peptides (pHLIP). These can also
be exploited in the design of nanoparticle-based therapeutics where the drug-containing
nanoparticle can be designed to target areas of low pH.64,65 Because there are few tissues in
the body that are highly acidic (muscle and kidneys are notable exceptions) this provides a
unique route of specific tumor targeting of therapeutics, but also may explain the muscle and
renal toxicities exhibited by many chemotherapeutics.

1.11 Acidosis is immunosuppressive
Specifically, in GBM, acidic extracellular pH promotes a glioma stem-cell like
phenotype through the impact of acidic pH on the tumor microenvironment.66 Immune
responses can also be impacted by acidosis such that cytokine production by activated T cells
can become inhibited.67 There is metabolic competition in the tumor microenvironment as
nutrients may be diverted from anti-tumor immune cells to the tumor cells themselves
resulting in decreased anti-tumor immunity.68 Acidosis (including lactic acid) impairs many
aspects of immune function including chemotaxis, proliferation, and cytokine production. In
acidic conditions, T cells are not able to effectively recognize or respond to cancer-specific
antigens. There are also direct effects on neutrophil and macrophage function.67 Therefore,
the acidic pHe has a twofold effect on cancer progression, both by directly increasing
proliferation and invasion and decreasing anti-tumor immunity.
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Altered anti-tumor immunity is emerging as a hallmark of cancer. However, it should
come as no surprise that altered metabolism, acidosis, and hypoxia (previously established
as necessities to promote tumorigenesis) all contribute to decreased immune function in the
tumor microenvironment. Although immunotherapy is a novel approach to cancer
treatment, using the body’s naturally occurring immunity to combat tumor cells, its
applicability to gliomas has been questioned due to the immune privileged site of the CNS.
Sitting behind the selective blood-brain barrier (BBB), it was thought that immune cells did
not readily penetrate the CNS and further it is well known that many chemotherapeutics and
other pharmaceuticals do not penetrate the CNS with high efficacy. Initial studies with
immunotherapy in GBM were suboptimal as difficulties with treating GBM stemmed from a
lack of understanding of tumor biology, metabolism, and the microenvironment. In a recent
review of the difficulties with immunotherapy in GBM, many of these factors were
examined.69 Although the BBB was thought to maintain this separation, recent evidence
suggests that a “glymphatic system” is present and located within the dura, allowing immune
cells to cross into the CNS.38 Lymphocytes have been found in the tumor microenvironment
and immunoglobulins are also able to cross the BBB by carrier-mediated transport involving
a specific receptor. Further, antigen-presenting cells have also been found in many areas of
the brain. Although peripheral immune cells are unable to enter the brain due to the integrity
of the BBB, in disease states the BBB becomes disturbed, facilitating the invasion of immune
cells into the tumor microenvironment.
Specific interest has revolved around programmed cell death molecule 1 (PD-1) and
its ligand (PDL1), which acts as an immune checkpoint and is expressed on microglia. PD1
inhibitors have gained recent attention for their role in promoting immune responses in
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renal cancer, lung cancer, and melanoma. PD-L1 has been found in human gliomas and
expression was found to correlate with tumor grade.70 Many different strategies for
immunotherapy for glioblastoma in preclinical (as well as clinical) studies are underway.71
PD1 is an inhibitory receptor that inhibits the T cell response after antigen activation and is
upregulated when surrounding T cells undergo apoptosis. Interestingly, the efficacy of antiPD1 therapies is dependent on extracellular acidosis, as low pH decreases the sensitivity of
immunotherapy.61
Further, a variety of other immune cells are impacted by the tumor
microenvironment, specifically macrophages and T cells, which are the foundation of the
anti-tumor

immune

response.72

In

general,

the

tumor

microenvironment

is

immunosuppressive and interrupts antigen presentation by downregulating MHC
expression. Immunosuppression is achieved by inhibiting T cell proliferation and proinflammatory cytokine release, as well as by activating regulatory T cells. The upregulation
of glycolysis also creates an environment where glucose supply is restricted having
significant consequences on T cell metabolism and inhibiting their ability to secrete
cytokines.68 Therefore, even if tumors are highly antigenic, the T cells may not have the
nutrient source in order to respond appropriately. The pro-inflammatory cytokines such as
interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNFα) are downregulated
through IL-10, an immunosuppressive cytokine. The immunosuppressive cytokines include
IL-6, IL-10, and TGFβ and their secretion is upregulated in the tumor microenvironment. In
GBM, TGFβ promotes both tumor growth and invasion by promoting a GBM stem cell
phenotype and angiogenesis. Hypoxia, through activation of HIF-1, will directly activate
regulatory T cells (Treg) to modulate the immune response as well as promote the
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differentiation of macrophages into tumor-associated macrophages (TAMs), which secrete
immunosuppressive cytokines. Similarly, acidosis results in the decreased release of proinflammatory cytokines (TNFα and IFN-γ) by macrophages.67 In summary, the entirety of the
tumor microenvironment, which is driven by initial genetic mutations and altered
metabolism, plays a role in immune evasion and suppression to augment tumor cell
progression.

1.12 Implications for clinical cancer imaging
In cancer imaging, a variety of methods have repeatedly demonstrated that
extracellular pH is spatially heterogeneous throughout tumors and can be correlated with
increased lactate levels.73 Further, the intracellular pH of tumors remains neutral to alkaline
even in the presence of a very acidic extracellular environment.74,75 Finally, the pH gradient
between the intratumoral and peritumoral environment is steeper with less invasive
tumors; therefore, the pH gradient can be used as a marker of tumor invasiveness. More
invasive tumors have more extensive pH abnormalities and the acidic pH spreads far beyond
the tumor boundary.76 The genetic mutations driving initial cancer formation, the altered
metabolism resulting in the upregulation of glycolysis, and the variably hypoxic and acidic
tumor microenvironment are now all thought to be hallmarks of cancer and most
interestingly, to each be related to one other. Further, the most recent developments in
cancer therapy, immunotherapy, are now being found to be dependent on the tumor
microenvironment as hypoxia and acidosis directly impact the anti-tumor immune response.
The role of developing novel techniques to image the tumor microenvironment in both
preclinical models and in clinical practice will only become more relevant and of greater

26

importance as cancer research continues to expand. In the next chapter, the imaging
methods to characterize the vascular tumor microenvironment and measure the pHe will be
discussed in detail.
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Chapter 2: Metabolic Imaging Methods in Cancer
2.1 Abstract
Acidification of the tumor microenvironment by altered cellular metabolism is a
hallmark of cancer. Metabolic dysregulation promotes a switch to glycolysis even in the
presence of oxygen, termed the Warburg effect, and enables overproduction of lactate and
protons that initially accumulate in the intracellular compartment only to be later extruded
into the extracellular space. Therefore, there is great interest in imaging acidosis found in
solid tumors. However, imaging methods to measure pH, especially for tumors not located
on the skin surface, are challenging. Methods to measure pH have evolved from placing pH
electrodes directly into surface tumors or using optical imaging methods to noninvasive
imaging methods using magnetic resonance imaging (MRI) and spectroscopy (MRS) or
positron emission tomography (PET). Each technique has certain advantages and
disadvantages, vary in their spatiotemporal resolution, and may use endogenous contrast or
the infusion of exogenous pH-sensitive contrast agents. In this chapter, after a general
introduction to MR methodology, a review of the methods available for imaging the pH in the
tumor microenvironment will be explored.

2.2 Magnetic resonance imaging (MRI) and spectroscopy (MRS)
MRI is a noninvasive medical imaging modality that does not use ionizing radiation
to detect hydrogen atoms of water and is utilized for its excellent tissue contrast properties
and capability for three-dimensional imaging. The principles of nuclear magnetic resonance
(NMR) govern MRI, resulting in several applications such as spatially encoding information
with linear magnetic field gradients to yield an image (MRI) or investigating a range of
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frequencies to yield a spectrum of molecules other than water (MRS). Since the 1970s, when
the use of MRI as a medical imaging tool was realized when it was shown that normal and
cancerous tissue resulted in different MRI contrast,77 MRI has continued to expand in the
medical community and become a prominent technique in diagnostic imaging. To fully
appreciate the underlying methods that contributes to the utility of MRI, the basis of the MRI
signal will be discussed.

2.2.1 Nuclear Spin
Protons and neutrons within an atom have an intrinsic angular momentum (spin) such that
atomic nuclei that have an odd number of protons and/or neutrons have a non-zero spin.
The rotating charged particles generate a magnetic moment. Each spin is randomly oriented;
however, when an atom with a net nuclear spin (such as 1H) is placed in an external magnetic
field (B0), the magnetic moment will align with B0 in one of two orientations: parallel with B0
in a low energy state, or anti-parallel with B0 in a high energy state where the difference in
energy between the states for 1H nuclei is given by Equation 2.1 where g is the gyromagnetic
ratio and h is Planck’s constant (h =6.62 x 10-34 m2kg/s).
∆E = γℎB!

(Equation2.1)

For an ensemble of spins, the system forms an equilibrium and it is the difference in
number of spins between these two states that leads to a non-zero magnetization, usually
termed net magnetization (M0). The fact that M0 depends on the difference in spin
populations and not the total number of spins leads to the inherent low sensitivity of MRI.
The net magnetization depends on the total number of spins (N), the external magnetic field
strength (B0), the temperature (T) and Boltzmann constant (k = 1.38 x 10-23 m2kg/s2K) as
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given by Equation 2.2 and illustrates that greater magnetization is achieved at high spin
concentration and higher magnetic field strength.
𝑀! =

"# ! $ ! %"
&'(

(Equation 2.2)

The nuclear spins in an external magnetic field rotate at a characteristic resonance
frequency (Larmor frequency) that is dependent on the gyromagnetic ratio and the external
magnetic field strength (B0) according to Equation 2.3.
𝜔 = 𝛾𝐵!

(Equation 2.3)

For example, the 1H nucleus has a g of 42 MHz/T such that 11.7T, the resonance
frequency is 500 MHz; however, each nucleus has a characteristic resonance frequency at a
given magnetic field strength. Many elements have an isotope that will have a net magnetic
moment; however, few elements have isotopes with a net magnetic moment at high natural
abundance. The 1H nucleus is a notable exception with a net magnetic moment, a high
gyromagnetic ratio, a natural abundance near 100%, and an extremely high tissue
concentration (from the signal in water and fat) making this the most sensitive and
important isotope for MRI experiments. A comparison of other nuclei with 1H is shown in
Table 2.1.
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Nuclei Spin Natural Abundance (%)

Gyromagnetic Ratio (MHz/T)

1H

1/2

99.985

42.48

19F

1/2

100

40.08

31P

1/2

100

17.25

23Na

3/2

100

11.27

13C

1/2

1.11

10.71

2H

1

0.015

6.54

17O

5/2

0.0373

5.8

14N

1

99.63

3.08

Table 2.1. Comparison of nuclei based on their natural abundance and gyromagnetic ratio.
Nuclei with the highest gyromagnetic ratios and highest natural abundance have the greatest
NMR sensitivity.
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2.2.2 Excitation
The MR experiment is based on using radiofrequency (RF) energy at the resonance
frequency in order to manipulate the different populations of spins. The B1 field refers to
magnetization applied perpendicular to B0 that briefly rotates spins out of alignment with B0
in a process termed excitation. RF pulses are applied using a transmitter coil that is tuned to
the resonance frequency of the nuclei under study and impedance matched to allow efficient
power transfer. Depending on the NMR experiment type, the same RF coil can be engineered
to also be a receiver or an alternative RF coil can be used as the receiver.
The direction of the main magnetic field (B0) is defined as the z direction by
convention and the net magnetization is aligned in the same direction (Mz). The amount of
rotation of the magnetization (Mz) out of alignment with B0 can be varied by the intensity or
duration of the applied B1 field. An excitation pulse is achieved when Mz is tipped 90°, such
that the magnetization is completely in the xy-plane (Mxy) and the Mz component is 0. If the
duration of B1 is doubled, an inversion pulse is achieved and Mz is rotated 180°, such that the
magnetization is equal to -Mz. After the RF is switched off, the magnetization begins to return
to equilibrium in a process termed relaxation. Magnetization in the xy-plane precesses
around the z axis at the resonance frequency and is the signal that is ultimately detected in
MR experiments.

2.2.3 Relaxation
After excitation, the spins relax back into alignment with B0 in a process governed by
the relaxation parameters T1 (longitudinal relaxation in the direction of B0) and T2
(transverse relaxation in the xy-plane), which is detected as the MR signal. The
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magnetization as a function of time is governed by the relaxation processes and
mathematically represented by the Bloch equations. The magnetization in each direction
(Mx, My, or Mz) is shown in Equation 2.4.
dM)
M)
= γM* B! − γM* B+,* −
dt
TdM*
M*
= γM. B+,) − γM) B! −
dt
T/0#
/1

= γM) B+,* − γM* B+,) −

0# 20"
3$

(Equation 2.4)

The T1 relaxation time is the first-order rate constant that governs the relaxation of
the Mz component of magnetization back into equilibrium and is based on the exchange of
energy with the surrounding environment (lattice). After a 90° RF pulse, the net
magnetization is tipped into the xy-plane such that Mz=0 after which the Mz then recovers
along the z axis. The T1 relaxation is governed by Equation 2.5 where TR is the repetition
time, or time between successive excitations (the amount of time Mz is allowed to recover).
%&
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(Equation 2.5)

T2 is based on spin-spin interactions and loss of phase coherence due to the
interaction between nearby spins and refers to the loss of the spin ensemble (i.e., the
magnetization) in the transverse plane. As the protons spin, they induce small magnetic
fields that impact neighboring spins. After the B1 field is applied, all spins are in phase;
however, as the spins relax, they lose phase coherence, decreasing the net magnetization in
the xy-plane according to Equation 2.6 where TE is the echo time and is the time between
the RF pulse and data acquisition.
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(Equation 2.6)

However, magnetic field inhomogeneities result in spins losing phase coherence even
faster than would be expected. The observed transverse relaxation rate is called T2* and
accounts for the inhomogeneities that occur due to a variety of reasons including
susceptibility artifacts in tissues or the presence of any nearby paramagnetic materials. The
T2* is always shorter than T2, is measured in a different manner than T2 and can be beneficial
if contrast agents that have strong T2 effects are used. MRI acquisition with multiple TE
values is used to measure both T2 and T2* using spin echo and gradient echo methods,
respectively.
The relationship between T2 and T2* is given in Equation 2.7 where T2’ is the
relaxation effects due to susceptibly effects or magnetic field inhomogeneities.
+
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(Equation 2.7)

The T2* is also related to the spectral linewidth according to Equation 2.8, where w1/2 is the
linewidth at half maximum, such that short T2* results in significant line broadening.
+
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(Equation 2.8)

As the spins relax, they induce a voltage in an RF receiver coil. The MR signal eventually
decays back to zero as all spins are back in their equilibrium alignment with B0, and no longer
releasing RF energy to the lattice.

2.2.4 Sequences
Magnetization cannot be detected directly in the Mz direction, but must be present in
the Mxy plane. To manipulate the magnetization, pulse sequences are used that alter the
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alignment of the net magnetization. The two most common MRI sequences that are used are
the spin echo and the gradient echo.
The spin echo sequence is a 90° pulse to rotate Mz into the xy-plane and followed after
a time delay by a 180° pulse to refocus the spins that have dephased during the delay. After
an identical delay, the spins will be back in phase resulting in an echo, which is when data is
acquired. The total delay, from excitation pulse to data acquisition is the TE. Due to the
refocusing pulse, the susceptibility effects and magnetic field inhomogeneities will be
cancelled out resulting in pure T2 decay. The T2 can be measured using a spin echo sequence
and varying the TE, which will yield an exponentially decreasing function governed by T2
(Equation 2.6). Additionally, the T1 can be measured using a spin echo sequence and varying
the TR, which will yield an exponential rise-to-max equation with T1 as the time constant
(Equation 2.5). While a spin echo sequence provides excellent image quality, the scans are
long. The spin echo sequence can be accelerated by applying multiple 180° pulses within a
single TR resulting in acquisition of multiple echoes.
The gradient echo sequence is similar to the spin echo, but instead of using a
refocusing RF pulse, uses gradients to produce the echo. Since there is no refocusing pulse,
this sequence is used to measure T2*. The T2* can be measured by varying the TE, which will
yield an exponentially decreasing function similar to T2.
The variations in the MR signal, represented in gray scale in MR images, are based on
the amount of net magnetization remaining when measured at specific time intervals after
excitation. The pulse sequence chosen is used to maximize one form of contrast, and usually
in an imaging session multiple imaging sequences are performed to gain the most
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information as the complex combination of parameters are altered in different ways based
on changes in anatomic structure and physiology.

2.2.5 Contrast
Different amounts of T1 or T2 weighting can be encoded onto an image based on the
selection of the TR and TE; short TE and short TR yield T1 weighting while medium TE and
long TR yield T2 weighting. In T1-weighted images, short TR does not allow much
magnetization to recover and therefore it reaches a steady state where the signal intensity
is low. At long TR, most of the magnetization has recovered and signal intensity is high. At a
given TR, the faster (shorter) the T1 relaxation time, the more signal recovers and it appears
brighter in the image. In T2-weighted images, short TE does not allow much magnetization
to dephase and therefore the signal intensity is high. At long TE, most of the magnetization
has dephased and signal intensity is low. At a given TE, the faster (shorter) the T2 relaxation
time, the more signal that decays and it appears darker in the image. Other weighting
measures can also be encoded in sequence design including proton density, apparent
diffusion coefficient (ADC), and magnetization transfer.
Intrinsic T1 contrast is usually insufficient for identifying pathological tissue. For
example, although tumors do typically have higher T1 values than surrounding tissue, the
contrast is unable to identify anatomic demarcations. To increase the contrast, agents can be
administered to alter the relaxation properties of the MR signal in voxels in which the agent
is present. Contrast agents for MRI may be either diamagnetic or paramagnetic; however,
most commonly used contrast agents rely on the presence of a paramagnetic ion to induce
magnetic field distortions and shorten T1 relaxation times. Some common clinically used
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contrast agents are shown in Figure 2.1. However, many of the lanthanide metals used for
these purposes are toxic and therefore need to be conjugated to a macrocyclic chelate which
provides a stable molecular structure to deliver the metal while avoiding any undesired
toxicity. The most common toxicity is nephrogenic systemic fibrosis and occurs most
frequently in those with impaired renal function.
Contrast agents work by shortening the relaxation rates in a concentration dependent
manner. Due to the concentration dependence, greater contrast is achieved in regions where
the contrast agent accumulates to a greater extent. Contrast agents are evaluated based on
their relaxivity (r1 or r2) and reduces the relaxation times (T1 or T2) according to Equation
2.9 where T1,0 is the intrinsic T1 relaxation time without the contrast agent and [CA] is the
concentration of the contrast agent.
+
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+ r+ [CA]

(Equation 2.9)

Figure 2.1. Molecular structure of commonly used gadolinium-based contrast agents. The
macrocyclic versions of these agents are used most frequently due to improved safety
profiles. The macrocyclic agents are based on a 1,4,7,10-tetraazacyclododecane backbone.
Reproduced with permission.78
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Table 2.2. Relaxivities for common contrast agents. Agents with higher relaxivities have a
great effect on the relaxation rates, which leads to greater contrast at the same agent
concentration.
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Therefore, in pathologies where contrast agents are taken up to a greater extent than
healthy tissue will become readily visible on appropriately weighted MRI. Most clinically
used contrast agents contain gadolinium and reduce T1 to a greater extent than T2. However,
there are agents that more efficiently reduce T2 and are traditionally based on Fe in the form
of superparamagnetic iron oxide (SPIO). The reduction in T1 and/or T2 relaxation leads to
positive or negative contrast in T1 or T2-weighted imaging, respectively.
Because these agents work by exerting effects on the relaxation of the water signal,
they are not directly detected. However, MRS techniques (described in a later section) can
directly detect resonances that emanate from protons on the contrast agent. Gadolinium,
however, is the most paramagnetic lanthanide agent and has much higher relaxivity,
resulting in much shorter relaxation times. Additionally, the T2 shortening results in
significant line broadening that results in the signal being undetectable by MRS. Agents with
other lanthanide metals (e.g., thulium), while less paramagnetic, have relaxation times that
result in less signal broadening and allow hyperfine shifts that can be directly detected.
Lanthanide agents can act as contrast agents by shortening relaxation times, but in some
cases can also act as shift agents by causing a change in the chemical shift as is most
commonly seen in 23Na MRS.

2.2.6 Magnetic Resonance Imaging (MRI)
In order to generate an image in MRI, magnetic field gradients are applied to allow
spatially localized volumes to be specified. Gradient coils create linearly varying magnetic
fields that change the resonance frequency of the spins, such that the resonance frequency
of individual spins becomes dependent on spatial location. In slice-selective 2D imaging, a
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slice is first designated by applying a slice-selective RF pulse corresponding to the resonance
frequency range defined by the magnetic field gradient in the slice orientation desired. The
slice thickness is determined by the strength of the slice-selective gradient and the RF pulse
bandwidth. The two in-plane directions (spatial encoding) are specified by frequency
encoding and phase encoding after slice selection. The phase is encoded prior to data
acquisition in one dimension while the frequency is encoded during data acquisition in the
other perpendicular dimension using a similar approach with magnetic field gradients as
used for slice selection. Each unique volume (voxel) is identified with a unique frequency
and phase and the signal intensity corresponding to the frequency and phase is used to
generate an image.

2.2.7 Diffusion weighted imaging (DWI)
MRI methods have also been adapted to be sensitive to the diffusion of water. The
apparent diffusion coefficient (ADC) is a measure of movement of water molecules within an
MRI voxel.79 Diffusion-weighted imaging is based on the spin echo pulse sequence, but
utilizes an additional diffusion encoding gradient before and after the 180° refocusing pulse.
Nuclei that remain within the imaging voxel during this diffusion time, contribute to the
imaging signal, while nuclei that diffuse out of the imaging voxel no longer contribute to the
signal. Therefore, by measuring the signal at different durations of the diffusion time can
allow the ADC to be quantitatively measured. The strength of the diffusion gradient (denoted
b values) is based on the gradient strength (G), duration (d) and delay (D) according to
Equation 2.10 when using symmetric diffusion gradient pulses.
6
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(Equation 2.10)

Similar to how T2 is measured by spin echo MRI (Equation 2.6), the ADC can be measured
using a spin echo sequence by varying the b values to yield an exponentially decreasing
function governed by ADC (Equation 2.11).
M = M! e28(:;<)

(Equation 2.11)

In solution, diffusion is unrestricted, resulting in high values for ADC. However, in
cells and tissues, the inhomogeneous environment results in barriers to diffusion due to cell
membranes and the tissue structure that result in a reduction in ADC. In cancer imaging, the
ADC is linked to the cellularity of the tumor as more highly cellular tumors have greater
diffusion restriction and lower ADC values.80 Heterogeneity within tumors are also reflected
in varying ADC values; in particular, regions of necrosis which are more acellular, have
higher ADC values.

2.2.8 Dynamic Contrast Enhanced MRI
Dynamic contrast enhanced (DCE) MRI is a tool that models the dynamic uptake of an
exogenous contrast agent and uses a mass conservation equation to model vascular
parameters based on the delivery, exchange, and clearance of the contrast agent in different
tissue compartments.81 Contrast agents are delivered by an intravenous injection and are
present initially only in the blood. However, in some vasculature the contrast agent
extravasates into the interstitial (extracellular) space. The arterial input function (AIF) is
modeled based on the contrast agent concentration in a blood vessel over time and can be
measured by selecting a region in a large blood vessel in the image. The AIF is based on a
bolus delivery of the contrast agent followed by a distribution period where concentration
of the contrast agent in the blood decreases. While the gold standard AIF is based on blood
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sampling during imaging and directly measuring the contrast agent in blood samples, this is
frequently not possible.
Throughout the delivery of the contrast agent, a series of fast T1-weighted images are
acquired. Since the images are acquired while the contrast agent concentration is changing,
the signal intensity also changes as the amount of contrast-induced relaxation effects are
concentration dependent. The signal intensity rises fastest when the bolus of contrast agent
in blood first reaches the tissue and extravasates and is followed by a slow washout period.
The measured signal intensity (S) is based on the acquisition parameters (TE, TR, flip angle:
a) and changes as the T1 and T2* relaxation parameters change with the changing
concentration of the contrast agent throughout data acquisition according to Equation 2.12.
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Analysis of DCE data can either rely on non-parametric analysis or parametric
analysis.82 Nonparametric approaches are used most commonly clinically, because they do
not rely on modeling, but rather on the rate of signal intensity rise or area under the curve
approaches; however, these methods do not allow for quantitative measures of vascular
parameters. Parametric measures require the signal intensity curve to first be converted to
a concentration signal using Equation 2.9, which requires measurements of the intrinsic T1
(T1,0) and relaxivity of the contrast agent. The data is then fit to a pharmacokinetic model so
that tissue parameters can be quantified.83 The model is based on perfusion (Fp) and
permeability (PS), which is determined by the rate of exchange of the contrast agent from
the blood compartment (vp) to the extracellular compartment (ve).
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The two-compartment exchange model is governed by Equation 2.13. Applying mass
balances to both the extracellular and blood compartments shows how the plasma,
extracellular, and arterial concentrations of the contrast agent (Cp, Ce, and Ca, respectively)
change with time.
dCH PS
FH
=
CC@ − CH D + CCI − CH D
dt
vH
vH
dC@ PS
=
CC − C@ D
dt
v@ H
C1 = vH CH + v@ C@

(Equation 2.13)

The total concentration of the contrast agent (Ct) is given by the sum between the
extracellular and plasma compartments. An additional vascular exchange parameter (Ktrans )
is derived from the PS term according to Equation 2.14.
PS =

J./012
+2

3./012
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(Equation 2.14)

While a variety of other models have been proposed and tested, they largely are based
on making assumptions from the two-compartment exchange model.82 Limitations of these
approaches are assumptions about the distribution of the contrast agent in the
compartments (well mixed) as well as fast exchange between compartments.

2.2.9 Magnetic Resonance Spectroscopy (MRS)
When placed in an external magnetic field, nuclei within a molecule experience a
unique magnetic environment based on electron distributions and the presence of
neighboring nuclei. The magnetic properties of nuclei (resonance frequency and relaxation
parameters) depend on the chemical environment in which the nuclei are found. The
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resonance frequency of each nucleus is determined by the effective magnetic field, which is
dependent on the chemical environment and the degree of electron shielding. Since different
nuclei within a molecule experience different degrees of electron shielding from the external
magnetic field (B0), the effective magnetic field of each nucleus (B) is shown in Equation
2.15 where s is a shielding constant.
B = B! (1 − σ)

(Equation 2.15)

The effective magnetic field is more commonly defined by the chemical shift (d) as given by
Equation 2.16 where w is the resonance frequency of the nuclei and wref is the resonance
frequency of a reference compound and is reported in units of ppm.
δ=

K2K/67
K/67

x10L

(Equation 2.16)

When obtaining a spectrum, each of the nuclei within a molecule experience unique
magnetic environments and frequencies where the sample has resonance will absorb more
energy, leading to more RF energy being returned and resulting in peaks in the spectrum.
Unlike in MRI, it is not the tissue water that is being measured, but rather the intensity and
chemical shifts of protons of distinct metabolites. MRS is based on the differences in chemical
shifts of different metabolites, resulting in excellent chemical specificity and allowing for the
study of metabolism in vivo. The area under the peaks in a spectrum is proportional to the
number of nuclei (i.e., concentration of a specific metabolite) and can be split into multiplets
by the interaction of neighboring nuclei (scalar or J coupling). Most metabolites need to have
a concentration of at least 0.5 mM (due to spatial and temporal resolution) for detection by
MRS at 11.7T, but higher concentration (as well as larger volumes from which the signal is
acquired) lead to both higher signal and sensitivity. Due to the lower concentration of
metabolite signals, MRS necessitates a lower spatial resolution in comparison to MRI.
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By far, 1H MRS is most frequently used due to high natural abundance and high
gyromagnetic ratio; however, MRS can be used with any nuclei that has a nuclear spin (e.g.,
31P, 23Na, 19F, 13C, etc.) (Table 2.1). In 1H MRS, the water signal is several orders of magnitude

larger than the signal from metabolites that are trying to be detected, which necessitated
technique development to suppress the water signal. Further, although the chemical shifts
are based on the specific chemical environment of metabolites, many resonances overlap
requiring methods such as using shift reagents, differences in relaxation/diffusion
properties, frequency selective excitation, or scalar coupling to determine which metabolite
corresponds to which peak. Although the integrated area under the resonance in an NMR
spectrum is representative of metabolite concentration, it can be difficult to quantify due to
contributions by difference in T1 and T2 weighting, diffusion, and exchange. To quantify the
NMR signal, a reference standard must be used (internal references being preferred).
Further, most biologic samples are inherently inhomogeneous and the NMR signal will not
be the same throughout the sample. Further, multiple spatial localizations are possible
(similar to how information from the signal can be encoded in space for MRI) by applying
the RF pulse combined with phase encoding gradients in a technique termed magnetic
resonance spectroscopic imaging (MRSI). Together, MRI and MRS are powerful tools for
imaging and quantifying metabolites in tissues and can be adapted to imaging the tumor
microenvironment.

2.3 Magnetic resonance (MR) methods to measure pH
pH-sensitive MR-based methods have been developed to measure areas of acidosis
within tumors. In cancer imaging, pH dependent techniques are of critical importance
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because of the acidic environment and the relationship between acidosis and tumor
invasion. pH has been associated with the ability of tumors to invade the basement
membrane for both local tumor invasion and progression to metastatic disease.84 Given the
importance of pHe in defining the tumor microenvironment, noninvasive imaging of pHe is a
potentially important biomarker of aggressive tumors and monitoring therapeutic response.
A variety of MR methods have been proposed and developed for measuring the pH;
however, different methods are more sensitive to either measures of the intracellular pH
(pHi) or extracellular pH (pHe). While a variety of relaxation and chemical exchange methods
have been studied, MRS and spectroscopic imaging has had more success in quantitative pH
measurements. MRS has decent spatial resolution, is sensitive and specific for measuring pH
in vivo, and is generally based on chemical shift differences between pH dependent and pH
independent resonances. Here, many of the MR methods used to measure pH are discussed,
which also have been recently reviewed.85,86

2.3.1 Relaxivity
Intrinsic relaxation in MRI is not pH dependent. However, MRI relaxation-based
methods to measure extracellular pH have been attempted using lanthanide-based contrast
agents. Clinically used paramagnetic gadolinium agents (Table 2.2) provide contrast;78
however, they do not by themselves provide pH or physiological information. Gadolinium is
frequently used as a T1 contrast agent in MRI as it is the most efficient lanthanide at having
relaxation effects on bulk water, shortening the T1 relaxation time and leading to increased
signal intensity on T1-weighted imaging. Using large Gd3+ complexes incorporating
phosphonate groups, the relaxation effects of the contrast agent can be designed to be pH

47

dependent. The most common chelate with pH sensitivity is 1,4,7,10-tetraazacyclododecane1,4,7,10-tetrakis(acetamido-methylenephosphonic acid) (DOTA-4Amp8-) which has shown
promise. The pH dependence is due to the protonation of the pendant arms of the chelate,
which results in changing effects on relaxation due to the proximity of water molecules to
the paramagnetic metal. Therefore, by measuring the relaxation parameters, the pH can be
determined.87 The pKa of phosphonates are in the physiological range and are therefore
effective for being sensitive to small changes in physiological pH. Further, administered
contrast agents tend to remain extracellular and therefore provide a readout primarily of
pHe.
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Figure 2.2. MRI protocol for relaxivity-based pHe measurement. Calibration is performed to
convert changes in T2 relaxation to contrast agent concentration. The T1 change using a pHsensitive contrast agent is then calibrated using the concentration determined from the
other agent. Using the calibration, in vivo pHe maps are generated as demonstrated in a C6
rodent glioma model. Reproduced with permission.88
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However, methods based on changes in relaxation are technically challenging
because the relaxivity depends on other factors including the agent concentration, making
quantification of pH very difficult as illustrated by Figure 2.2. Therefore, a second agent that
is typically not pH responsive is required to act as a standard and an approach is used where
one agent is used to determine the agent concentration and the other agent is used for the
pH measurement.88,89 Limitations of this approach include the administration of two
contrast agents and assuming that the biodistribution of the two administered agents are the
same. Further, the two agents must be administered serially as relaxation effects from each
agent cannot be detected simultaneously from the same imaging voxel. Since the method is
based on relaxivity changes to the water signal, the sensitivity is higher than other methods
and allows pHe mapping at high spatial resolutions comparable to standard anatomical MRI.
Instead of using two agents, other applications have utilized the pH dependent T1 and
T2 contrasts from the same agent.89 In this case, the pH independent measurement allows
quantification of the contrast agent concentration, while the pH dependent measurement
yields quantification of pH. Other methods have been proposed to account for the
concentration dependence in the relaxivity measurement. Synthesizing Gd-DOTA-4 Amp
derivatives that include a radiotracer (that may be detectable by PET) could be used for
determination of concentration from a single molecule.90 However, this requires access to
combined MRI-PET technology which is not readily available.

2.3.2 CEST
Chemical exchange saturation transfer (CEST) MRI relies on exchangeable protons in
certain molecular functional groups (-OH, -NH, -NH2) in exchange with protons of
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surrounding water molecules. In CEST, a RF saturation pulse is applied at the resonance
frequency of the exchangeable group, nulling the MR signal. As water protons exchange with
this group, the water signal is reduced in a process that is pH dependent and depends on the
exchange rate constant that is specific to each exchangeable group. The pKa of the functional
group will govern the rate of chemical exchange.
Therefore, this measurement relies on the presence of either endogenous or
exogenous molecules that are CEST active. Diamagnetic agents (diaCEST) can be found
naturally and include amino acids and sugars, as well as other organic molecules containing
functional groups with exchangeable protons. Using endogenous contrast holds appeal
because it does not require the administration of a contrast agent. The most common pH
sensitive endogenous pool is found in amide groups and amide proton transfer (APT) has
been used to measure pH.91 However, since this method relies on amide groups found on
amino acids and proteins, it tends to be weighted towards pHi. Further, using a single CEST
contrast is not enough to quantitatively measure pH as CEST contrast does depend on the
concentration of the exchangeable protons. Exogenous diaCEST agents can also be
administered with the most common being ipromide and iopamidol, which are commonly
used contrast agents for other medical imaging modalities, and are pH sensitive.92
Paramagnetic agents (paraCEST) contain lanthanide metals and are based on the
structure of the gadolinium-based contrast agents used clinically.93-95 The benefit of the
paraCEST agents is that the resonance frequency of the exchangeable protons are located far
away from the water peak so there are no competing background effects that must be
considered, leading to greater specificity in the measurements. Agents containing a variety
of paramagnetic metals have been used for this application. ParaCEST agents either have an
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exchangeable proton group or use the exchange of water molecules near the paramagnetic
core of the molecule for CEST contrast. In all cases, the agents are designed so that the
exchange rate is pH sensitive. However, due to the large chemical shift dispersion of the
exchangeable proton groups, high B1 fields are required for saturation and limit their
translation due to tissue heating concerns.
When there are multiple exchange sites, either on the same molecule or in a
combination of two molecules, a ratiometric approach can be utilized to eliminate the
concentration-dependent nature of the pH measurement. A ratiometric approach has been
used with amine and amide proton exchange in a method termed amine/amide
concentration independent detection (AACID) that eliminates the need for quantifying the
contrast agent concentration and allows quantitative pH mapping.96 diaCEST methods using
endogenous contrast is difficult to interpret because it is dependent on amino acid/protein
concentration, which can change in different tissue types and in comparing healthy tissue to
disease states. However, diaCEST methods have promise for clinical translation because they
do not require the administration of contrast agents, have low saturation power
requirements, and are based on readily implementable pulse sequences that are available on
clinical scanners. Therefore, amine and amide proton transfer has been studied on
endogenous pools in glioblastoma and has shown contrast compared to surrounding healthy
tissue; however, absolute pH quantification from these methods remains challenging.
Another concern with exogenous diaCEST agents is the necessity for large concentrations of
the CEST agent (>30 mM) at clinical magnetic field strengths, which may in itself alter the pH
being measured and is not practical for clinical applications. The CEST effect in diaCEST
experiments are also impacted by a variety of other factors including temperature,
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concentrations of ions, and perfusion. Direct saturation of the water resonance as well as
overlap with magnetization transfer from macromolecules also impacts the interpretability
of the measurements. Applications of CEST with both amide groups97 and amine groups on
amino acids98 have been used to measure the pH in tumors, including GBM. Recent
developments with CEST99 and amide proton transfer (APT)100 have also been used as
potential biomarkers of tumor proliferation.

2.3.3 MRS
31P, 19F,

and 1H MRS has been used to detect both endogenous and exogenous

compounds which are generally representative of the intracellular and extracellular pH,
respectively. The compounds used have high pH sensitivity, are metabolically stable, have a
high signal to noise ratio (SNR) with reasonable imaging times, and are non-toxic.
31P

MRS can be used for pH determination since phosphorus is abundant, has a high

sensitivity, and there are many phosphorylated metabolites that can be detected whose
resonances are pH dependent.

31P

MRS was one of the first MR techniques applied for

measuring pH. Specifically, the most easily detected metabolites are Pi, PCr, and ATP and the
intracellular pH can be measured because the difference in chemical shifts between PCr and
Pi is pH dependent.101 However, for measures of pHe, exogenous agents such as 3aminopropyl phosphonates (3-APP) are required.75 3-APP has a pH dependent chemical shift
and since the agent remains extracellular, reports on pHe. Together, these methods have
allowed for quantification of the pH gradient (pHi-pHe).
19F

MRS can also be used for direct detection of 19F containing exogenous MR probes.

19F MRS is promising due to the 100% natural abundance of 19F and little to none endogenous
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19F

background signal. These properties result in specific detection and relatively high SNR

allowing pH measurement with higher sensitivity and less compartment artifacts than 31P
MRS. Exogenous fluorinated vitamin B6 derivatives are commonly used as pH probes and
interestingly, these compounds insert into cell membranes and are able to report on both
the intracellular and extracellular environments, allowing the intracellular-extracellular pH
gradient to be determined.102 Other fluoroaniline sulfonamide agents have been used for pHe
measurement where the chemical shifts of the

19F

resonances are pH dependent.103 Like

other MRS techniques, the sensitivity is low and requires delivery of a sufficient
concentration of the agent to the tumor (mM range). These agents do not have specific
uptake in tumors, requiring larger doses of the administered agent and suffer from some of
the agents not being stable under physiological conditions. Further, MRS with any non-1H
nuclei, requires specialized equipment that is not always readily available.
1H

MRS is the most commonly used MRS isotope and is useful because of its higher

sensitivity, improved spatial resolution and shorter imaging times and is available in most
MR scanners for readily available implementation. 1H has a very high natural abundance and
is found in high concentrations in the physiological environment, primarily in water and fat
but also in nearly all metabolites. Many of these metabolites are present in the mM
concentration necessary for detection and can be detected directly. However, no detectable
endogenous 1H MRS signal is inherently pH sensitive. Although in vivo measures of histidine
have been attempted due to the presence of multiple pH sensitive resonances,
concentrations are too low for accurate pH quantification requiring supplementing the
signal with administered histidine, which complicates the measurement as the pH measured
is an average of pHe and pHi.104 Therefore, pH measurements with 1H MRS requires
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exogenous imidazoles to be used as pH probes.105 Other agents such as 2-imiadazole-1-yl-3ethoxycarbonyl propionic acid (IEPA) have a pH sensitive resonance that does not overlap
with endogenous signals, localizes in the extracellular space, can be detected with 1H MRS
and provides a measure of pHe.106
Hyperpolarized 13C MRS has also been used for pH measurements using a variety of
different administered substrates.107-109 Dynamic nuclear polarization involves changing the
distribution of magnetic spins so that there is a greater difference in spins between two
states, increasing the sensitivity of NMR. This has most commonly been done with

13C

by

using microwave irradiation to transfer magnetization from electrons to adjacent nuclei at
extremely low temperatures (1-4 K). Although hyperpolarization can lead to several orders
of magnitude increase in sensitivity, the hyperpolarization is quickly lost at higher
temperatures with T1 relaxation times of less than 1 min. Therefore, the hyperpolarizer must
be located immediately adjacent to the MR scanner and must be administered immediately
after being formed, and then imaged immediately after being injected. Even under ideal
circumstances, the timing of these events means that the actual sensitivity gain in the actual
scan is much lower. A variety of substrates have been used including 13C-labeled zuymonic
acid, bicarbonate, or lactate. These measures again tend to be a weighted average of pHe and
pHi as the substrates can freely cross cell membranes.

2.3.4 BIRDS
An expansion and more recent application of an MRSI technique is Biosensor Imaging
of Redundant Deviation in Shifts (BIRDS), which exploits the pH-dependent chemical shifts
of the non-exchangeable protons on lanthanide chelates. Instead of using relaxivity
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differences (which are inherently concentration dependent), this technique expands the use
of lanthanide contrast agents, similar to those used for enhancing MRI contrast, by using MRS
and chemical shift imaging to directly measure the chemical shifts emanating from protons
on the contrast agent itself. Because the pH dependence is based on the chemical shift (and
not relaxivity), the pH readout is not concentration dependent. Thulium (Tm3+) based agents
have the highest pH sensitivity and are therefore frequently used because they can give pH
readouts with lower concentrations of the agent.110 Additionally, by modifying the chelate to
include an amino group, the contrast agent can have both CEST and BIRDS properties,
allowing added redundancy for measuring pH.111,112 The BIRDS methodology is discussed in
much greater detail in Chapter 3.

2.4 Other pH imaging methods
In addition to the MRI/MRS based methods for measuring pH, it should be mentioned
that a variety of other techniques have been utilized for imaging acidosis in cancer.
2.4.1 Direct electrode recordings
pH electrodes work by using a H+-selective glass electrode to measure the
concentration of H+ ions and convert into a pH value on a logarithmic scale. pH electrodes
can be inserted directly into tumors to measure the pH; however, this is a highly invasive
procedure and each recording involves a new insertion requiring many recordings to
spatially map pH. Although these may be considered the gold standard because it can be
externally calibrated using solutions of known pH, likely these measurements are a weighted
average of the intracellular and extracellular environment as they rupture the cells upon
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insertion. Due to the need to directly insert the electrode, tumors just under the skin are the
most suitable to this kind of approach and has been applied in the study of melanoma.

2.4.2 Optical imaging methods
Optical imaging methods are based on using pH dependent fluorescent molecules
which can be detected using microscopy methods. Optical methods allow for rapid
measurement with high temporal resolution and very high spatial resolution. However, the
optical methods are usually limited in their FOV such that only part of the tumor or
surrounding tissue can be imaged at a time and have very poor depth penetration such that
only excised tissue or surface tumors right under the skin can be studied.
There are a variety of optical imaging probes that are responsive to pH. For example,
pHLIP proteins insert into cellular membranes only at low pH (normally <6.5).113,114
Therefore, these proteins can be targeted to solid tumors where the pH is low. The pHLIP
proteins are fluorescent and with fluorescent imaging, regions of low pH can be identified;
however, these methods typically do not result in quantitative pH values, but only
demonstrate if the pH is below a threshold value which is dependent on the properties of the
pHLIP protein. In another optical technique termed fluorescence ratio imaging microscopy
(FRIM), a single fluorophore is detected at two different emission wavelengths, such that the
concentration of the fluorophore is not needed for quantification. the pH is determined by
measuring the fluorescence at two different wavelengths. This normalizes for the
concentration of the fluorophore as well as differences in the acquisition parameters (such
as intensity). In a similar approach, semi-napthorhodafluorescin-1 (SNARF-1) can be used
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due to its pH dependent emission spectra and by measuring fluorescence at two different
wavelengths can yield concentration-independent pH measurements.6
Some limitations of these methods are the autofluorescence of tissues and quenching
of the fluorescent signal in deeper tissues. Further, fluorescent probes need to have pKa
values in the physiological range, which can be challenging as many of them have maximum
pH sensitivities at much higher pH values. Benefits include that they are less invasive than
pH electrodes, provide high spatial resolution of pH mapping, can be optimized to measure
the pHe or pHi depending on the fluorophore chosen, and are very sensitive such that only
very low concentrations of the fluorophore are needed for detection.

2.4.3 Positron emission tomography
Positron emission tomography (PET) relies on the administration of small doses of
radioactive isotopes (radiotracers) conjugated to molecules designed to target specific
physiological targets in the body and is used as a molecular imaging tool.115 The radioactivity
is localized using the decay properties of the radiotracer and regions of radiotracer
accumulation are identified. PET is performed routinely clinically using the

18F-

fluorodeoxyglucose (18FDG) tracer, which detects upregulation of glucose uptake as a proxy
for increased glycolytic metabolism, in cancer.116 Although PET is very sensitive, allowing
detection of small amounts (nM) of the radiotracer, PET has lower spatial resolution, on the
order of 2-3 mm clinically, due to the nature of the detected signal.
pH sensitive PET tracers have also been developed. Although initial attempts using
the pH-dependent ionization of radiotracers were unable to detect acidification in tumors,117
current approaches involve radiotracers that have been conjugated to pH low insertion
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peptides (pHLIP) similar to those use for the optical methods described previously.
Detection of these proteins that insert into the cell membranes in a pH-dependent manner
have been successfully used to identify acidosis in tumors.114,118,119 However, due to the
sigmoidal nature of peptide insertion, these methods are generally non-quantitative and can
only be used to determine if the pH is below a threshold value similar to their optical
counterparts. Recently,

18FDG

has been synthesized to be in a molecular “cage” using a

glycosylamine linkage that is released in a pH-sensitive manner under acidic conditions,120
demonstrating acidic conditions in tumors which can be increased through systemic
bicarbonate administration. While promising, the PET methods are unable to provide
absolute quantification of pH and suffer from lower spatial resolution, making studying pH
gradients in tumors challenging.

2.5 Applications to cancer imaging
In cancer imaging, these methods have repeatedly demonstrated that pHe is acidic,
with a corresponding alkalinization of pHi, in many tumor types and can be spatially
heterogeneous. The pH gradient between the intratumoral and peritumoral environment
can be used as a marker of tumor invasion into surrounding tissue as more invasive tumors
have acidic pH that spreads beyond the tumor boundary. Further, through the combination
of different imaging methods, pHe can be compared to aid in the confidence of the
measurements as well as compare to other measures that are expected in acidic
environments, such as a correlation with increased lactate levels from 1H MRS. However,
each imaging modality comes with differences in the spatial resolution achievable, the need
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for the administration of exogenous agents, and the ability of the method to yield a
quantitative pH value.
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Chapter 3: Methodological descriptions of BIRDS for molecular imaging
of pH and temperature

3.1 Abstract
Biosensor Imaging of Redundant Deviation in Shifts (BIRDS) is a magnetic resonance
spectroscopic imaging (MRSI) technique that relies on the temperature and pH-dependent
chemical shifts of non-exchangeable protons on lanthanide-containing paramagnetic
contrast agents. pH and temperature are physiologically relevant parameters with many
medical applications. As discussed in Chapters 1 and 2, an acidic extracellular space is a
hallmark of the tumor microenvironment, where acidosis has been postulated to promote
the aggressive and invasive characteristics of tumors and also inhibit the therapeutic
response. Therapeutic hypothermia has applications in cerebral ischemia and traumatic
brain injury (TBI) where temperature measurements are needed to evaluate efficacy of
neuroprotective procedures. Therefore, an imaging method such as BIRDS that allows for
quantitative and spatial pH and temperature mapping is highly desirable.
Here we describe the development and implementation of BIRDS in the context of
evaluating the acidic pHe in glioblastoma models in rodents in small-bore 11.7T clinical
scanners, where acidic pHe represents tumor invasion in untreated tumors. Since there are
no other tomographic pHe mapping methods and directly altering pHe is difficult to
implement, we looked to assess the quantitative BIRDS-based temperature readout, which
could be compared against direct temperature recordings, in a hypothermia model because
temperature is much more easily altered than is pH. Selective brain cooling using an
innovative cerebrospinal fluid (CSF) cooling platform was used to induce hypothermia in the
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brain. Temperature mapping of healthy sheep brain in wide-bore 7.0T clinical scanners
provided dynamic temperature measurements from the whole brain. The brain temperature
decreased significantly with cooling over all defined brain regions to levels known to be
neuroprotective, while maintaining systemic normothermia, and was in agreement with
thermocouple measurements. Rapid and synchronized temperature fall/rise upon cooling
onset/offset was observed reproducibly such that dynamic thermal mapping can provide
high spatiotemporal temperature measurements to aid in optimizing selective
neuroprotective protocols. All temperature mapping work in this chapter has been
previously published and is used with permission.121

3.2 Introduction to BIRDS
An acidic microenvironment is a hallmark of most solid tumors due to a metabolic
shift towards glycolysis even in the presence of oxygen (Warburg effect) and immature
vasculature that does not permit the clearance of waste products.41 The reduced
extracellular pH (pHe) has been associated with promoting tumor cell proliferation and
promoting angiogenesis and invasion5,122-124 as well as creating an immunosuppressive
environment.33,125 Further, the low pHe leads to a poor response to many therapies,7 and
neutralization of pHe has been proposed as an effective therapeutic strategy.126,127 Given the
important contribution of extracellular acidosis to shaping the tumor microenvironment, it
would be desirable to be able to quantitatively and spatially map pHe for evaluating the
metabolic state of the tumor and how metabolism changes during tumor growth and
response to therapy.
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Here we describe a magnetic resonance spectroscopic imaging (MRSI) technique
termed Biosensor Imaging of Redundant Deviation in Shifts (BIRDS) which exploits the pH
and temperature based dependent chemical shifts of non-exchangeable protons on
lanthanide-based contrast agents for quantitative pH (and temperature) measurements.
While there are other methods that have been developed for organ-wide absolute pH
tomographical measurement, there are several assumptions of which to be aware when
comparing pH readouts across different modalities as discussed in Chapter 2. First, some
methods are weighted more towards extracellular pH, while others are weighted more
towards intracellular pH. 31P magnetic resonance spectroscopy (MRS) is the gold standard
for quantitative pH measurement; however, this method is heavily weighted towards
intracellular pH because the readout is dependent on inorganic phosphate and
phosphocreatine.75,128 Further, the reduced sensitivity of

31P

necessitates large imaging

volumes, decreasing the spatial resolution achievable. Many magnetic resonance imaging
(MRI) methods are available for pH readout. A variety of chemical exchange saturation
transfer (CEST) techniques have also been proposed for quantitative pH mapping.91,129-131
The CEST readout exploits the MRI detectable exchange between protons in dilute pools (of
hydroxyl, amide, or amine protons in various endogenous or exogenous molecules, both
small and large) and bulk water. However, the diamagnetic CEST contrast using endogenous
exchangeable pools is heavily influenced by protein concentration and a variety of other
physiological factors making quantification difficult. Additionally, many of these methods
rely on knowledge of the contrast agent concentration for pH quantification, which is difficult
to measure in in vivo applications. There are also paramagnetic CEST agents that can provide
simultaneous temperature and pH measurements.132 Finally, there has been success using
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MRS detection of hyperpolarized 13C substrates (e.g., lactate, bicarbonate) that have led to
quantitative extracellular pH measurements. But caution must be used with hyperpolarized
13C

MRS since these small molecules easily cross cell membranes.
However, BIRDS is a unique method that achieves higher spatial resolution pH

measurements by exploiting the higher sensitivity of 1H MRI with the specificity of 1H MRS.
As explained below, due to several unusual features of BIRDS agents, the 1H MRSI data
acquisition is acquired at ultra-high speed but with little compromise of MRI-like spatial
voxel sizes.
Contrast agents used for BIRDS are based on the macrocyclic structure used in
commercially available gadolinium-based contrast agents. The pendant arms of these
molecules can be optimized to allow for greater specificity in measuring the physiological
parameter of interest (e.g., pH or temperature). For example, the contrast agent TmDOTMAis a carboxylate that only exhibits temperature dependence, whereas TmDOTP5- is a
phosphonate that gives pH sensitivity (in addition to temperature). While many
paramagnetic metal ions can be complexed to the different chelates, Tm3+ containing
compounds have shown the largest hyperfine shifts of their 1H resonances, which provide
higher specificity for temperature and pH readouts.
Additionally, since BIRDS specifically detects the proton resonances and the chemical
shift is the measured property, as opposed to their effects on water relaxation, the BIRDS
readout of pH is concentration-independent. The hyperfine shifted resonances of the
detected resonances are diverted far from water (-140ppm, 60ppm, and 80ppm in
TmDOTP5-) so that there is no overlap with any intrinsic metabolites, increasing the
specificity of the measurement. Further, due to the presence of multiple detected proton
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resonances that shift in different directions with changing pH and temperature, the
measurement is redundant and allows for simultaneous quantification of both pH and
temperature.
The chemical shift of each chelate proton resonance depends on the spatial location
of that proton in relaxation to the paramagnetic ion, which also affects the temperature and
pH dependencies of each proton resonance. Protons that are closer in proximity to the
paramagnetic ion will have resonances that are farther shifted away from the water peak
due to changes in the effective magnetic field experienced. In vitro calibrations of the pH and
temperature dependence of the chemical shifts are conducted under a variety of conditions
to demonstrate the reliability of the pH calibration that is applied in vivo. The method also
allows for complete three-dimensional acquisition over the entire tissue or organ of interest
because of the extremely shortened relaxation times of these resonances,133 and since the
contrast agents remain extracellular, the measurements are weighted towards the
extracellular compartment.134
Due to the presence of the paramagnetic metal, both the longitudinal (T1) and
transverse (T2) relaxation times are extremely short (<5ms) allowing for fast averaging and
insensitivity to shim and magnetic field inhomogeneities. Moreover, because the √(T2/T1) of
the BIRDS readout is high, the measurement is quite stable across magnetic field strengths.
The paramagnetic nature of these agents also provides T2 contrast that can be used for
relaxation-weighted MRI and some versions of these molecules include exchangeable
protons which can also be used for paramagnetic CEST applications.132
BIRDS is limited by the signal to noise ratio (SNR) such that a sufficient concentration
of the agent (>1mM) must accumulate in the tissue of interest for adequate sensitivity to
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accurately make the pH or temperature measurement. In tumors, leaky vasculature allows
the agent to accumulate to a sufficient degree; however surrounding tissue may have low
agent concentrations. The concentration of the contrast agent can be increased by reducing
the clearance of the agent through surgical or pharmacologic renal inhibition. For
applications involving novel contrast agents and advanced imaging methods, animal models
must be used. To pre-clinically evaluate BIRDS, orthotopic xenograft models of glioblastoma
(GBM) are beneficial because they resemble human tumors and allow for the invasion of the
tumor into the surrounding tissue. A variety of tumor models22,25 have been used in this
regard including the 9L and RG2 models that are used in immunocompetent Fisher rats as
well as the human-derived U87 and U251 models in Athymic/Nude rats. With this
background of the rational for BIRDS pHe and temperature mapping, the methodology and
technicalities will be discussed for performing BIRDS on preclinical tumor models. The
methods will reflect the in vitro calibration of BIRDS and its application to the in vivo
measurement of pHe in the tumor microenvironment. BIRDS was also further developed into
a longitudinal pHe mapping platform to allow for evaluation in changes in the metabolic
features of the tumor microenvironment during tumor progression. While all initial
development of BIRDS was performed on animals with renal ligation to increase the
concentration of agent in the surrounding tissue, longitudinal measurements using BIRDS
can be achieved by temporarily inhibiting renal clearance using probenecid.135
Since there are no other tomographic pHe mapping methods to compare with BIRDSreadout of pHe and directly altering pHe at a systemic or local level is difficult to implement,
we evaluate BIRDS temperature mapping because temperature is much more easily altered
using cooling methods and can be compared against direct temperature electrode
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recordings. We then demonstrate the BIRDS method in a hypothermia model in sheep. While
although a different application, these measurements demonstrate the dynamic and
sensitive nature of the temperature measurements and their accuracy against previously
recorded temperature measurements in the same model system.

3.3 Methods for tumor pHe mapping
3.3.1 Characterization of temperature and pH sensitivity in BIRDS
A

database

of

thulium

(III)

1,4,7,10-tetraazacyclododecane-1,4,7,10-

tetra(methylenephosphonate) (TmDOTP5-; Macrocyclics) samples are needed to construct
the pH and temperature calibration curves in vitro which can then be applied for in vivo
analysis. The characterization is performed at various temperatures and pH values. All data
were acquired on a 11.7T (500 MHz) vertical bore magnet (Bruker) with temperature
control. Samples of 10 mM TmDOTP5- in DI H2O were prepared in NMR tubes (Wilmad Lab
Glass). To each sample, 10% by volume deuterium oxide (D2O; Sigma) was added along with
3 mM trimethylsilylpropanoic acid (TSP; Sigma) as a chemical shift standard. Seven samples
were prepared over the physiological pH range (6-8). The pH of each sample was measured
using a pH meter and the pH of each sample was adjusted using small volumes of dilute
Hydrochloric acid (HCl; Sigma) or Sodium hydroxide (NaOH; Sigma). For each pH value, data
were acquired over a range of temperatures (30-40 °C).
Spectra for each sample were acquired, line broadened (50 Hz) and baseline and
phase corrected. The chemical shift of each proton resonance (H2, H3, H6) was measured
(Figure 3.1). Chemical shift data for each proton resonance were plotted in 3D against both
temperature and pH and the temperature and pH sensitivity were then quantified by fitting
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the data to a 2nd order polynomial. The calibration is based on the difference in chemical
shifts between sets of proton resonances.134 For the best accuracy, the average of
temperature and pH calibrations from two sets of proton resonances are used as shown in
Equation 3.1 and Equation 3.2. The difference in the H2 and H6 chemical shifts (x=H2,
y=H6 in the following equations) and the difference in the H3 and H6 (x=H3, y=H6) chemical
shifts are used for calibration where the constants ai and bi are from a multi-parametric nonlinear least squares fit.
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The pH and temperature dependencies of TmDOTP5- that are used in the calibration for in
vivo experiments are shown in Figure 3.1.
To account for the impact of other ions or proteins in the blood on the chemical shift,
the calibration is also validated in the presence of different physiological concentrations of
ions (Na+, K+, etc.) and in the presence of proteins (BSA, blood, etc.). Similar samples were
prepared by varying the concentration of different ionic salts by adding sodium chloride
(NaCl; Sigma), potassium chloride (KCl; Sigma) or calcium chloride (CaCl2; Sigma). The ionic
concentrations were varied over the physiologic range with Na+ (130-150 mM), K+ (5-10
mM), and Ca2+ (0-4 mM). For completeness, the calibration can be repeated by dissolving
TmDOTP5- in PBS, 4% BSA, or blood plasma. While Na+ and K+ concentrations were not found
to influence the chemical shifts or the resulting calibration, Ca2+ does have an effect.
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Since Ca2+ does influence the chemical shifts, an in vivo concentration for Ca2+ is
assumed to be 1 mM for applications of the calibration.134 Using the calibration curve yields
spatial pH maps in vivo that are representative of the extracellular pH (pHe) as the contrast
agent does not cross the cell membrane and therefore only reports on the extracellular
environment. However, in the brain, the agent is located in interstitial, vascular, and CSF
spaces and the pH reported will be a volume-weighted average of the pH in the voxel.
Different contrast agents can be used with the BIRDS method, such as TmDOTMA-, which
only has chemical shift sensitivity to changing temperature.136 However, any reporter
molecule requires the same extensive characterization, calibration, and validation before
use, but the general method is adaptable to a variety of chemical moieties that each have
different reporter properties.
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Figure 3.1. In vitro characterization of TmDOTP5- for temperature and pHe measurements.
Chemical structure and NMR spectrum of 10 mM TmDOTP5- acquired at 11.7 T (A).
Temperature and pH dependence of the H2 (B), H3 (C), and H6 (D) proton chemical shifts.
The sample contained 4 mM TmDOTP5- with 1 mM CaCl2 and 3 mM TSP for reference. The
3D plots show the best fit of the chemical shifts for each proton resonance as a function of
pH and temperature. Reproduced with permission.134

70

3.3.2 Animal preparation for in vivo tumor studies
Most solid tumors maintain an acidic pHe; however, the degree of acidosis can vary
based on primary tumor site and type.133,137 Here a glioblastoma (GBM) model is used as a
representative tumor. Although GBMs in the brain come with a variety of limitations
regarding access, tumor size monitoring, and drug delivery due to the presence of the bloodbrain barrier, the benefit is that the head is not prone to respiratory or other motion,
eliminating this concern from the imaging experiments. Another consideration is the growth
characteristics of the tumor. Tumors that are highly infiltrative before forming a mass may
lead to symptom development prior to a large tumor developing. Less infiltrative tumors,
although less representative, provide the benefit of becoming larger allowing better contrast
agent or drug delivery. U87 and U251 are both human-derived GBM cell lines that can be
intracranially injected in athymic mice or rats. Both of these tumor types result in a disrupted
blood brain barrier, which allows contrast agents/drugs to pass into the tumor. However,
for any sort of longitudinal scanning, the tumors may have to be initially imaged when the
tumors are smaller.
The following procedures are used for generating U87 or U251 tumor xenografts in
the brain of athymic/nude rats. Note that a variety of different cell lines (e.g., 9L, RG2, etc.)
as well as patient derived xenografts (PDX) have been reported in the literature and can be
used with cell-specific culture and injection protocols in both mice and rats.22 All animal
protocols and procedures are approved by the Yale University Animal Care and Use
Committee. Animals are maintained in an animal facility maintained by the Yale Animal
Resources Center.
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U87 and U251 cells were acquired from the American Type Culture Collection (ATCC).
Cells are maintained in T75 flasks containing culture media supplemented with 10% fetal
bovine serum (FBS) and 100 units/mL penicillin and 100 µg/mL streptomycin. U87 cells are
maintained in 10 mL of supplemented high-glucose (4.5 g/L) Dulbecco’s modified eagle
medium (DMEM), while U251 cells are maintained in 15mL low-glucose DMEM (Gibco). All
cells are maintained in an incubator at 37 °C and 5% CO2 atmosphere.
On day of intracranial injection, U87 or U251 cells are harvested from culture at high
confluence (>70%). Cells are resuspended in serum-free DMEM at a concentration of 40,000
cells/µL for U87 and 100,000 cells/ µL for after a manual cell count using a hemocytometer.
A total of 5 µL of the cell suspension is loaded into a 10 µL syringe (Hamilton) connected to
a 26G beveled needle, which is used with a microinjector (Micro4, World Precision
Instruments) system.
Athymic/ nude rats (Envigo) are anesthetized with isoflurane (2-3%) and provided
appropriate pre-emptive analgesia (buprenorphine, 0.05 mg/kg). The animal head is shaved,
sanitized using washed of betadine and 70% ethanol, and positioned in a stereotactic holder
(Kopf Instruments). The scalp is opened by making a 2-3 cm incision using a scalpel and then
using two pairs of hemostats to hold the skin back to expose the skull where the bregma is
visually identified. A drill is positioned directly over the bregma and then moved 3 mm to
the right. The drill is turned on and lowered until the tip of the drill just penetrates through
the skull, before being turned off and raised. The needle and microinjector syringe containing
the cell suspension is positioned over the burr hole. The needle is lowered 3.5 mm into the
cortex and then raised 0.5 mm. The 5 µL cell suspension is then injected at a rate of 1 µL/min
after which the needle is left in place for 5 min before slowing withdrawing the needle (0.5
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mm/min). The burr hole is then sealed with bone wax, the incision is closed with sutures,
and the incision site is sanitized. The animal is removed from the stereotactic holder and
placed in a clean cage on a heating pad until the animal recovers from anesthesia. Postsurgical analgesia (carprofen, 5 mg/kg and buprenorphine 0.05 mg/kg) is continued for 48
hours. The animal is monitored daily for changes in body weight or any signs of neurological
symptoms.

3.3.3 Animal setup for magnetic resonance imaging/spectroscopy experiments
The animal is anesthetized with 2-3% isoflurane in O2 in an induction chamber prior
to transferring the animal to a heating pad on the bench. Since the imaging procedures
require the intravenous administration of contrast agents, a tail vein catheterization is
performed. A needle attached to PE10 (Braintree Scientific) line filled with heparinized
saline is inserted into the lateral tail vein (either right or left) and secured to the tail with
tape. The functionality of the infusion line is verified by drawing blood back into the line and
confirm that there is no resistance when pushing ~100 µL of heparinized saline.
The animal is then placed on a custom-made rat holder with a nose cone that allows
for gas (1.5% isoflurane anesthesia) delivery. The head is centered, making sure that it is
relaxed and flat, and held in place with small foam pieces to prevent animal motion during
the imaging scan. Ointment is applied to the animal’s eyes to prevent drying. After
positioning the animal in the animal holder, the animal is positioned under a 1.5cm diameter
RF surface coil.
Animal monitoring during the experiment is important since in small bore animal MR
scanners, the animal is not visible during the experiment. In particular, respiratory
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monitoring is essential to monitoring depth of isoflurane anesthesia. Respiratory monitoring
is conducted by placing a pneumatic pillow under the chest of the animal, which is integrated
with animal monitoring software (Small Animal Instruments). For sufficient anesthesia
throughout the experiment, the respiratory rate should be maintained between 30-60
breaths per minute.
Additionally, maintaining animal body temperature is also vital. Animals under
anesthesia naturally have a decrease in core body temperature that may result in delayed
recovery after a survival experiment or possibly even death. Warm water is circulated from
a water bath, maintained at 44-48 °C, through a warming pad that is placed on top of the
animal to maintain body temperature around 37 °C. For athymic rats (or other animals
without fur), a paper towel should be placed between the animal and the heating pad so as
to prevent burns on the skin. The temperature is monitored using a rectal optical
thermocouple probe.

3.3.4 Contrast Agent Preparation
Prior to the start of imaging, the contrast agents used for BIRDS, such as TmDOTP5-,
are prepared. However, these agents are cleared by the kidney relatively quickly, similar to
the clinically used gadolinium contrast agents.78 To increase the circulation time of the
agents, renal clearance needs to be decreased. In terminal experiments, this can be done
directly by renal ligation, resulting in near zero clearance of the agent throughout the
duration of the experiment. However, for experiments necessitating longitudinal imaging, a
nonsurgical approach must be used. This can be achieved by using probenecid, an organic
anion transporter inhibitor, which is used to temporarily pharmacologically inhibit the renal
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clearance of the agent.138-140 We find that a predose of the probenecid prior to the start of the
contrast agent infusion along with an additional coinfusion while administering the agent
leads to the greatest increase in agent concentration.135 Note that the concentration of the
agent within the contrast-enhancing region of the tumor is largely unaffected by these
strategies as the blood brain barrier is compromised within the tumor and the agent is
delivered to the tumor even without renal inhibition. However, the contrast agent in the
brain is greatly reduced without methods to decrease renal clearance.
A stock solution of probenecid (Sigma) is prepared at a concentration of 100 mg/mL
by dissolving probenecid in 0.5 M NaOH. The pH of the solution is measured using a pH
meter, and then adjusted down to 7.4 by the addition of saturated KH2PO4 (Sigma). A single
dose (1.5 mL) of TmDOTP5- (Macrocyclics) is prepared fresh before each experiment based
on the individual animal weight (1 mmol/kg). The volume of the dose, as opposed to the
concentration, is fixed during preparation since the infusion is planned for a set amount of
time. The amount of TmDOTP5- needed is the animal weight in kg multiplied by the molecular
weight of TmDOTP5- (914.2 g/mol). To this solution, 100 mg/kg probenecid is added (using
the probenecid stock solution the volume added in µL is equal to the animal weight in grams).
The volume of the solution is then brought up to 1.5 mL and is vortexed until there are no
signs of any particulate in the solution.
To perform the contrast agent infusion during imaging, a PE10 line that has been
flushed with saline from a syringe pump is run to the bore of the magnet and connected to
the tail vein catheter. First, a 100 mg/kg predose of probenecid is infused over 10 min with
the rate set by the infusion volume. For example, if 250 µL of probenecid solution needs to
be infused, the syringe pump rate is set at 25 µL/min. At the end of the infusion, the infusion
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line is disconnected from the tail vein catheter and flushed with saline. After a 20 min waiting
period to allow the probenecid to take effect, the infusion of the TmDOTP5- and probenecid
solution is begun at a rate of 15 µL/min for a total infusion time of 100 min. The initial
infusion of TmDOTP5- must be performed slowly to monitor animal physiology; however,
after an initial period (usually ~30 min), the injection can be sped up in order to reduce the
infusion time. The rate of infusion should be decreased if any changes in animal physiology
(respiratory rate) is observed; however, an increase in the respiratory rate is usually seen
during the beginning of agent infusion.

3.3.5 MRI and BIRDS Acquisition
All data is acquired on a high-field, horizontal-bore small animal MRI scanner. All
experiments were either performed on an 11.7T Bruker scanner (21cm bore size, amplifier
with peak power of 500 W, and gradient system with 400 mT/m maximum amplitude, 150
µs rise time) or a 9.4 T Bruker scanner (16cm bore size, amplifier with peak power of 500
W, and gradient system with 500 mT/m maximum amplitude, 180 us rise time). An RF coil
setup is required for acquiring MR and BIRDS data. A small (1.5cm) single loop surface coil
tuned to 500 MHz (1H resonant frequency at 11.7 T) is used for BIRDS experiments. The
surface coil diameter must be large enough to allow coverage of the entire tissue of interest
(e.g., brain); however, the diameter must be kept small enough to allow efficient RF power
transfer yielding high SNR.
The animal holder and RF coil are slid into the magnet bore and the animal is
positioned in a straight position in the isocenter. All details provided are for a Bruker scanner
running ParaVision 5 or higher. Prior to the start of imaging, the RF coil is tuned and matched
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to the acquisition frequency. A fast low angle shot (FLASH) sequence is performed to obtain
scout images in three perpendicular imaging planes to serve as a fast localizer scan to
position the animal in the center of the imaging field of view (FOV). Next a rapid acquisition
with relaxation enhancement (RARE) sequence is performed where the power, shim,
frequency offset, and receiver gain are optimized using automated setup features in
Paravision. A point resolved spectroscopy (PRESS) sequence is used for second-order
shimming over an ellipsoid ROI using the B0 map and the MapShim feature in Paravision.
Once all setup is complete, the imaging experiments can begin and can vary based on which
contrasts are desired. For BIRDS experiments for pH imaging, an anatomical image and
spectroscopic imaging (MRSI) sequence must be acquired at a minimum.
A T2-weighted multi-slice spin echo sequence (MSME) is performed to generate
anatomical images as well as quantitative T2 maps (Figure 3.2B). Imaging parameters
include a repetition time (TR) of 6 s and equally spaced echo times (TE) ranging from 10 to
100 ms. It is important that the FOV (25x25 mm) is the same for the anatomical imaging
scans as well as for BIRDS to allow for easy coregistration between the two methods. Further,
the slice thickness of the anatomical scans should be chosen to match the resolution of the
BIRDS scans. A slice thickness of 1 mm is used for the anatomical imaging and a resolution
of 1x1x1 mm3 for the 3D MRSI. Although the in-plane resolution will differ, the slices can
easily be aligned. If needed, a 3D FLASH sequence at reasonable isotropic resolution can be
performed for anatomical coregistration (Figure 3.2A). Coregistration is important for
longitudinal studies where the same animal is to be scanned on multiple occasions and also
if other imaging sequences (e.g., DCE, CEST, etc.) necessitating different coil setups are
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performed on the same animal and the animal must be removed from the bore and
repositioned.
After all MRI is performed and prior to the start of BIRDS, the contrast agent infusion
is started (see section 3.4). After 30 min of TmDOTP5- infusion, global spectroscopy scans
optimized to the chemical shifts of the paramagnetic resonances of TmDOTP5- can be
performed to ensure that the three resonances of TmDOTP5- are visible (see Figure 3.1). A
peak with high SNR at the expected chemical shifts confirms that the infusion of agent was
successful, although it does not confirm specifically the location of the agent within the FOV.
While continuing the agent infusion, these scans are repeated until adequate SNR has been
achieved, usually after 45 min (Figure 3.2D). If no signal is detected, the infusion has likely
failed and the tail vein line will need to be repositioned in either a more proximal location
up the tail or using the other lateral tail vein. Once the first MRSI scan is complete, spectra
should be visualized to ensure that acquisition was successful.
Once sufficient agent has accumulated, as evident in the global spectroscopy scans,
the 3D MRSI scan optimized for BIRDS with TmDOTP5- is performed. The sequence utilizes a
dual-band Shinnar-Le Roux (SLR) RF pulse with duration 205 µs, bandwidth of 40,000 Hz
and power of 150 W. The offset of the pulse is -19,800 Hz at 11.7T to ensure that all three
proton resonances of TmDOTP5- are excited. The RF pulse has a short duration and very wide
bandwidth, but with a null in the middle (minimizing excitation of the water peak).
Therefore, the bandwidth of the pulse must cover the chemical shift range where the three
proton resonances are expected so that all three resonances can be excited during the same
scan. The offset of the pulse must be chosen so that the dual bands cover this chemical shift
range. The pulse power must also be optimized to achieve as close to a 90° pulse possible, as
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this would lead to the highest SNR. Due to the bandwidth. the required power tends to be
high and as such, a small surface RF coil is needed for efficient power transfer during
excitation. Other acquisition parameters include a TE of 285 µs and a TR of 5 ms. The
paramagnetic agents used for BIRDS have incredibly short T1 and T2 relaxation times (<2
ms). Therefore, the TR of the MRSI experiment must be extremely short (<5 ms) to have
adequate SNR. This also necessitates that no additional features or modifications to the pulse
sequence are possible. However, the very short TR does allow for extensive averaging. These
experiments are normally acquired in ~18-20 min depending on the number of averages
(~120-170 averages) and spherical encoding factor (usually 0.55), and are repeated
continuously throughout the duration of the agent infusion. During data analysis, the signal
from multiple experiments can be summed to increase the SNR further.
At the end of the contrast agent infusion and the BIRDS scans, the global MRS scan is
repeated to confirm that the agent concentration has continued to increase throughout the
experiment (See Figure 3.2D). The spin echo MRI sequence for T2 mapping is also repeated.
TmDOTP5- acts predominately as a T2 contrast agent, which can be seen as signal darkening
in the tumor upon administration of the agent (See Figure 3.2C). The contrast agent
concentration can be estimated in multiple ways. The transverse (r2) relaxivity of the agent
can be measured at the given field strength and the T2 values measured before and after
administration of the agent along with the known r2 relaxivity, allows a voxel scale
estimation of the contrast agent concentration.
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Figure 3.2. Example of in vivo imaging of U87 tumors in rat brain with administration of the
contrast agent TmDOTP5-. A high-resolution 3D FLASH sequence is performed for
coregistration (A). The image can be reconstructed in any orientation (axial reconstruction
shown). Coronal anatomical T2-weighted images (TE: 30 ms, TR: 6 s) and quantitative T2
maps are acquired before and after administration of TmDOTP5- (B). Signal darkening in the
T2 weighted images and a reduction in T2 values within the tumor after administration of the
contrast agent confirms delivery of the agent to the tumor. Note that in the surrounding brain
there is also a reduction in T2 values, suggesting that agent (at a lesser concentration) also
extravasates into the brain. The increased contrast can be used to mask the tumor (C). The
brain is outlined in white and the tumor is outlined in black. Global CSI scans are performed
throughout administration of the contrast agent. The H6 proton resonance is shown before
(0 min) and after (100 min) of contrast agent infusion (D). The global signal from the H6
peak of TmDOTP5- increases throughout the contrast agent infusion, suggesting that the
delivery of the agent was successful.
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3.3.6 MRI and BIRDS Analysis
All MR data is acquired and processed using Paravision software, while all postprocessing and data analysis is performed in Matlab (Mathworks) using custom scripts
written in house for Bruker imaging systems. The Matlab scripts are integrated into a
package which allows for both MRI and MRSI datasets to be processed in a streamlined
fashion.
Reconstructed images from the T2-weighted sequence and all imaging parameters
(FOV, matrix size, number of averages, position offsets, number of slices, slice thickness, echo
times, and repetition time) are loaded. The signal intensity data is fitted to single exponential
functions to allow for quantitative, multi-slice, 2D longitudinal (T1) or transverse (T2)
relaxation maps to be generated. Similar fitting algorithms are also possible for apparent
diffusion coefficient (ADC) mapping from diffusion-weighted imaging data. For MRSI data,
the fid and all acquisition parameters (RF offset, spectral window, RF pulse parameters, and
encoding in addition to all listed parameters above) are loaded. Selection of specific imaging
parameters and geometric orientations are possible for image visualization and
spectroscopic evaluation.
For analyzing BIRDS data, the anatomical images are visualized and appropriate
regions of interest (ROIs) around the tumor and the brain are manually selected. The brain
(white) and tumor (black) ROIs are outlined on the anatomical images (See Figure 3.2C). To
mask the MRSI data around the selected ROI, the resolution of the ROI from anatomic
imaging is converted into the resolution of the MRSI dataset by resampling the CSI dataset
at the same resolution acquired for the anatomical imaging and identifying all tumor voxels.
CSI voxels that are more than 50% located within the anatomical mask are identified for
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masking of the CSI dataset. The ROI (either for the entire brain or only the tumor) is applied
to the dataset, so that only values from the correct ROI are maintained.
To analyze the MRSI data, the raw data is output as a “fid” file when using Bruker
software. The “slices” in the 3D MRSI dataset that correspond to the slices from the
anatomical images are identified. The chemical shift range to analyze for each peak is
selected based on the expected resonances for the H6, H2, and H3 protons at -143, 78, and
60 ppm, respectively, under physiological conditions. Generally, a chemical shift range of +/20 ppm of these values is analyzed. A Fourier transform of the fid data is performed using
the fft function in Matlab. On a voxel-by-voxel basis, the data are first-order baseline
corrected around each peak by using the linfit function in Matlab and zero-order phase
correction is performed around each peak by varying the phase of the spectrum from 0 to
180º and choosing the phase that leads to the most symmetrical peak shape. Line
broadening, typically 300-500 Hz, is applied to each peak. Using the previously created ROIs
at the resolution of the CSI dataset, the MRSI data is masked either around the entire brain
or around the tumor depending on the area of interest for the particular analysis. Voxels
outside of the tumor, in the otherwise healthy appearing brain, have low SNR because of the
agent not being able to cross the blood brain barrier in large amounts resulting in low tissue
level concentrations (<0.5 mM). Strategies can be employed to increase the agent
concentration in the brain including the long infusion time such that the agent concentration
remains high in the vascular compartment setting up a diffusion gradient from the vascular
compartment to the tissue. Further, by infusing over a long time, agent is constantly
replacing that which has been cleared, so tissue concentrations can increase with time.
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On a voxel-by-voxel basis, the chemical shifts of the three resonances from TmDOTP5and the water chemical shift are measured, and each of the three chemical shift values are
stored as a parameter in Matlab for each voxel. The calibration curve generated from section
3.1 is applied to each voxel using the measured chemical shift values in vivo, resulting in a
pH value for each voxel. When individual voxel pH values are displayed spatially, this results
in quantitative pH maps, as shown in Figure 3.3, covering the entire region over which the
contrast agent could be detected. These processes can be largely automated in Matlab.
However, SNR can become limiting in the brain. Further, due to the larger size of the voxels
in the MRSI scan, the factors that influence the chemical shift (namely pH) are an average of
the pH values within the voxel and there is likely a distribution of values. This can be
reflected in broadening of the peaks or non-Lorentzian line shapes. In voxels in which this
occurs, the automated peak fitting might not properly define the peak and manual correction
becomes necessary.
For a tumor average, the values in all identified tumor voxels are averaged; however,
different spatial analyses can also be performed. In this case, voxels on the tumor
boundary/periphery can be chosen and an average value from these voxels can be compared
to intratumoral values. Additionally, a spatial distribution of values can be obtained by
finding the center of mass (COM) of the tumor and then selecting all voxels in 1 mm
concentric circles from the tumor center allowing the gradient to be obtained. Care must be
made when interpreting pH values from voxels that contain large contributions from nontissue compartments including voxels at the edge of the brain where significant vascular
contributions may be present and SNR is low, as well as voxels that include the ventricles
and other regions with large volumes of CSF. Additionally, in healthy brain, there may be
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differences in the local environment between gray and white matter that are largely volume
averaged in the voxel size achievable with MRSI experiments.
Using BIRDS, the pHe has been measured in a variety of GBM rodent tumors including
9L and RG2 (Figure 3.3). In all tumors studied, the pHe was found to be acidic with the more
aggressive tumor (RG2) having a lower pHe and the acidification extending beyond the
anatomically-defined tumor boundaries.141 Studies such as this serve as the foundation for
treatment studies where it was shown that temozolomide, a common alkylating
chemotherapeutic agent used in the treatment of GBM was found to increase the
intratumoral pHe closer to normal values (Chapter 5), potentially serving as a biomarker of
the therapeutic response.142 However, in these prior studies, renal ligation was used to
increase the contrast agent concentration, precluding longitudinal measurements of pHe
throughout tumor progression or before and after treatment in the same animal. Given the
variation in pHe between individual tumors, it makes drawing conclusions from individual
animal studies challenging. The protocol described here allows for longitudinal studies in
both the context of untreated and treated tumors as described further in Chapter 4 and
Chapter 5, respectively. Additionally, pHe is a difficult physiologic parameter to validate in
vivo and the changes observed were based on in vitro calibrations. However, BIRDS also
allows for temperature measurements either alone (using TmDOTMA-) or in combination
with pHe (using TmDOTP5-). Since temperature is easier to manipulate using direct cooling
and can be compared to direct temperature recordings, the remainder of this chapter
demonstrates the utility of temperature mapping using BIRDS in the context of a
hypothermia model.
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Figure 3.3. Example of in vivo BIRDS pHe measurements in 9L and RG2 tumor types. The
anatomical T2-weighted images (i) are shown with corresponding CSI maps (ii) that were
acquired with the same FOV. Representative spectra in select voxels (iii) show the three
distinct resonances of TmDOTP5-. From the CSI data, quantitative pHe maps were produced
(iv) that show an acidic pHe within the anatomically-defined tumors. However, in the more
aggressive RG2 tumors, the acidic pHe spreads the tumor boundary. Reproduced with
permission.141
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3.4 Application to Hypothermia
In traumatic brain injury and its concomitant ischemic injury, the promise of
neuroprotection from therapeutic hypothermia remains elusive. The rapid and timely
delivery of therapeutic hypothermia for patients with traumatic brain injury (TBI) remains
problematic. Two recent randomized clinical trials – EuroTherm 3235 and POLAR RCTfailed to show a treatment effect of therapeutic hypothermia for TBI.143,144 Unlike patients
with cardiac arrest or neonatal hypoxic-ischemic encephalopathy, where the timely
application of hypothermia provides neuroprotection, patients with brain injury present a
complex array of conditions and comorbidities, which hinder early application of
prophylactic hypothermia.
Another potential confounding variable may relate to the method of hypothermia
delivery itself. In many previous studies, including the two large randomized trials, the
primary methodology to induce hypothermia was the use of intravenous solutions or
endovascular devices to achieve systemic whole body cooling. Here we evaluate an
innovative technology to induce localized hypothermia in the brain to temperatures known
to be neuroprotective, while maintaining overall systemic (i.e., body) normothermia.
Physical and ischemic brain injuries result in inflammatory processes and
dysregulated brain cooling mechanisms leading to brain temperatures higher than
measured core body temperatures.145 Therefore, decreasing the brain temperature
(therapeutic hypothermia) has been shown to be neuroprotective. Therapeutic hypothermia
has demonstrated efficacy and has become a mainstay in treatment of global cerebral
ischemia following cardiac arrest, with further evidence suggesting a neuroprotective

86

benefit after TBI and ischemic stroke. Together, these conditions represent major
contributors to morbidity and mortality in the United States.146
Despite hundreds of unsatisfying pharmacological attempts to identify drugs with
neuroprotective effects, hypothermia remains a viable therapeutic option that has
demonstrated efficacy. Experimental studies in animal models of ischemic stroke have
shown a clear benefit of hypothermia in reducing infarct volumes. Moreover, hypothermia
in animal models of TBI has demonstrated neuroprotective effects.147
Cerebral temperatures are easily approximated in the absence of pathology when
brain and body temperatures are similar and regulated by the hypothalamus. However, in
pathological states, brain temperature may deviate from body temperatures.148 Additionally,
under anesthesia, brain temperature decreases.149,150 Temperatures are elevated in ischemic
stroke lesions in the brain,151 and after brain injury temperature is usually higher than in
normal states. The greatest benefit of hypothermia is achieved in the time period
immediately following the physical or ischemic injury, and it is therefore critical to start
treatment immediately upon symptom/trauma onset. The neuroprotective effects may be
lost if hypothermia is induced after reperfusion.
Brain temperature is closely coupled to brain metabolism/perfusion, and tight
temperature control is critical for normal brain function.145 In animals, changes in brain
temperature of 2-3 °C have been observed with behavioral stimuli, providing a link between
increased brain metabolism/activity and temperature. There is a close relationship between
temperature and oxidative metabolism, which is a measure of brain activity.152 Although
temperature is increased in hypermetabolic states, thermoregulatory effects can
compensate to lower brain temperature. Since heat exchange in the brain is hindered by its
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location within the insulating skull, heat is removed primarily by an increase in blood flow.
Cerebral flow-metabolism coupling may be lost during hypothermia, where decreased
temperature leads to a decrease in both metabolism and blood flow.145
Although whole body cooling strategies have been proposed and tested, significant
side effects limit their use. These include shivering, decrements in cardiovascular function,
immunosuppression leading to higher rates of infection and pneumonia, ion/electrolyte
imbalances, and problems with coagulation and acid/base regulation.153 For ischemia, such
as after cardiac arrest, where many organ systems are affected, whole body cooling is likely
beneficial. However, for brain injury or focal ischemia during stroke, targeted brain cooling
may be more advantageous, by limiting systemic adverse effects. Despite the obvious need
for techniques that selectively cool the brain, and possibly even only cool the single affected
hemisphere, few current options are available.
The challenge in achieving this aim is to develop techniques that can be implemented
quickly in a clinical setting during the critical time window immediately following the injury
or onset of ischemia and before reperfusion injury. Methods to lower temperatures can be
either noninvasive or invasive.154,155 Noninvasive methods rely on cold packs/blankets,
which generally lower core body temperature as well as brain temperature, or pharyngeal
cooling which may be more selective but is limited to temperature decreases 1-3 °C.156,157 To
alleviate these effects, invasive methods try to directly cool the brain. This has been achieved
using endovascular approaches whereby intravenous or intraarterial catheters have been
inserted and used for intravascular injections of cooled saline/blood.158 While providing
direct and selective cooling, these methods result in transient cooling and are limited by the
volume of solution that may be infused, limiting the magnitude of the temperature decrease
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and the duration of the effect. Depending on catheter placement, these techniques can result
in more specific cooling of the brain with less impact on body temperature.
Here we utilize a novel cerebrospinal fluid (CSF)-cooling based platform which allows
for chilled saline to be pumped through a closed-loop catheter inserted into the lateral
ventricles of the brain.159 The refrigerant enters by one lumen of the catheter and exits by
another, never interacting directly with the CSF. This novel system cools the CSF
conductively and, via natural CSF flow, allows convective cooling of the entire brain. Invasive
strategies are generally used to provide selective cooling to the brain in an effort to reduce
the side effects associated with systemic whole-body cooling. While there are added risks
with invasive procedures, this method provides rapid, direct, and reversible cooling that can
be maintained over an extended time period.
To demonstrate the efficacy of intracerebral cooling is challenging, given the location
of the brain beneath the skull. Further, regional measurements of variations in temperature
within the brain, though usually lacking, are indeed required to understand the
neuroprotective effects of hypothermia, for example when particular brain regions are not
being effectively cooled. Although there are both intraparenchymal and intraventricular
temperature probes for directly monitoring brain temperature, these methods allow only for
localized temperature measurements at the precise site of the temperature probe. Dynamic
and more comprehensive measurements of temperature distributions during cooling are
necessary to understand the cooling efficiency of any cooling device prior to clinical
translation.
To achieve this we have used Biosensor Imaging of Redundant Deviation in Shifts
(BIRDS) with TmDOTMA- to yield quantitative, high-resolution temperature measurements
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across the entire brain.134,136 Using BIRDS, we measured the temperature maps in four
healthy sheep brains before, during, and after the onset of cooling induced by the implanted
CSF cooling device. The results show sustained decreases in brain temperature across both
hemispheres upon the onset of cooling, with a return to baseline temperatures after the
cessation of cooling. Throughout all experiments, systemic normothermia of the animals was
maintained. Thus, temperature mapping with BIRDS provided a direct measurement of
cooling efficiency of a CSF cooling device, which can be further employed in evaluating
selective brain cooling strategies for therapeutic hypothermia.

3.5 Temperature study methods
Four juvenile crossbreed neutered male sheep (Ovis aries) weighing 26.5, 24.2 kg
(age: 14 weeks), 34.5, and 32.0 kg (age: 22 weeks) were supplied by Thomas D. Morris, Inc.
(Reisterstown, MD, USA). The lambs were pair housed, provided with environmental
enrichment, and acclimated in the Yale Animal Resource Center (YARC) for 9-10 days prior
to surgery and imaging procedures. The room temperature was maintained at 22.2 ±1.1 °C
with a photoperiod of 12 hours of light and 12 hours of darkness. Water and hay were
provided ad libitum and animals were fed 2-3% of body weight daily with commercially
prepared ruminant diet (Teklad 7060) supplemented with fresh vegetables. Each animal
was examined and determined to be healthy and free of clinical disease by Yale veterinary
clinicians.
The Animal Care program is fully accredited by the Association for the Assessment
and Accreditation for Laboratory Animal Care International (AAALAC), and all procedures
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and experiments were approved in advance by the Yale University Institutional Animal Care
and Use committee (IACUC).
Each fasted lamb was premedicated with acepromazine (0.05 mg/kg) dosed
intramuscularly and then induced with ketamine (2.7 mg/kg) and diazepam (0.2 mg/kg)
intravenously to allow endotracheal intubation and subsequent maintenance on isoflurane
gas (1-3%) via mechanical ventilation. Buprenorphine (0.01 mg/kg) was given
intramuscularly to provide opioid analgesia and lactated Ringers solution was administered
intravenously at the continuous rate of 4ml/kg/hour for fluid maintenance. Thermal
support was provided with a circulating warm water pad to control and maintain body
temperature (38-39 °C), and an orogastric tube was placed to allow venting of gas thus
preventing excessive rumen distension.
Prior to the initial incision a local anesthetic injection of 0.5% bupivacaine solution
(1 mg/kg) was made at the surgery site to provide multimodal analgesia. Continuous
monitoring of the depth of anesthesia and stability of vital signs in the surgery suite was
accomplished using a Mindray DPM6 patient monitor (Mindray DS USA, Inc). Burr holes
were made bilaterally 1.5 cm anterior and lateral to the posterior fontanelle at an angle of
10° from the sagittal plane on each side. A pediatric slotted stylet was inserted into through
each burr hole and guided anatomically into the lateral ventricle. Proper location in the
lateral ventricle was confirmed by CSF flow, and pressures were measured by manometry.
The cooling catheters were designed by CoolSpine, LLC (Woodbury, CT) and contain
three lumens: two lumens accomplish the delivery and removal of supersaturated saline in
a closed loop circuit, which is maintained at -7 to -10 °C. Additionally, the third lumen
functions as an external ventricular drain (EVD) for intracranial pressure management. This
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lumen was modified to allow contrast agent infusion during the imaging procedures.
TmDOTMA- (7mg/kg) was infused directly into the lateral ventricles at an infusion rate of
1ml/h. Two cooling catheters were placed via the burr holes directly into both the right and
left lateral ventricles (named right and left catheters, respectively). This technique is
consistent with capabilities of common clinical practice in neurological intensive care units.
Continuous monitoring of the depth of anesthesia and vital signs in the MRI suite was
accomplished using an Invivo Precess 3160DCU patient monitor (Invivo Corporation
Orlando, FL USA). Following the completion of the imaging procedures, each animal was
euthanatized with an intravenous dose of sodium pentobarbital-based euthanasia solution
(Euthasol®).
The magnetic resonance imaging (MRI) and spectroscopy (MRS) datasets were
obtained on a Varian 7.0T/68cm horizontal-bore spectrometer (Magnex Scientific Ltd.)
using a 1H resonator/surface coil RF probe. The MR images were acquired using a 128 x 128
gradient-echo (GE) pulse sequence with a field of view (FOV) of 10cm x 10cm, with 17 slices
of 5mm thickness with a repetition time (TR) of 200ms and an echo-time (TE) of 5ms. The
17x17x17 3D chemical shift imaging (CSI) datasets were acquired with spherical encoding
of k-space as previously described133 with a TR of 20ms and a FOV of 15.3cm x 15.3cm x
15.3cm. A single-banded refocused 900 Shinnar-Le Roux (SLR) radiofrequency (RF) pulse of
40 kHz bandwidth and 500 µs was used for selective excitation of the TmDOTMA- methyl
group protons.
The CSI data was reconstructed to 34x34x17 resolution with a voxel size of
4.5x4.5x9.0 mm3. The spectra were line broadened (200 Hz), phased (zero order) and
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baseline corrected (first order) in Matlab. The temperature was calculated in each voxel from
the chemical shift of TmDOTMA- methyl group (δCH3) according to Equation 3.3:
𝑇 = 𝑎+ + 𝑎- (𝛿RS7 + 103) + 𝑎7 (𝛿RS7 + 103)-

(Equation 3.3)

where δCH3 is the measured chemical shift of the methyl resonance of TmDOTMA- and a1, a2
and a3 are 34.45± 0.01, 1.460±0.003 and 0.0152±0.0009, respectively, from linear least
square fitting of calibration data over the physiologic range of temperature values.136 The
temperature from each voxel was measured and plotted in an axial slice, which was
coregistered with anatomical imaging to show the spatial distribution of the temperature
values throughout the brain.
During the imaging session, baseline anatomic images were acquired before the
TmDOTMA- infusion. Next, baseline temperature maps were acquired to establish the basal
brain temperature. Then the flow of cooling solution was started through the right catheter
at a rate of 35 mL/min, during which CSI data for temperature mapping was obtained. Each
animal underwent a cooling paradigm with temperature maps acquired at 10 min intervals
throughout all phases of cooling and recovery.
In two animals, flow was initiated in the right catheter and after cooling for 40 min,
flow was then directed through both catheters with increasing flow rates up to 48 mL/hr
before cooling was stopped and the temperature was allowed to recover. In two additional
animals, flow was initiated in the right catheter for 30 min and then stopped for 10 min to
allow the temperature to recover. The flow was then restarted in only the left catheter for 30
min. Again after a cooling period, the flow was either stopped and the temperature was
allowed to recover or flow was initiated through both catheters. Throughout all phases of
cooling and recovery, CSI data was obtained every 10 min for temperature mapping. A final
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CSI dataset for temperature mapping was obtained at the end of the experiments after the
cessation of cooling to show the return of temperature towards normothermia.
For consistency of the analysis when calculating cooling or recovery rates, we used
temperature measurements obtained during the first cooling event in each sheep. The initial
cooling phase was considered to be the period after the baseline temperature mapping and
until the first period of recovery (during which the flow through the catheter had been
stopped). Similarly, the initial recovery phase was the first period during which flow through
the catheter was stopped, but before flow of the cooling solution was restarted. The rate of
temperature change k was calculated based on the change in temperature (∆T) divided by
the time interval over which the change occurred (∆t).
𝑘=

∆(
∆U

(Equation 3.4)

The subsequent diverse time courses of temperature change in individual animals
(when flow was initiated either through each catheter or when flow was increased through
both catheters) showed that BIRDS is able to capture dynamic changes in temperature
throughout cooling and is indicative of the robustness and reproducibility of the method.
Regional variations of temperature were assessed by assigning voxels to ROIs
corresponding to different brain regions based on a previously published high-resolution
sheep brain atlas. All statistics were performed based on average ROI temperature values.
All temperature measurements, changes in temperature, and rates of change of temperature
are all reported as mean ± standard deviation. All comparisons were assessed using a twotailed t test where p values <0.05 were considered to be significant.
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3.6 Temperature study results
3.6.1 MR Imaging of Catheter Placement
Four sheep underwent catheter placement in both the right and left lateral ventricles.
Gross anatomy of the sheep brain provides landmarks that were used for identification of
morphological features and for registration to imaging datasets (Figure 3.4A). The
intraventricular catheter (Figure 3.4B) is composed of a tube with a distensible sac at the
end to allow variable expansion according to the available ventricle volume and shape. The
catheter was designed to circulate chilled saline in a closed circuit via two cooling lines, one
for inflow and the other for outflow, to and from the distensible sac. A third (central) line
was used for release of the CSF pressure created by the expansion of the distensible sac
during cooling. The contrast agent was infused via a thin delivery line (P10) positioned
inside the central (pressure-release) line (Figure 3.4B).
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Figure 3.4. Representative anatomical images of the sheep brain and description of the
cooling device. The gross anatomy of the sheep brain (A) is shown with several axial slices
identified. The cooling catheter used for intraventricular cooling (B) was inserted at an angle
into the lateral ventricles of both hemispheres. Representative high-resolution anatomical
MR images corresponding to axial slices in (A) are shown in (C), along with the approximate
location of the catheters in slice d. Using a previously published anatomical atlas,160 a lower
resolution CSI-based anatomical atlas was generated, and 17 distinct regions of the brain
were identified and color-coded (D). The region identifications are summarized in Figure
3.5. The MR images acquired during the temperature studies (E) were used for localization
of various brain regions.
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Figure 3.5. Identification of specific brain regions as shown in a sheep brain atlas. The
identified regions from the anatomical atlas

21

were rescaled to the resolution of the CSI

datasets used for temperature mapping. The numbering of the regions used here is the same
as that used in the high-resolution anatomical atlas. However, some of the small regions in
the high-resolution anatomical atlas were combined in the CSI atlas reducing the number of
regions from 53 to 17. Therefore, the numbering of the regions is not continuous because,
when several regions were combined into one, we named the combined region using the
name of the largest original region.
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A previously published high resolution anatomical atlas of the sheep brain (Figure
3.4C) was used to group its 53 high resolution brain regions161 into 17 separate larger brain
regions (Figure 3.4D and Figure 3.5), that were subsequently used for regional
temperature mapping analysis. The regrouping of some of the smaller anatomical regions
into larger ones was necessary for better overlap with the lower resolution
(4.5mm×4.5mm×9mm) CSI grid. The numbering of the regions used here is the same as that
used in the high-resolution anatomical atlas. However, some of the small regions in the highresolution anatomical atlas were combined in the CSI atlas, reducing the number of regions
from 53 to 17. Therefore, the numbering of the regions is not continuous because, when
several regions were combined into one, the combined region was named using the number
of the largest original region. T2-weighted anatomical images of the sheep brain were used
to verify the approximate position of catheter placement (Figure 3.4E).

3.6.2 Temperature Mapping
BIRDS was successfully used for 3D temperature mapping of sheep brain after
administration of TmDOTMA- at a resolution of 4.5x4.5x9.0 mm3, acquired in about 10 min
and repeated throughout several cooling and recovery processes for each animal (Figure
3.6). The temperature was calculated according to Equation 3.3. Average baseline
temperature in the sheep brain was 38.5 ± 0.8 °C, with corresponding body temperature of
39.2±0.4 °C. We used a sagittal slice through the center of the brain to show the temperature
distribution in the sheep brain (Figure 3.6A) pre-cooling, post-cooling, and after recovery,
corresponding to distinct time points in the temperature time course (Figure 3.6B, marked
with #, * and $, respectively). For all animals, three independent BIRDS measurements were
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made to establish a baseline temperature before cooling. After chilled saline began to be
circulated in the catheters, temperature measurements using BIRDS continued throughout
the duration of the experiment. Separate measurements of the left and right hemispheres
(Figure 3.6B) are shown for each of the 17 brain regions investigated. The time course for
temperature in all 4 animals shows reproducible temperature changes throughout the
cooling and recovery process (Figure 3.7). Although brain temperature fluctuated rapidly
with the onset/offset of cooling, body temperature remained nearly constant and
normothermic throughout the duration of the experiment (Figure 3.6B). The water bath
temperature used to maintain the body temperature in the anesthetized animals was not
adjusted throughout the experiment, such that the temperature fluctuation represents
maintenance of body temperature despite thermal support.
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Figure 3.6. Representative example of temperature variation during intraventricular
cooling in a sheep brain. During the experiment, several baseline temperature maps were
obtained. Temperature maps were then acquired every 10 to 15 min during repeated cooling
and recovery cycles, using catheters lateralized to a single hemisphere or in both
hemispheres. At the end of the experiment, the flow rate of the chilled saline through the
catheter was increased from 35 to 42 mL/min to show that further temperature reductions
could be achieved. Temperature maps of a central sagittal slice before cooling (#), after
cooling (*), and after recovery ($) are shown in (A). The corresponding time-points are
indicated using the same symbols on the temperature versus time curve in (B). The average
temperature over time in each of the 17 anatomically defined regions was calculated (B).
Additionally, the core body temperature was also measured throughout the duration of the
experiment and is shown for comparison. The time course shown represents sheep 4 as
shown in Figure 3.10 and Figure 3.11.
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Figure 3.7. Experimental temperature time courses for all four sheep. Each sheep had two
intraventricular catheters implanted, one in each of the right and left lateral ventricles. After
baseline temperature measurements, cooling was always started by circulating chilled saline
through the right catheter (#). In some animals, cooling was switched to the left catheter (&),
while in others cooling was stopped (*) to allow the temperature to return to baseline. The
circulation was then switched to the left catheter and the experiment repeated. In some
animals, the flow was oriented so that it would go through both catheters (@). The flow rate
was always initially set to 35 mL/min; however, in some animals the flow was increased to
42 mL/min ($) to determine if greater reductions in temperature could be achieved.
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Core Body

Baseline

Nadir

%

%

Temp

Brain

Brain

Decrease

Decrease

(CBT, °C)

Temp

Temp

CBT vs

BBT vs

(BBT, °C)

(NBT, °C)

NBT

NBT

p value

Sheep 1

38.9 ± 0.3

37.6 ± 0.2

33.9 ± 0.4

12.8

9.8

p<0.0001

Sheep 2

38.2 ± 0.5

38.3 ± 0.2

33.8 ± 0.2

11.4

11.7

p<0.0001

Sheep 3

38.5 ± 0.2

38.7 ± 0.2

35.7 ± 0.2

7.4

7.9

p<0.0001

Sheep 4

39.9 ± 0.7

39.5 ± 0.3

33.4 ± 0.4

16.3

15.3

p<0.0001

Mean

38.9 ± 0.8

38.5 ± 0.7

34.2 ± 0.9

12.0

11.2

p<0.0001

Table 3.1. Temperature results for each sheep. Core body temperatures are calculated as an
average of all values prior to initiation of cooling. Baseline brain temperatures are calculated
as global brain temperatures just before initiation of cooling. Nadir brain temperatures
represent the lowest global brain temperatures reached throughout cooling. Percent
changes in temperature are calculated relative to both core body temperature and baseline
brain temperatures. All values are reported as mean ± SD. Statistical analyses are performed
using a two-tailed Student’s t test with p values <0.05 considered significant.
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Global brain temperatures were measured as an average of all temperature
measurements over the entire brain (Table 3.1). An average 11% decrease (4.2 °C) in brain
temperature was observed in the four sheep, while the brain temperature decreased an
average of 12% relative to core body temperature. The results of the temperature
measurements pre- and post-cooling and after recovery in the 17 regions are shown for the
left (Figure 3.8A) and right (Figure 3.8B) brain hemispheres. The differences in baseline
temperatures between all regions were distributed throughout a 0.7 °C range. Moreover,
based on anatomical identification of brain regions using the high-resolution sheep brain
atlas, the 17 brain regions were further combined into two main regions: one superficial
(termed non-core) and one deep (termed core) (Figure 3.9). We employed this two-zone
separation to better understand the differences between superficial and deeper brain
structures. The core contained the regions identified as the subcortex, midbrain, olfactory
tract, temporal lobe, occipital lobe, and parahippocampal cortex. The rest of the 17 regions
were combined into a non-core (superficial) region. When grouped by core and non-core
regions, the results show non-significant temperature differences (p>0.05) between left and
right brain hemispheres in both core and non-core regions, pre- and post-cooling and after
recovery (Figure 3.8C). Post-cooling temperatures reached 35.5±0.6 °C vs. 35.6±0.2 °C in
the right and left hemispheres of the brain, respectively, showing no differences relative to
catheter placement (Figure 3.8C). When left and right hemispheres were analyzed together
(Figure 3.8D), the pre-cooling (baseline) temperature of the core of the brain was slightly
warmer than non-core regions (~0.2 °C) but was not significant (p=0.26). Post-cooling,
average brain temperature (including both core and non-core regions) decreased
significantly (p<0.0001, 38.5±0.7 °C vs. 35.6 ±0.6 °C) and after recovery temperatures
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increased significantly (p<0.0001, 35.6 ±0.6 °C vs. 37.6 ± 0.4 °C). No significant differences
were found between core and non-core regions. Interestingly, the temperature after cooling
did not differ significantly throughout the different regions of the brain. Although there were
slight differences in basal temperatures between core and non-core regions of the brain, the
initially warmer core regions reached the same temperature after cooling as the non-core
regions, reflecting greater cooling efficiency of the core regions of the brain (Figure 3.8C and
3.8D).
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Figure 3.8. Absolute temperature measurements from various regions of the brain. The preand post-cooling, and the recovery temperatures are reported for the 17 brain regions
(shown in Figure 3.6) as average +/- SD in the left (A) and right (B) hemispheres across all
animals. Based on their location, these 17 brain regions were further combined into core
(deep) and non-core (superficial) regions (Figure 3.9). The core regions (subcortex,
midbrain, occipital lobe, olfactory tract, parahippocampal cortex and temporal lobe) are
identified by gray circles in (A) and (B), while the rest are the non-core regions. The average
temperature in the left and right hemispheres for the core and non-core regions is reported
before cooling, after cooling, and after recovery (C). No significant changes are observed
between the right and left hemisphere of the brain. Average temperatures across the entire
brain (D) are also shown. In all regions and for the entire brain, statistically significant
temperature decreases (p<0.0001) were achieved during cooling with corresponding
significant temperature increases (p<0.0001) after recovery.
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Figure 3.9. Identification of core and non-core regions of the brain. Anatomic regions were
classified as either core or non-core based on their physical location in the brain. Of the 17
identified regions, 6 were identified as core regions (subcortex, midbrain, occipital lobe,
olfactory tract, parahippocampal cortex and temporal lobe).
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3.6.3 Temperature Changes and Rates of Change During Cooling and Recovery
To further quantify the efficiency of cooling, regional variations in the magnitude of
temperature change and the rate of change in temperature throughout the brain were
calculated. For consistency, we calculated the temperature changes and the corresponding
cooling rates only during the first cooling event, done in each of the four sheep using the
catheter positioned in the right ventricle. Similarly, we calculated the temperature changes
during recovery and the corresponding recovering rates only during the first recovery event.
Cooling using one intraventricular catheter resulted in a rapid temperature decrease
throughout both core and non-core regions in each sheep (Figure 3.10A). Similar
temperature changes during cooling were also measured in both the left and right
hemispheres (light vs. dark colors in Figure 3.10C and 3.10D). Post-cooling, the absolute
temperature throughout the brain was significantly lower, with changes in the range from 2.1°C (in the non-core region of sheep 2, Figure 3.10C) to -4.7°C (in the core region of sheep
4, Figure 3.10C). When averaging the measurements in all 4 sheep, temperature changes of
-3.2±0.5 °C and -3.1±0.5 °C were observed in the core of the left and right hemispheres,
respectively (Figure 3.10D). In the non-core regions of the brain, the average temperature
changes were -2.9±0.4 °C and -3.1±0.4 °C for the left and right hemispheres, respectively
(Figure 3.10D). Although slightly greater temperature decreases were observed in core vs.
non-core regions of the brain (~0.2 °C), this was not found to be significant (p=0.43, Figure
3.10D).
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Figure 3.10. Temperature changes during cooling and recovery. Spatial distributions of the
absolute temperature change in an axial slice (slice c in Figure 3.5) during the first cooling
event using the right catheter (A) and during the first recovery (B) in all four sheep.
Quantification of the absolute change in temperature during cooling and recovery are shown
for both the left and right hemispheres for core and non-core regions of the brain in
individual animals (C). Average absolute temperature changes are reported for all animals
(D) with significant differences (p=0.01) between core and non-core regions of the brain
during recovery. Temperature changes are all reported as average +/- SD. The dashed line
in (A) and (B) represents the demarcation between the core (bottom) and non-core (top)
regions.
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During the recovery period, the temperature in the core regions of the brain increased
to a greater extent than in the non-core regions (Figure 3.10B, 3.10C and 3.10D). In the
core regions, the average temperature changes during recovery were 3.4±0.3 °C and 3.3±0.4
°C for the left and right hemispheres, respectively, while in the non-core regions these were
3.0±0.2 °C and 2.9±0.2 °C (Figure 3.10D). Although there are no significant differences
between the left and right hemispheres, there is a greater temperature change (0.4 °C)
observed in the core regions versus non-core regions (p=0.01, Figure 3.10D). The measured
temperatures after recovery show a reestablished temperature gradient in the brain, with
core regions slightly warmer than the non-core regions (37.8±0.1 °C vs. 37.6±0.1 °C, Figure
3.10D).
To further investigate how fast the brain is cooled, the rate of temperature change
(Equation 3.4) was compared between core and non-core regions of the brain.
Synchronized temperature fall/rise upon cooling onset/offset was observed with cooling
rates ranging from 0.05 to 0.11 °C/min and recovery rates ranging from 0.06 to 0.21 °C/min
(Figure 3.11C). Cooling rates were identical between core and non-core regions, but slightly
faster (but not significant) rates were detected during re-warming in core regions (p=0.18,
Figure 3.11C and 3.11D). However, there were no differences between ipsilateral or
contralateral hemispheres of the brain relative to catheter placement. The average cooling
rates were -0.082±0.009 °C/min and -0.080±0.010 °C/min in the core of the left and right
hemispheres, respectively, while in the non-core regions the rates were -0.074±0.024
°C/min and -0.079±0.026 °C/min (Figure 3.11D). The average recovery rates were
0.118±0.024 °C/min and 0.116±0.026 °C/min in the core and 0.103±0.012 °C/min and
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0.100±0.014 °C/min in the non-core regions of the left and right hemispheres, respectively
(Figure 3.11D).
We also examined whether the volume of the ROI had an effect on the absolute
temperature changes and on the rates of cooling/recovery. The subcortex was the largest
ROI used in the analysis (volume: 12 mL), while there were many ROIs with smaller volumes
(1-3 mL; Figure 3.5). The results show that the temperature changes during both cooling
and recovery (Figure 3.12A and 3.12B), but also the cooling and recovery rates (Figure
3.12C and 3.12D) were independent of the size of the various brain structures being cooled.
Further temperature decrease was achieved either when we cooled using both
catheters or when we increased the flow rate of the circulating chilled saline (Figure 3.7).
When cooling the brain using both catheters, we achieved an additional temperature
decrease of 1.7±0.5 °C in the contralateral (left) hemisphere, and 1.2±0.3 °C in the ipsilateral
(right) hemisphere (sheep 1 and 2, Figure 3.7). Moreover, after we increased the flow rate
through both catheters from 35 to 42 mL/min we achieved another additional temperature
decrease of 0.9±0.3 °C in the contralateral (left) hemisphere, and 1.0±0.4 °C in the ipsilateral
(right) hemisphere (sheep 2 and 4, Figure 3.7). The maximum temperature decrease
observed was 6.5±0.1 °C measured in several gyrus regions (ectolateralis, lateral, posterior
sylvian, suprasylvius and sylvian) in the right hemisphere in sheep 4 (Figure 3.7) where the
lowest temperature reached was 32.8 ±0.2 °C.
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Figure 3.11. Rates of temperature change during cooling and recovery. Spatial distributions
of the rate of temperature change in an axial slice (slice c in Figure 3.5) during the first
cooling event using the right catheter (A) and during the first recovery (B) in all four sheep.
Quantification of the rate of temperature change during cooling and recovery are shown for
both the left and right hemispheres for core and non-core regions of the brain in individual
animals (C). Average rates of temperature change are reported for all animals (D) with no
significant differences between the core and non-core regions of the brain or the left and
right hemispheres. Rates of temperature changes are all reported as average +/- SD. The
dashed line in (A) and (B) represents the demarcation between the core (bottom) and noncore (top) regions.
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Figure 3.12. Effect of ROI volume on absolute change in temperature and rate of the
temperature change. Although the anatomically-defined ROIs are of different sizes, the
absolute change in temperature, as well as its rate of change, are independent of the size of
the ROI.
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3.7 Temperature Study Discussion
Therapeutic hypothermia is neuroprotective; however, prior methods to achieve
hypothermia rely on systemic body cooling, resulting in many adverse effects. Although
some targeted cooling methods have been proposed, their effects are modest. External
cooling devices may only lower brain temperature by <1 °C.162 Further, measuring the effects
of hypothermia is challenging. With systemic body hypothermia, cooling measurements
made on the brain surface are not reflective of temperature in deep brain structures. Since
metabolism continues in the presence of hypothermia to varying degrees, the temperature
throughout a tissue may not be uniform. Therefore, dynamic measurements of spatial
temperature distribution made throughout the target tissue are needed to better understand
the interaction between cooling and metabolism.
In this work we used temperature mapping with an MRSI method (BIRDS) to measure
the temperature distribution throughout the brain during cooling as well as after cooling
was stopped (recovery). The usage of a CSF-based intraventricular cooling catheter
represents an innovative method for brain cooling. In a prior experiment, we demonstrated
cooling of the brain with this CSF-based technology.159 Brain temperatures in that effort
were measured by needle-based temperature sensors that were inserted into the brain
parenchyma at a depth of 15 mm posterior and anterior to the ventricles. As those results
were site specific and required an additional burr hole for the insertion of the temperature
sensor itself, we undertook this current effort to achieve a more comprehensive and less
invasive mapping of cooling throughout the brain.
Measuring the cooling rates allows for a dose-response relationship to be established.
The amount of cooling (or the “dose”) is reflective of the flow rate of saline and the
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effectiveness of heat transfer between the CSF and the cooling solution. The dose-response
relationship can be easily tuned using the cooling rates measured with BIRDS. For example,
to achieve a temperature decrease of 2°C in a brain region where the measured cooling rate
was 0.1°C/min, we need 20 minutes of cooling. However, faster cooling can be achieved with
higher flow rate of the cooling solution.
The procedure used to insert the catheter is similar to that regularly performed by
neurosurgeons to safely access the intraventricular region of the brain to relieve intracranial
pressure using ventricular access devices placed in the lateral ventricles. These procedures
are commonly and safely performed in the neuro ICU and although not without risks, have a
history of successful outcomes in the literature.163 In addition, expanding this procedure to
induce therapeutic hypothermia would add significant benefits without increasing risks.
Other methods currently in use to induce hypothermia, such as intravascular
infusions of chilled saline/blood, are also invasive and come with their own risks and may
be limited in the degree and length of time hypothermia can be maintained. In contrast, using
a CSF cooling catheter, hypothermia could be maintained for as long as the catheter is
implanted. Catheters used for intracranial pressure monitoring can be left in place for
several days. Therefore, this cooling method is well suited for maintaining hypothermia as
long as the temperature of the circulated chilled saline solution is maintained. Moreover, a
benefit of the current system is that cooling can be turned off at any point allowing for rapid
rewarming, or the flow could be adjusted to maintain specific temperature reductions in the
brain.
Although the circulated saline does not enter and is not in direct contact with the CSF,
the intraventricular catheter device allows for rapid cooling of the CSF, which then flows
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throughout the brain, providing generalized cooling via convection. The surface of the brain
in contact with the CSF is very large and is increased even further by interactions with the
vasculature in perivascular and interstitial spaces.164 Therefore, by cooling the CSF we were
able to efficiently and uniformly remove the thermal energy from the brain and thus to
modify its thermal environment.
This is somewhat similar to the primary means of heat removal from the brain via
cerebral blood circulation, where changing the vasodilation results in increased blood flow
and more efficient heat removal (whereas vasoconstriction results in heat accumulation).165
Although the catheters were inserted through the right and left hemispheres of the brain, the
positions of both catheters are near the center of the brain (Figure 3.4), which may explain
the relatively uniform temperature distribution during cooling/recovery in the ipsilateral
versus contralateral hemispheres.
The supersaturation of the saline solution flowing through the intraventricular
catheter can lower the water freezing point; thus the circulating saline has a temperature of
-7 to -10 °C in the water pump reservoir. However, one limitation of the current experimental
setup is that the non-MR-compatible pump was located ~7 meters away from the magnet
bore, allowing the saline solution to warm up while flowing through the delivery line.
Therefore, the temperature of the cooling fluid reaching the animal was warmer than in our
prior experiments.159 Thus, we expect that even greater and faster brain temperature
decreases may be achievable inside the magnet, with optimization of the delivery method
(for example using a thermally isolated delivery line). In human application in the neuro ICU,
the length of the cooling lines would be minimal and such issues would not pertain.
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A historical thermal map of the primate brain has previously been constructed and
illustrated temperature differences of 0.3-0.5 °C between brain regions, with the highest
temperatures seen in the deep regions of the brain.166 In the case of basal temperature data
in the sheep brain, we observed variations between brain regions of up to 0.7 °C, in good
agreement with prior literature values demonstrated in a sheep brain.167
The effects of anatomic site and activity on brain temperature have been reviewed
extensively;164 these studies highlight potential hemispheric differences in temperature, but
also demonstrate temperature fluctuations due to sleep, arousal, and stimulation. In
addition, under anesthesia there are also differences in brain temperature from the awake
state, with temperature reductions seen, and minimal fluctuations in temperature.
We did not observe any interhemispheric differences, with regional differences
between the right and left hemisphere generally not exceeding 0.3 °C. It has been noted that
regional brain temperatures increase more rapidly than arterial temperatures, suggesting
that local heat production due to increased metabolism is primarily responsible. In humans,
deep brain temperature is less than 1 °C higher than body temperature.168 Ambient
environmental temperature can impact superficial cerebral sites, but has no effect on deep
brain structures or blood temperature.
Temperature mapping with BIRDS using TmDOTMA- has been well characterized and
validated.136 In contrast to previous applications of BIRDS for temperature mapping, where
TmDOTMA- was injected into circulating blood, here we directly injected the agent into the
CSF via the intraventricular cooling catheter. Other temperature mapping techniques, such
as phase shift MRI have been applied to monitor temperature changes in the brain.156
However, the phase shift MRI method can only report a change in temperature, and not the
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absolute temperature. Furthermore, accuracy is reduced because the sensitivity of the
temperature measurement by phase shift MRI is on the order of 0.01 ppm/°C, compared to
0.7 ppm/°C for BIRDS with TmDOTMA-.
The error in temperature measurement is directly related to the signal-to-noise ratio
(SNR) observed for the –CH3 proton resonance.136 The SNR values higher than 5 measured
in the sheep brain indicate an error in the temperature measurements smaller than 0.01 °C.
Similar cooling experiments were previously performed in sheep by our group, in which the
local temperature was measured using thermocouples in four brain regions. The
temperature changes (1.4 - 5.7 °C) and the rates recorded are similar to those observed here
with BIRDS.
In terms of changes during cooling seen within individual sheep in this study, the
absolute temperature for Sheep 4 decreases much more than in the other three sheep. This
can be attributed to the baseline temperature being higher by nearly 1 °C in this animal. Also,
since the brain metabolism competes with the cooling process, this higher temperature
decrease could be due to a lower brain metabolism in this sheep, possibly because of a
deeper state of anesthesia. We also observed that the absolute temperature for sheep 1 and
2 during recovery increased by about 1 °C more than in the other two sheep (Figure 3.10B
and 3.10C), most likely because of a lower brain temperature at the beginning of the
recovery period, achieved while cooling the brain using both catheters (in sheep 3 and 4 only
the right catheter was used for cooling before the recovery period).
Although the number of animals used (n=4) was low, the aim of the current study was
to assess the degree of hypothermia achieved by intraventricular cooling by measuring 3D
temperature profiles throughout the brain. One limitation of this study is that there was no
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secondary validation of the temperature changes measured with BIRDS. However, direct
temperature recordings using the same cooling system have been made previously using
thermocouple probes inserted directly in four cortical brain locations.159 These
thermocouple measurements provided similar results, with temperature decreases of 3.7 °C,
which are in agreement with the current BIRDS results from the cortical (non-core) regions
of the brain (3.0 °C). This comparison is summarized in Table 3.2. However, comparisons
between these two measurements must be mindful of the following differences. For the
thermocouple measurements, cooling was induced using two catheters (right and left) with
continuous cooling for 3 hr. For BIRDS, cooling was varied between the right and left catheter
(or both) and was stopped and started over the course of 2 hours to better study the
dynamics of the temperature changes induced by the cooling catheter. Moreover, for the
thermocouple measurements, the temperature reported is an average value from four
temperature sensors placed in the anterior and posterior cortex of both the right and left
hemisphere, while for BIRDS we used the average cortical temperature. It should also be
noted that there is variability between animals for both thermocouple and BIRDS
measurements, which may be due to the effectiveness of the catheter placement, the level of
brain metabolism and/or anesthesia depth.
Moreover, the temperature measurements with BIRDS have been validated in vivo in
the rodent brain under several different activity states.136,169 The TmDOTMA- MR signal is
not dependent on ion concentrations or pH, which is important for its application to disease
states, such as TBI or stroke, which are known to induce both ion imbalances and
dysregulated osmoregulation. The measurements made in this current study are performed
in otherwise healthy brain tissue, which should have uniform characteristics allowing for
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quantitative temperature mapping without other contributing factors. Systemic body
temperatures measured by a rectal probe were monitored throughout the duration of this
study and showed only minimal changes (±1 °C) in systemic temperature throughout the
experiment (Figure 3.6 and Figure 3.7). Note that typically animals under anesthesia
experience a decrease in body temperature; therefore, while the animals were under
anesthesia, a body warming blanket was used to maintain the body temperature despite the
cooling of the brain tissue. This is an applicable strategy that could be employed clinically, as
heat gain by the body is not expected to significantly increase brain temperature, permitting
maintenance of systemic normothermia.
Hypothermia is the only treatment shown to be neuroprotective in global cerebral
ischemia following circulatory arrest. This provides positive implications for potential
neuroprotection in TBI and ischemic stroke. Further, hypothermia has been a mainstay of
surgical procedures involving deliberate cardiac arrest, including many forms of open heart
surgery (in which core body temperatures are commonly lowered to below 18 °C).170
Although significant hypothermia is required following spontaneous cardiac arrest, the data
following ischemic stroke are less clear, with neuroprotective effects being demonstrated
with much smaller levels of cooling (e.g., core body temperature reductions to 34 °C).171
Lowering the temperature results in reduced cellular metabolism and lower oxygen
demands of any tissue and reduces the stress placed on damaged cells. The greater the tissue
cooling, the greater the reduction in oxygen consumption, and therefore oxygen demand,
allowing cells to tolerate inflammatory and ischemic conditions better. There are also
affected mechanisms at the cellular level, whereby hypothermia reduces the development of
inflammation and necrosis in ischemic regions.
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Thermocouple

BIRDS

Sheep #

1

2

3

4

5

1

2

3

4

Baseline

38.7

38.8

38.2

37.5

37.8

37.6

38.2

38.6

39.4

33.4

37.3

33.8

31.8

36.0

35.7

36.2

35.7

34.7

5.4

1.4

4.4

5.7

1.8

1.9

2.0

2.9

4.7

-13.9

-3.6

-11.4

-15.1

-4.7

-5.1

-5.2

-7.5

-11.9

T (°C)
Cooling
T (°C)
Delta T
(°C)
%
Change

Table 3.2. Comparison of previously reported thermocouple temperature measurements to
BIRDS temperature measurements during cooling using the intraventricular catheter. Brain
temperatures reported by thermocouple are the average of four thermocouples inserted in
into anterior and posterior regions of both the right and left cortex. 159 Brain temperatures
reported by BIRDS are the average of all cortical (non-core) voxels. The baseline temperature
is the brain temperature just before initiation of cooling. The cooling temperature is the
brain temperature after cooling. These two values are then used to calculate the change in
temperature (ΔT) and the percent change in temperature from baseline. Note that the
temperatures reached after cooling using the thermocouples were after 3 hours of
continuous cooling, whereas the temperatures measured by BIRDS were after cooling in a
single catheter for 30-40 min.
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Ischemia leads to neuronal damage through several mechanisms including energy
depletion, excitotoxicity, calcium influx, membrane damage, formation of free radicals, and
activation of protein kinases.171 In the case of TBI, treatment is challenging due to the
heterogeneity of the presenting modes of injury and clinical symptoms.146 Further, the time
after injury or the onset of ischemia will always be a confounding factor in understanding
the effects of hypothermia.
Although questions will always remain about the optimal cooling methodology,
targeted temperature, and duration of hypothermia, selective and targeted cooling strategies
show potential for improved management of localized brain injury and ischemia, where
temperature mapping with BIRDS could provide the means to assess the efficiency of the
cooling strategies throughout the whole brain. In the future we plan to compare different
cooling strategies and to assess therapeutic efficacy of mild hypothermia in a large animal
model of TBI.

3.8 Conclusion
Recent clinical trials failed to demonstrate the promise of therapeutic hypothermia in
TBI, yet neuroprotection against ischemic injury remains a high clinical priority. Despite the
myriad of successful animal studies in TBI as well as in other morbidities, use of topical
cooling has been unsuccessful. However, perhaps it is not the hypothermia itself that has
limited the translation of therapeutic hypothermia, but rather the method of delivery has not
been effective. The use of this novel CSF-based cooling platform results in significant and
uniform cooling throughout the cortex of the sheep brain, which has similar ventricular
landscape as the human brain. Interestingly, by using a single catheter, the technique can

121

induce cooling throughout both hemispheres of the brain. Temperature mapping with high
spatiotemporal resolution using BIRDS was feasible in the sheep brain both before and after
induction of hypothermia. BIRDS allows for rapid imaging that has high temperature
sensitivity, allowing for robust and accurate temperature mapping. In these experiments,
CSF-based cooling provides a very efficient method for inducing therapeutic hypothermia,
raising promise for improved clinical treatment of TBI or ischemia, because the brain can be
selectively cooled, obviating the adverse side effects of whole body cooling.
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Chapter 4: Imaging Hallmarks of the Tumor Microenvironment in
Glioblastoma Progression

4.1 Abstract
Glioblastoma progression involves multifaceted changes in vascularity, cellularity,
and metabolism. Capturing such complexities of the tumor niche, from the tumor core to the
periphery, by magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI) has
translational impact. In human-derived glioblastoma models (U87, U251) we made
simultaneous and longitudinal measurements of tumor perfusion (Fp), permeability
(estimated with the transfer constant Ktrans), and volume fractions of interstitial (ve) and
plasma (vp) spaces from dynamic contrast-enhanced (DCE) MRI, cellularity from apparent
diffusion coefficient (ADC) MRI, and extracellular pH (pHe) from an MRSI method called
Biosensor Imaging of Redundant Deviation in Shifts (BIRDS). Spatiotemporal patterns of
these parameters during tumorigenesis were unique for each tumor. While U87 tumors grew
faster, vascularization seemed more aggressive for U251 tumors, as reflected by the higher
rate of increase for Fp, Ktrans, and vp parameters. Perfused regions between tumor periphery
and core with U87 tumors exhibited higher Fp, while Ktrans of U251 tumors remained lowest
at the tumor margin, suggesting primitive vascularization. Tumor growth was uncorrelated
with ve, ADC, and pHe. U87 tumors showed correlated regions of reduced ve and lower ADC
(higher cellularity), suggesting ongoing proliferation. U251 tumors had higher core ve and
elevated ADC (lower cellularity), suggesting necrosis development. The entire tumor was
uniformly acidic (pHe 6.1-6.8) early and throughout progression, but U251 tumors were
more acidic, suggesting lower aerobic glycolysis in U87 tumors. Characterizing these cancer
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hallmarks with DCE-MRI, ADC-MRI, and BIRDS-MRSI is useful for exploring tumorigenesis
as well as timely therapies targeted to specific aspects of the tumor microenvironment.

4.2 Introduction
Glioblastoma (GBM) is the most frequently occurring and aggressive primary brain
tumor in adults.172 Despite intensive surgical and medical intervention, prognoses remain
poor with an average survival of less than 2 years.173 Magnetic resonance imaging (MRI) with
transverse (T2) or longitudinal (T1) relaxation times can elucidate potential changes
between tumor and normal tissue and is used for initial clinical identification upon symptom
onset, although biopsy remains the gold standard for diagnosis. Specifically, contrastenhanced T1-weighted and T2 fluid-attenuated recovery (FLAIR) images are used for clinical
detection and size monitoring after treatment;174 however, there remain numerous unmet
imaging needs as many findings are nonspecific and do not allow for direct mapping of the
tumor microenvironment that may be reflective of treatment response.175 Further, these
imaging contrasts largely ignore spatial heterogeneity as tumors are extremely diverse in
their anatomic features, do not highlight variation in tumor metabolism and vasculature
which are reflective of different genetic mutations in GBM, and are confounded in the setting
of different therapies, especially anti-angiogenic therapies, that results in drastic changes in
the imaging findings despite little change in the structural tumor architecture.16 Therefore,
more specific imaging methods are needed to characterize tumor progression as well as to
evaluate therapeutic response. In this study, we aim to demonstrate multi-modal
longitudinal characterization of the GBM microenvironment in preclinical GBM models to
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highlight the spatial heterogeneity that exists in tumor cellularity, vascularity, and
metabolism and how it changes throughout tumor progression.
Tumorigenesis in GBMs is highly complex and involves metabolic changes in tumor
cells and interactions with the surrounding microenvironment. GBMs, like other solid
tumors, display many of the hallmarks of cancer including dysregulated metabolism and
vascularization which drives the promotion of angiogenesis.2 Angiogenesis, the development
of new blood vessels, occurs in tumors in response to the development of hypoxia and to aid
in delivery of nutrients to the metabolically active tumors. However, the newly formed
vasculature is tortuous and leaky. The tumor microenvironment is shaped by these
abnormalities in the vascular architecture leading to heterogenous and inadequate
perfusion.
GBMs are highly heterogeneous due to tumor growth patterns and development of
necrosis. Spatial heterogeneity, not only in morphology, but also in perfusion and
metabolism may contribute to differing patient prognoses and therapeutic efficacy. Thus,
detecting and measuring tumor size does not fully capture the tumor phenotype. Hypoxia
develops in specific regions of the tumor and contributes to tumor aggressiveness.
Therefore, imaging methods to quantify the vascular architecture of tumors is important for
tumor characterization and has been studied using a MRI technique termed dynamic
contrast enhanced (DCE) MRI.176 DCE-MRI models the dynamic uptake and exchange of
gadolinium-based contrast agents between the vascular and tissue spaces, specifically those
regions in which the agent has extravasated into the extravascular space. This can identify
tumor regions that have high vascular permeability or conversely, regions that are underperfused and indicative of regions of hypoxia. The images are acquired with a high temporal
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resolution and the signal intensity-time curves are then converted to a contrast agent
concentration term that is then fit to a two-compartment exchange model.82 This allows for
several vascular parameters to be quantified, including the plasma flow (perfusion), vascular
permeability, extracellular volume fraction, and plasma volume fraction.
Additionally, GBMs undergo a metabolic upregulation of glycolysis even in the
presence of sufficient oxygen, a phenomenon termed aerobic glycolysis (Warburg effect).
This leads to elevated production of intracellular acids and lactate, which are then extruded
thereby acidifying the extracellular environment.3,41 Specifically, extracellular acidosis,
defined as a reduction in the extracellular pH (pHe) in relation to intracellular pH (pHi), is
an important indicator of tumor aggressiveness as the reduction in pHe has been directly
linked to increasing tumor invasiveness, reduced therapeutic response, increased
angiogenesis and immunosuppression.8 In normal brain tissue, the pHe is ~7.2-7.4, but in
tumors there is a drastic reduction in pHe to ~6.2-6.8.141 Metabolic abnormalities are not
confined to tumor cells, but also shape the tumor microenvironment leading to distinct
locations both within and beyond the tumor boundary that are more prone to cancer cell
survival.177
Thus, metabolic imaging methods have become a focus in the past decade for tracking
cancer. Several imaging methods have been proposed and studied for measuring both pHi as
well as pHe.86 While pH electrodes are the gold standard, a variety of imaging methods
including optical, PET, and magnetic resonance imaging and spectroscopic methods have
been used for quantitative pH mapping. However, these methods vary in their specificity for
pHe (vs pHi) and their ability to quantify the pH. In this study, for pHe imaging we use a
magnetic resonance spectroscopic imaging (MRSI) method called Biosensor Imaging of
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Redundant Deviation in Shifts (BIRDS). BIRDS uses the pH-sensitive chemical shifts of nonexchangeable protons of lanthanide-based contrast agents.134 The chemical shifts are
characterized in relation to their temperature and pH sensitivities in vitro. The signals are
resilient and can be observed even in the presence of strong T2 contrast agents, and therefore
are unaffected by the presence of other contrast agents.178 BIRDS agents have been modified
to increase their delivery and thereby their sensisitvity.132,179,180 Further, BIRDS has been
used to map the pHe in a variety of tumor models.181,182
Quantitative BIRDS-pHe mapping has revealed highly acidic tumors where pHe
changes can reflect tumor viability and response to therapy.141,142 However, BIRDS-pHe
mapping requires the use of paramagnetic contrast agents, such as thulium 1,4,7,10tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonate) (TmDOTP5-), and limitations
due to the need for sufficient contrast agent accumulation have previously prevented
longitudinal pHe measurements. However, organic anion transporter inhibitors (e.g.,
probenecid) can slow the renal clearance of the contrast agent.135 Here we demonstrate that
a co-infusion of probenecid and TmDOTP5- can allow for repeated longitudinal pHe mapping
in the same tumor over time and when combined with multi-modal imaging can be useful in
measuring tumor growth and monitoring the tumor microenvironment in human-derived
models of GBM. We were able to measure tumor growth and map pHe in the same U87 and
U251 gliomas reproducibly and found that despite significant tumor growth, acidosis
plateaus early in tumor formation once the tumor is identifiable by imaging methods.
In this study, the cellularity, vascularity, and acidosis of untreated U87 and U251
human-derived GBM models were measured longitudinally throughout tumor progression.
U87 and U251 orthotopic glioma models exhibit many characteristic microenvironmental
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features of human GBM in different aspects including the development of necrosis, rapid
growth, invasion into surrounding tissue, and differences in vascularization that lead to
hypoxic regions and enhanced angiogenesis.183,184 However, a limiting factor in translating
preclinical GBM treatment studies is being able to longitudinally and non-invasively map the
tumor microenvironment in the same tumor over days and weeks. The vascularization of
these tumors is important for delivery of MRI contrast agents, including gadolinium agents
used for the DCE method and TmDOTP5- used for BIRDS.
Here we describe a multi-modal MRI study of mapping the vascularity, cellularity, and
acidosis in the tumor microenvironment in the same imaging space longitudinally
throughout tumor progression, which enabled interrogating spatiotemporal changes of
these parameters through tumor progression. We hypothesized that there would be
restructuring of the vasculature over time in these models, and that metabolism would
change throughout progression. While common measures of tumor progression are only
tumor

size,

we

hypothesized

that

these

measures

would

provide

additional

characterizations of the changing tumor microenvironment that were not solely related to
the size of the tumor and changes might develop earlier during tumor formation.
Characterization of the vascular and metabolic microenvironment in tumors is essential for
choosing therapeutic strategies as well as for monitoring tumor progression and therapeutic
response.
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4.3 Methods
4.3.1 Cell Culture
U87 cells were purchased from American Type Culture Collections (ATCC) and U251
cells were from Dr. Meser Ali at Henry Ford Hospital. All cells were maintained in an
incubator in a 5% CO2 atmosphere at 37 °C. Dulbecco’s modified eagle’s medium (DMEM)
was supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillinstreptomycin. U87 cells were cultured in high glucose (4.5 g/L) DMEM and U251 cells were
grown in low glucose (1.5 g/L) DMEM. All cells were used at low passage (<20). Cells (U87
and U251) were harvested at high confluence (>80%) and suspended in serum-free DMEM
prior to intracranial injection.

4.3.2 Animal Models of GBM
All animal protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) at Yale University. Female athymic/NUDE rats were acquired from
commercial vendors (Envigo) and weighed 150-250g. Animals were maintained in
temperature and humidity-controlled rooms with food and water provided ad libitum.
Animals were housed for a minimum of two weeks prior to experimentation.
For intracranial injection of U87 and U251 cells, the animals were anesthetized with
isoflurane (2-3%). The animals were positioned in a stereotactic holder and the scalp was
sterilized with betadine and 70% ethanol. Local anesthetic (Bupivacaine, 2 mg/kg) was
administered prior to a midline incision of their scalp. After exposing the skull, a hole was
drilled using a motorized drill at a position 3 mm to the right of the bregma. A 5 µL
suspension of 2x105 U87 cells or 5x105 U251 cells was loaded into a 10-µL Hamilton syringe
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equipped with a 26G needle. The needle was positioned through the burr hole and injected
3 mm below the dura into the right striatum. The cells were injected using a microinfusion
pump at a rate of 1 µL/min over 5 minutes. The needle was then left in place for 5 minutes
prior to being removed at a rate of 0.5 mm/min to prevent any leakage of cells from the
injection site. The burr hole was sealed with bone wax and the incision site was sutured and
sterilized. Animals were given carprofen (5 mg/kg, subcutaneously) for analgesia during the
procedure which was continued for 48 hours postoperatively. Animals were monitored daily
for weight loss or development of any neurological symptoms. Tumors were allowed to grow
for 10 days prior to initial MRI experiments to monitor for tumor growth.

4.3.3 MRI
All imaging data were acquired using an 11.7 T Bruker horizontal-bore spectrometer.
10-15 days after cell injection, animals underwent T2-weighted MRI to check for tumor
formation using a spin-echo sequence with TR 6000ms and 10 TE (10-100ms), FOV
25x25mm2, matrix 128x128, and slice thickness 1 mm. During imaging, body temperature
was maintained using a circulating warm water heating pad and Paralube vet ointment was
applied to the eyes to prevent dryness. Imaging was repeated every 3-7 days until a tumor
was identified on T2-weighted imaging, typically 1-2mm, prior to beginning the multi-modal
imaging protocol. Due to experimental variations, tumors were initially identified at days 1028 for U87 tumors and days 13-69 days for U251 tumors. After tumor identification, animals
underwent the full multi-modal imaging protocol, which was then repeated every 4-7 days,
unless predetermined humane endpoints were met (e.g., body weight loss, clinical
neurological signs), in which case the animals were immediately imaged and euthanized.
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For the multi-modal imaging studies, which require the administration of contrast
agents, a tail vein infusion line was first established prior to the experiment. During this
procedure, the animal was anesthetized with 3% isoflurane and placed on a heating pad to
maintain body temperature and ointment was placed on the eyes. A 30G needle was inserted
into a PE10 (Braintree Scientific, LLC) line and filled with heparinized saline. The needle was
inserted into the lateral tail vein of the rat and checked for backflow to ensure correct
placement within the vein, prior to being anchored to the tail with tape. Heparinized saline
(~50 µL) was flushed through the line approximately every 20 min throughout the
remainder of the imaging session to ensure proper functioning of the infusion line and to
prevent clotting.
The animal was placed in a prone position within a volume (8 cm) transmit/surface
(3.5 cm) receive radio-frequency (RF) coil (RAPID MR International). The animal and coil
were then placed in the isocenter of the magnet bore. Body temperature was monitored
using a rectal fiber-optic temperature probe and the breathing rate was monitored using a
respiratory monitor.
The imaging protocol consisted of the following order of sequence acquisition which
were acquired over a 6 hour imaging session. Positioning and power optimizations were
performed using Bruker-defined gradient-echo (GE) and fast spin-echo (FSE) sequences.
Shimming was done on an ellipsoid voxel to bring the H2O linewidth down to less than 30
Hz. Quantitative T2 mapping was performed by acquiring T2-weighted images acquired using
the same parameters listed above for initial tumor identification. Diffusion-weighted
imaging was performed using an EPI sequence with 6 b values (0-3000 s/mm2). Apparent
diffusion coefficient maps were generated by fitting voxel-level data to a monoexponential
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function in MATLAB. Quantitative T1 mapping consisted of T1-weighted images acquired
using a RARE sequence with TE 10ms, 5 TR (400-8000ms), slice thickness 0.7mm with
0.3mm gap, 25 × 25 mm FOV, 128 × 128 matrix. Quantitative T1 maps were generated by
fitting voxel-level data to a monoexponential function in MATLAB. The multi-TR T1 sequence
was then repeated after DCE-MRI (see below) to serve as a post-contrast image which was
used, along with T2 images, to delineate tumor boundaries. Because this was acquired at the
end of the DCE acquisition, it represented late (20 min after contrast agent infusion) contrast
enhancement. A contrast enhanced T1-weighted 3D FLASH was also acquired with TE 5ms,
TR 30ms, and 0.33mm isotropic resolution for high-resolution coverage of the entire tumor
for coregistration.

4.3.4 DCE-MRI
DCE-MRI was acquired using a dual-echo spoiled gradient echo acquisition (TR/TE:
39ms/2.5-5ms) with a flip angle of 15° every 5 seconds over 22 min. At 2 min into the
dynamic scan, a bolus IV injection of 0.25mmol/kg gadobutrol (Gadavist, Bayer HealthCare
Pharmaceuticals Inc.), a clinically available macrocyclic gadolinium agent, was injected and
then flushed with heparinized saline. For co-registration, DCE-MRI acquisition was done
over three central slices of the tumor aligned with the same positioning, FOV (25 × 25 mm),
and matrix (128 × 128) as the T1 sequence.
Measurements from pre-contrast T1-weighted images were used to transform the
signal time-intensity curves into time-concentration curves (TCCs), using the dual echo
acquisition to correct for the T2 effect of the contrast agent. The arterial input function (AIF)
was measured by collecting arterial blood samples at discrete time points post-injection in a
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representative animal. A hematocrit of 0.45 was assumed for deriving the contrast agent
concentration in the blood. The raw AIF was fit to a bi-exponential curve and applied to the
analysis for all datasets. A region of interest (ROI) was placed in the tumor, including the
contrast-enhancing rim, which was the area used for all analyses.
To measure vascular parameters [Ktrans (volume transfer coefficient, min-1), Fp
(plasma flow rate, min-1), ve (interstitial volume fraction, unitless), vp (plasma volume
fraction, unitless)], a two-compartment exchange model (2XCM) was used to fit the DCE data.
The parameters were estimated by fitting each voxel using least squares regression using
MATLAB.185 All parameters were quantified on a voxel by voxel basis in the predefined ROI,
and spatially plotted in MATLAB overlaid on T2-weigheted images.

4.3.5 BIRDS pHe Measurements
Prior to the start of pH mapping, the animal was removed from the magnet bore and
transferred to a custom-built 1.4 cm single loop surface coil. The animal was repositioned in
a ventral position such that the tumor was located where coil sensitivity was highest and
then the animal and coil were reinserted into the magnet. Position and optimization scans
were performed as described previously. Next, quantitative T2 mapping was performed for
tumor localization. For BIRDS pHe measurements, 100 mg/kg probenecid was administered
over 10 min and followed after 20 min by a co-infusion of 100 mg/kg probenecid and 1
mmol/kg TmDOTP5-. Probenecid was used to increase the plasma concentration of the
circulating contrast agent and reduce its rate of renal clearance. All infusions were
performed using a syringe pump at a rate of 15 µL/min for a total infusion time of 100 min.
MRSI began 45 min after the start of the infusion and the total imaging time was 56 min.
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Chemical shift imaging for BIRDS was performed to measure the chemical shifts of the pHedependent proton resonances of TmDOTP5- to calculate pHe within each voxel at an isotropic
resolution of 1mm3 as previously described.133,134,141 A 205 μs dual-banded Shinnar-Le Roux
pulse with a bandwidth of 40kHz was used for excitation of the H2, H3, and H6 resonances
of TmDOTP5-. The pHe in each voxel was quantified and the average pHe of all voxels within
the tumor boundary defined by T1 contrast enhancement was measured. At the end of the
BIRDS experiment, post-contrast quantitative T2 mapping was performed such that
reductions in T2 could be related to contrast agent concentration and T2 contrast could be
used for identifying tumor margins. Although Gd3+ is injected earlier in the experiment, the
agent does not impact the chemical shifts from TmDOTP5-, largely clears from the tumor
prior to starting BIRDS and at this concentration does not have significant T2 effects.

4.3.6 Histology
At the end of the imaging experiment, animals were perfused and the brain was
extracted and fixed in 4% paraformaldehyde prior to slicing into 3 mm coronal slabs. The
tissue was paraffin-embedded and sectioned into 10 µm slices. Sections were deparaffinized
and rehydrated prior to hematoxylin and eosin (H&E) staining using standard protocols. In
a subset of tumors, tissue sections also underwent immunohistochemistry (IHC) for
proliferating cell nuclear antigen (PCNA) and vascular endothelial growth factor (VEGF) with
hematoxylin as a counterstain. In brief, sections were deparaffinized and rehydrated prior
to antigen retrieval and peroxidase blocking. Sections were incubated with primary
antibodies (PCNA, VEGF) followed by incubation with a biotinylated secondary antibody and
3,3-diaminobenzidine (DAB). All stained sections were mounted on glass slides and
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microscopy was performed (4×, 10×) for digitization and visualization using an automated
high-resolution microscope with stitching capabilities (Keyence, IL, USA).

4.3.7 Statistical Analysis of Parametric Maps
Each parameter was assessed within the tumor boundary defined by both T2 and T1
contrast enhancement at each time point. Average tumor values were quantified as the
average of all tumor voxels over three imaging slices. Values in all cases are reported as mean
± standard deviation. Parametric maps were registered in the same space and voxel level
distributions were shown to reflect the heterogeneity in parameter measurements.
For the spatiotemporal analysis of each parameter, the imaging slice with the largest
tumor cross-sectional diameter was selected. The total number of voxels across all three
tumor slices were utilized to calculate the tumor volume. Each voxel was also assigned a
depth value based on distance from the tumor margin, within the 2-dimensional plane of the
selected slice. The depth values for voxels of each tumor were individually rescaled so that
the largest depth for each tumor would be 1, and we call this rescaled parameter the distance
to the tumor margin (0 is tumor margin or periphery, 1 is center of tumor). Various
relaxation, diffusion, DCE and pHe parameters were plotted against distance from the tumor
margin and tumor volume. Fitting was done using quadratic surfaces (2nd order
polynomials). Given internal tumor heterogeneity, the Bisquare fitting algorithm was used
to make the fitting robust to outliers. For easier comparison, each of the coefficients for the
polynomial surface fit were normalized to the median parameter value (averaged medians
for both U87 and U251 tumors) and the largest tumor volume (for the respective tumor type,
U87 or U251).
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4.4 Results
4.4.1 Tumor Growth
Both U251 and U87 tumors were monitored longitudinally over up to three time
points. A total of 25 time points acquired across 14 rats with U87 tumors and 24 time points
acquired across 12 rats with U251 tumors were used in the analysis. Tumor volume was
measured using both T2-weighted and contrast-enhanced T1-weighted imaging to manually
identify tumor margins over all imaging slices (Figure 4.1). After tumor detection, size
increased exponentially in both U251 and U87 tumors (Figure 4.1). Tumor growth was
normalized to when tumors were first identified by imaging (Day 0), usually once reaching
1-2 mm in cross-sectional diameter. The tumor size at time of initial scan was 18.4±7.1 mm3
for U87 tumors and 20.7±9.2 mm3 for U251 tumors. By the final time point, tumor volume
reached 166.9±35.2 mm3 for U87 tumors and 103.9±24.6 mm3 for U251 tumors. While at the
initial time point the two tumors were approximately of the same size, at the final time point
both tumors grew significantly larger but U87 tumors were ~60% larger than U251 tumors
(p<0.0004). At the same time points, cellularity (from ADC), vascularity (from DCE), and
metabolism (from BIRDS) were also successfully monitored longitudinally in the same
subjects (Figure 4.2).
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Figure 4.1. Longitudinal growth characteristics of U87 and U25 tumors. T2 and contrast
enhanced T1-wegithed imaging contrasts are shown at three time points in the same U87 (A)
and U251 (B) tumors. The tumor is outlined in black and the brain in white. Tumor volume
was measured across all imaging slices and quantified by multiplying the number of tumor
voxels by the imaging spatial resolution and slice thickness. Imaging timepoints across all
tumors are included.
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Figure 4.2. Longitudinal multi-modal imaging of U87 and U251 tumors. The apparent
diffusion coefficient (ADC) maps reflect cellularity, the Ktrans maps from DCE reflect
vascularity, and the pHe maps from BIRDS reflect acidosis. Imaging was performed at three
different timepoints in the same U87 (A) and U251 (B) tumors. The tumor was masked using
T2-weighted and contrast-enhanced T1-weighted imaging. Vascular parameters from DCE
and pHe from BIRDS were calculated in the masked tumors.
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4.4.2 MRI Relaxation (T1, T2, and contrast-enhanced (CE) T1)
Quantitative T1 and T2 relaxation maps were acquired across all time-points in
addition to the advanced vascular and metabolic imaging methods. In both U87 (Figure 4.3)
and U251 (Figure 4.4) tumors, T1 and T2 values were higher in the tumor compared to
surrounding tissue. T1 values between tumors were not significantly different at the final
time point (p=0.22), but increased with tumor progression from the initial to final timepoint
for both tumor types (U87: 2.24±0.13 s vs. 2.53±0.07 s, p<0.0001; U251: 2.19±0.09 s vs.
2.47±0.04 s, p=0.0009). For T2 the values between tumors were moderately different at the
final time point (p=0.026), but there was a trend in increasing T2 with tumor progression for
both tumors types (U87: 41.3±2.9 ms vs. 43.3±2.1 ms, p=0.16; U251: 38.5±2.5 ms vs.
41.0±1.5 ms, p=0.06).
Tumors displayed contrast enhancement (CE T1) and significantly (p<0.001) reduced
T1 values within the tumor core after gadobutrol infusion on T1-weighted images in U87
(Figure 4.3) and U251 (Figure 4.4) tumors. For CE T1 values between tumors were not
significantly different at the final time point (p=0.26). CE T1 increased with tumor
progression for U87 (1.12±0.10 s vs. 1.29±0.16 s, p<0.03) but not for U251 (1.27±0.20 s vs.
1.16±0.25 s, p=0.43). U87 tumors displayed homogenous signal enhancement that was
confined by the tumor margins (Figure 4.3); however, U251 tumors exhibited much greater
heterogeneity in enhancement patterns with contrast accumulating in central tumor regions
as well as leaking into surrounding brain tissue, resulting in contrast enhancing regions
changing based on time since contrast agent administration (Figure 4.4). These patterns
were reflected in post-contrast quantitative T1 mapping such that with tumor progression,
U87 tumors had higher post-contrast T1-values than U251tumors. This was somewhat
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expected given the same amount of contrast agent in a larger tumor volume resulting in
decreased concentration and lesser T1 shortening.
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Figure 4.3. Multi-slice, multi-parametric imaging of U87 tumors. All data is from a single
imaging session for a single animal. Cellularity (ADC), vascularity (Fp, Ktrans, ve, vp with DCE)
and metabolism (pHe with BIRDS) as well as quantitative T2 and pre/post-contrast T1
mapping are included. Three imaging slices were used for all imaging contrasts, allowing for
extensive 3D characterization of the tumor microenvironment. Multi-slice measurements
were performed for all included time points.
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Figure 4.4. Multi-slice, multi-parametric imaging of U251 tumors. All data is from a single
imaging session for a single animal. Cellularity (ADC), vascularity (Fp, Ktrans, ve, vp from DCE)
and metabolism (pHe from BIRDS) as well as quantitative T2 and pre/post-contrast T1
mapping are included. Three imaging slices were used for all imaging contrasts, allowing for
extensive 3D characterization of the tumor microenvironment. Multi-slice measurements
were performed for all included time points.
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4.4.3 ADC and DCE
Quantitative ADC maps were generated across 3 imaging slices at each timepoint
from diffusion-weighted imaging at multiple b values. Since ADC has been shown to be
correlated with tumor cellularity,80 the ADC was used as an indication of the proliferative
status of U87 (Figure 4.3) and U251 (Figure 4.4) tumors. ADC parameter distributions were
homogeneous for both tumor types. ADC values between tumors were not significantly
different at the final time point (p=0.26), nor did they change for either tumor between time
points (p=0.72 for U87; p=0.75 for U251). With tumor progression and increasing tumor
size, ADC trended towards lower values across both tumor types.
There was heterogeneous dynamic uptake of gadobutrol within the tumor core as
measured with DCE and reflected in the vascular parameters. Further, tumor progression
was associated with an increased heterogeneity in all vascular parameters. Fp and Ktrans were
lowest at the tumor margin in both U87 (Figure 4.3) and U251 (Figure 4.4) tumors. For all
DCE parameters the values between tumors were not significantly different at the final
timepoint compared to the initial timepoint for either U87 or U251 tumors (Table 4.1).
However, the parameter values were highly heterogenous within each tumor which leads to
the large standard deviations. At the final time point, there also was no difference between
the tumor types for Ktrans (p=0.33), ve (p=0.30), and vp (p=0.73); however, the perfusion (Fp)
tended to be higher in U87 tumors although this did not reach significance (p=0.08).
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trans

K

-3

-1

(10 min )

-3

-1

Fp (10 min )

ve

vp

U87
Time Point 1

12.43±1.34

22.14±11.17

0.21±0.07

0.028±0.016

Time Point 3

14.48± 5.90

50.74±40.27

0.20±0.06

0.038±0.043

p value

0.39

0.09

0.72

0.54

U251
Time Point 1

8.89±4.11

14.41±7.09

0.35±0.17

0.063±0.051

Time Point 3

12.20±2.61

23.19±8.96

0.25±0.10

0.045±0.031

p value

0.10

0.09

0.18

0.45

Table 4.1. Quantitative values and statistical comparisons for Ktrans, Fp, ve, and vp vascular
parameter values. Parameter values are quantified from DCE-MRI for U87 and U251 tumors
between the initial and final time point. Parameter values were averaged across all 3 slices
from all tumors and are reported as average ± standard deviation. Two tailed t tests are used
to compare changes in the parameter values with tumor progression.
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4.4.4 BIRDS
Signal enhancement after gadobutrol administration corresponded to regions of
signal darkening after TmDOTP5- in T2-weighted images providing multiple contrasts for
measuring tumor size. Further, coinfusion of probenecid and TmDOTP5- allowed for
successful repetitive pHe mapping in the same tumor for the first time. At all timepoints, the
intratumoral pHe was lower (pH 6.1-6.8) than the pHe of the brain parenchyma (~7.1)
indicating that the intratumoral microenvironment becomes acidic early during tumor
growth, once the tumor becomes detectable by imaging methods. However, longitudinal pHe
mapping using BIRDS revealed that as tumors become larger there is no clear corresponding
change in pHe. Acidosis developed early during tumor formation and remained acidic
throughout tumor progression. Across all timepoints, the average pH was higher in U87
compared to U251 (6.54±0.08 vs. 6.47±0.14; p=0.046). In U87 tumors, larger tumors had
the same pHe as smaller tumors (6.56±0.05 vs. 6.56±0.09, p=0.94) while in U251 tumors,
larger tumors were slightly more acidic although this was not found to be statistically
significant (6.44±0.15 vs. 6.58±0.06, p=0.12). The pHe remained relatively homogenous
throughout the tumor with minimal spatial variation. The pHe at the core of both tumors
reached similar values in smaller tumors; however, in U87 tumors, the pHe initially
decreased with progression, but was then higher in the largest tumors.

4.4.5 Spatiotemporal patterns of tumorigenesis
All parameters were quantified with increasing distance from the tumor margin
(spatial) and tumor volume (temporal) in both U87 (Figure 5) and U251 (Figure 6) tumors.
Coefficients for the polynomial surface fits of each 3D spatiotemporal plot were calculated
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for both U87 and U251 tumors, where quadratic fits were significantly superior to linear fits
to the 3D surface.

146

Figure 4.5. Spatial and temporal variation in parameter measurements throughout U87
tumor progression. With progression, tumor volume increases. The spatial distribution is
determined by measuring the distance from the tumor margin (0 is tumor margin, 1 is center
of tumor). Measurements include cellularity (ADC), vascularity (Fp, Ktrans, ve, vp from DCE)
and metabolism (pHe from BIRDS) as well as quantitative T2 and pre/post-contrast T1
parameter values are included. All imaging voxels across all timepoints and all tumors were
fit to a 2nd order polynomial to illustrate the variation of spatial parameter distributions with
tumor progression.
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Figure 4.6. Spatial and temporal variation in parameter measurements throughout U251
tumor progression. With progression, tumor volume increases. The spatial distribution is
determined by measuring the distance from the tumor margin (0 is tumor margin, 1 is center
of tumor). Cellularity (ADC), vascularity (Fp, Ktrans, ve, vp from DCE) and metabolism (pHe from
BIRDS) as well as quantitative T2 and pre/post-contrast T1 parameter values are included.
All imaging voxels across all timepoints and all tumors were fit to a 2nd order polynomial to
illustrate the variation of spatial parameter distributions with tumor progression.
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With increased tumor progression (increasing volume), there was a significant
increase in intrinsic T1 in both U87 and U251 tumors. However, there was a homogenous
distribution of the T1 and T2 relaxation measurements across U87 tumors independent of
tumor size. U251 tumors exhibited significant increases in T1 and T2 in central regions of
larger tumors that were not evident at initial tumor detection, possibly indicative of necrotic
cores and which were not evident in U87 tumors as supported by H&E histological findings
(Figure 4.7A), where necrotic regions are indicated by red arrows in U251 tumors and no
necrotic regions were observed in U87. Additionally, the spatial distribution of ADC values
was not uniform, with higher ADC values observed at the tumor margin and in the center of
the tumor. These differences were more pronounced in U251 tumors. The highest values of
ADC were observed in the central regions of large U251 tumors, the same regions that
exhibited higher T1 and T2 relaxation rates. The spatiotemporal patterns of changes in ADC
were similar in both U87 and U251 tumors as ADC was higher at the periphery regardless of
tumor size, as supported by PCNA IHC data (Figure 4.7A) with increased PCNA staining at
the tumor margins.
In U87 tumors, there was much greater homogeneity in the vascular parameter
values. The interstitial and plasma volume fractions tended to decrease with tumor
progression, indicating increased cellularity. Tumor progression also led to an increase in
plasma flow, while vascular permeability (estimated by Ktrans) remained constant. Although
the average vascular permeability did not change over time, there was an increase in
heterogeneity such that regions with higher vascular permeability also had higher plasma
volume fraction and plasma flow. In terms of spatial distribution, the highest value in Ktrans,
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Fp, and vp were seen in intermediary regions of the tumor, compared to the tumor center and
periphery.
In U251 tumors, there were notable differences in the interstitial volume fraction
with tumor progression. With tumor progression, the interstitial volume fraction increased
significantly in deeper regions of the tumor. This corresponded with a reduced plasma
volume fraction and plasma flow in central regions of the tumor. In U251 tumors, the
vascular permeability (estimated by Ktrans) increased with tumor progression and the spatial
heterogeneity actually decreased, reflective of higher Ktrans values throughout the tumor and
as supported by increased VEGF IHC staining throughout the tumor (Figure 7B).
At the time of initial tumor detection, when tumors were small, permeability and the
ve were comparable between U87 and U251 tumors and showed increasing values with
tumor progression that was most pronounced at the growing edge of the tumor. In both U87
and U251 tumors, Fp exhibited similar increasing trends during tumor progression, but at all
stages of tumor growth, perfusion tended to be higher in U87 tumors. Additionally, the
plasma volume fraction increased at the periphery of both U87 and U251 tumors with tumor
progression.
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Figure 4.7. MRI and pathology comparisons for U87 and U251 tumors. (A) Contrast
enhanced (CE) T1-weighted and T2 weighted MRI along with H&E staining and PCNA IHC are
shown for example U87 and U251 tumors. Necrotic regions (red arrows) form in the central
regions of U251 tumors as evident on H&E, which corresponds to regions of higher signal
intensity on T1-weighted images where contrast agent accumulates. Necrosis was not
observable in U87 tumors. Regions of increased proliferation (yellow stars) are highest on
the tumor margins and extend into surrounding tissue in U251 tumors. (B) MRI with
corresponding VEGF IHC in U87 and U251 tumors. Increased VEGF was observed in midregions of U251 tumors.
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4.5 Discussion
U87 and U251 tumors were characterized in terms of their cellularity, vascularity,
and metabolism throughout tumor progression with multi-parametric MRI/MRSI
methodology. Few longitudinal studies on preclinical glioma models have been performed
and normally focus only on one additional imaging contrast.186-188 The pHe has been
monitored longitudinally in C6 glioma models and results show only small changes in the
pHe with tumor progression.189 In this prior study, pHe was measured using hyperpolarized
bicarbonate 13C MRSI and the intracellular pH was measured using a ratiometric chemical
exchange saturation transfer (CEST) approach termed AACID. Here we show that pHe in both
U87 and U251 tumors also remained relatively stable throughout tumor growth. The acidic
microenvironment, with pHe values ranging from 6.1 to 6.8, developed by the initial
timepoint early during tumor progression and remained homogenous. However, U251
tumors were found to be slightly more acidic, suggesting that U87 tumors are metabolically
less glycolytic.
During tumor progression, spatiotemporal patterns of parametric values were
distinct for both U87 and U251 tumors, indicating differences in tumor architecture,
vascularity, and metabolism. Unique tumor growth patterns were evident between U87 and
U251 tumors, with U87 tumors growing to twice the tumor volumes of U251 tumors at the
final time point. While Fp, Ktrans, and vp heterogeneity increased with tumor growth, these
changes were more pronounced for U251 tumors. Although Ktrans remained lowest at the
tumor margin of both tumors, well-perfused regions developed in central tumor regions
between the periphery and core with U87 tumors exhibiting higher Fp. Although there was
no change in average values for ve and ADC with progression, regions with reduced ve

152

corresponded well with lower ADC (higher cellularity) in U87 tumors; for U251 tumors,
regions with higher ve and higher ADC were observed in the core suggesting development of
necrosis.
Despite U87 and U251 tumors being extensively used in the literature, different
growth patterns are evident in many reports.24,26,190 Differences in time to tumor formation
results from the difficulty of injecting large numbers of cells in small volumes. A larger
number of cells (5x105 cells in 5 µL) are injected for the U251 model compared to U87 (2x105
cells in 5 µL) and the variation in time to tumor formation is much greater. Additionally,
U251 tumors do not appear as a uniform mass early during tumor growth, making detection
more difficult and therefore the first scan more variable. U251 tumors are also smaller than
U87 tumors at the time of final scan due to development of neurological symptoms at smaller
tumor volumes in U251 tumors.
The size of the tumor based on contrast enhancement depends on the time from
contrast agent administration until measurement. Previous work comparing the tumor size
from contrast-enhanced imaging revealed the difference in size based on the time from
contrast administration with differences observed up to 30% greater at late time points.191
Although late enhancement T1-weighted images were acquired, the volume was calculated
based on demarcation of the tumor margin on T2-weighted images for consistent
measurements between the tumor types. Additionally, the DCE was acquired in only three
1-mm slices, which in small tumors would cover the entirety of the tumor and could be used
for volume measurement. However, in larger tumors, a greater number of slices was
required for full 3D coverage of the tumor. For this reason, the 7 slices of the T2-weighted
images were used for tumor volume measurements.
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The measurements from DCE-MRI reflect the extent of contrast agent extravasation
and washout from the tumor and relate these changes to local perfusion and vascular
permeability. Both U87 and U251 are well-vascularized tumors. Well-perfused regions (Fp)
developed between the periphery and tumor core with U87 tumors exhibiting higher
perfusion rates, but permeability (Ktrans) remained lowest at the tumor margin for both
tumors. A high interstitial volume fraction (ve) in the central regions of U251 tumors
reflected the development of necrosis. Additionally, this is correlated with increases in T2
and ADC reflective of increased free water that would be present in necrosis. Interestingly
tumor progression showed correlated changes between extracellular space (ve) and tissue
cellularity (ADC). For U87 tumors, regions with reduced ve corresponded well with lower
ADC (higher cellularity), whereas for U251 regions with higher ve and higher ADC were seen
in the core suggesting development of necrosis.
Histology was used to validate the presence of necrosis development in U251 tumors.
Central regions of U251 tumors had reduced cellularity as reflected by decreased
hematoxylin staining on H&E; however, U87 tumors showed no evidence of necrosis.
Necrotic areas on H&E corresponded to regions of higher ADC and increased ve also
suggestive of reduced cellularity as expected with necrosis. While both U87 and U251 are
positive for PCNA, as validated with IHC, U251 has much greater proliferation at the tumor
margin. Further, PCNA is expressed at high levels in peritumoral tissue in U251 tumors
indicative of proliferative cells outside of the demarcated tumor boundary.
VEGF IHC staining revealed increased angiogenesis in the mid-regions of U251
tumors that was not seen in U87 tumors. VEGF expression is regulated by hypoxia which
promotes angiogenesis and an increase in vascular permeability.37 U87 has higher perfusion
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throughout the tumor (increased Fp), which is supported by the lack of VEGF staining. Future
studies should validate this hypothesis using pimonidazole to stain for hypoxia. U251 tumors
have lower Fp and higher vascular permeability (Ktrans) in mid-regions of the tumor (between
the margin and center of the tumor) compared to U87 tumors, which is supported by
increased VEGF staining.
The acidic microenvironment (pHe 6.1-6.8) developed early during tumor
progression and remained homogenous. U251 tumors were more acidic, suggesting higher
glycolytic metabolism in U251 than U87 tumors. Although the pHe remains stable or slightly
increases at late time points in U87 tumors, the volume that is acidified is exponentially
larger, indicating significant changes in metabolic output (possibly due to increasing number
of cancer cells) despite the small variations in pHe. Given that the pHe remains acidic at the
tumor margin, further characterization of the pHe changes in the peritumoral regions may
shed insights into parenchymal transformation as well as the role of surrounding stroma on
tumor growth. U87 has a well demarcated tumor margin that remains well defined
throughout tumor progression indicating minimal invasion into the surrounding tissue. In
contrast, U251 tumors have a poorly defined tumor margin, contrast leaks into the
surrounding tissue, and ADC and T2 values are higher in the peritumoral region, making
measuring spatial variations in pHe at the tumor margin important for characterizing tumor
invasion into surrounding tissue. However, pHe distributions remain homogenous
throughout tumor progression and a stable marker of tumor metabolic output.
Our surface fitting ignored which tumor was associated with which animal, and
instead used tumor volume as a longitudinal progression proxy, rather than time of
progression in each animal. This was significant for several reasons. Firstly, determine the
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starting point for each tumor was infeasible due to tumor variability. Additionally, again due
to tumor heterogeneity, tumor progression did not occur at a same or predictable pace for
each animal. And finally, combining data from different animals allowed for the elucidation
of more universal and robust trends for the different tumor lines rather than a focus on
animal to animal tumor variations.
Our surface fitting analysis is powerful as it is able to reveal simultaneous patterns
and trends in both the temporal dimension (with tumor progression and increase in tumor
volume) as well as the spatial dimension (distance to tumor boundary). However, the
extraction of rich results (fitted surfaces in our case) from any given data comes at the
potential tradeoff of overfitting, thus requiring optimal design choices. One of these was the
degree of polynomial fitting. We chose to fit our surfaces to second degree (quadratic)
surfaces. Our data showed consistent quadratic relationships across different animals and
parameters, making a linear model inappropriate, and giving confidence in our choice of a
quadratic model. The lack of any discernable higher order patterns made any higher order
polynomials (cubic or higher) susceptible to overfitting and inappropriate for our analysis.
Our data is not a random sampling of voxels from across an inordinate number of
tumors, but rather is a collection of many voxels from single tumors in multiple animals.
While data from multiple tumors and animals were used, all the voxels from each tumor,
being from the same tumor, would naturally show some correlation. We have more
datapoints across a range of distances from tumor boundary that across a range of tumor
progressions/time points/tumor volumes. The result of this is that trends along the
"distance to tumor boundary" will be more robust that trends along the tumor
progression/tumor volume axes, and it should also be noted that quadratic fitting could be
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skewed by an outsized impact from tumors that are both of unusually large size and that
violate the normal tumor line trends. While this was a potential limitation, visual inspection
of the data did not indicate this to be the case and showed good interpolation between tumor
volumes, and argues for the merits of the analysis which has been possible here.
Given tumor heterogeneity, and the presence of small amounts of "outlier" tissues
such as blood vessels, we used an automatic outlier removal (or more accurately, an outlier
weighting) robust regression algorithm for our fitting. We chose the Bisquare algorithm as
it is a standard algorithm. However, to check robustness to choice of outlier removal, we also
analyzed our data with the Least absolute residuals (LAR) robust regression algorithm. Our
trends did not change, giving confidence that our outlier algorithm did not introduce any
processing artefacts into the results.
Several previous limitations of the BIRDS method for measuring pHe were addressed
in this study. For the first time, pHe is reported at multiple depths within the tumor from the
3D dataset allowing for spatial pHe characterization throughout a larger region of the tumor.
Additionally, while we have previously shown that the use of probenecid did increase tissue
concentrations of TmDOTP5-,135 this study presents the first application of longitudinal pHe
mapping using BIRDS. Although the ADC/DCE and BIRDS datasets were acquired with
different RF coils, animal positioning was standardized to ensure that the same regions were
imaged in both datasets and were acquired in the same imaging session. The slices used from
the BIRDS dataset were acquired with the same thickness as for the ADC and DCE
measurements such that they represent similar tumor regions. Although minor rotations in
the animal positioning prevent the slices acquired from the two methods to exactly overlap,
they represent the same tumor depths and spatial orientation. The tumor was masked
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independently in the DCE and BIRDS dataset to account for these small discrepancies in
positioning. Future use of a RF coil design that simultaneously captures the DCE and BIRDS
data would resolve these concerns. While probenecid is used clinically although not in this
context, TmDOTP5- is not approved for clinical use. However, transition metal probes with
similar pH sensitivities are being developed to increase translatability. Additionally, BIRDS
can be used in preclinical models to validate other pH sensing methodologies. Further, BIRDS
has recently been implemented on clinical 3T MRI scanners using a rabbit model of liver
cancer181,182 showing that the method is translatable to clinical MR scanners.

4.6 Conclusion
Vascular, cellular, and metabolic imaging provides rich information on the
microenvironment during tumor progression in GBM. For example, although U87 tumors
grew two times faster, U251 tumors were more aggressive as indicated by their prolonged
and reduced perfusion and pHe, a combination of which could be related to necrotic cores. In
addition to changing morphologic architecture and cellularity, the tumor vascular
microenvironment showed a reduction in extracellular volume, increased plasma flow, and
greater heterogeneity throughout tumor progression. Using a combination of probenecid
and TmDOTP5- allows for successful longitudinal BIRDS pHe quantification. Interestingly,
despite the morphologic and vascular remodeling, metabolic output remains stable and
equivalently glycolytic as evident by constant pHe, with the acidic microenvironment
developing early in tumor growth and remaining acidic during tumor progression. This
suggests the potential of pHe as a biomarker of tumor metabolism that is independent of
tumor size and may in future studies be used to monitor treatment response. The dynamic
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processes regulating transformation of the tumor microenvironment suggests tumor
characteristics that must be considered for targeted therapies and where the homogeneity
of pHe during tumor progression may prove useful for evaluating therapeutic responses in
the context of heterogeneous and changing relaxation, diffusion, and vascular parameters.
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Chapter 5: Normalization of the Intratumoral Extracellular pH as a
Biomarker of Therapeutic Response

5.1 Abstract
As seen in Chapter 4, gliomas maintain an acidic extracellular pH (pHe), which
promotes tumor growth and builds resistance to therapy. Given evidence that acidic pHe
beyond the tumor core indicates infiltration, we hypothesized that imaging the intratumoral
pHe in relation to the peritumoral pHe can provide a novel readout of therapeutic influence
on the tumor microenvironment. We used Biosensor Imaging of Redundant Deviation in
Shifts (BIRDS) to generate pHe maps in rat brains bearing either U251 or U87 tumors.
Following TmDOTP5- infusion, the MRI delineated tumor boundary was identified and BIRDS
was used to image the pHe gradient between intratumoral and peritumoral regions (DpHe)
in both untreated and temozolomide treated (40 mg/kg) rats bearing U251 tumors. Treated
rats had reduced tumor volume (p<0.01), reduced proliferation (Ki-67 staining; p<0.03) and
apoptosis induction (cleaved Caspase-3 staining; p<0.001) when compared to untreated
rats. The DpHe was significantly higher in untreated compared to treated rats (p<0.002),
suggesting that temozolomide, which induces apoptosis and hinders proliferation, also
normalizes intratumoral pHe. We also used BIRDS for longitudinal pHe mapping in rats
treated with sorafenib, a tyrosine kinase inhibitor. Treated U87 tumors displayed slower
tumor growth and increased pHe (p=0.01) within 4 days of starting therapy; however,
sorafenib-treated tumors exhibited reduced agent extravasation. In summary, BIRDS can be
used to map the DpHe in gliomas and provide a physiological readout of the therapeutic
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response on the tumor microenvironment. All temozolomide work in this chapter has been
previously published and is used with permission.142

5.2 Introduction
Gliomas account for more than 80% of all malignant brain tumors with most patients
progressing to highly malignant grade IV glioblastomas (GBMs). Patients with GBMs have a
median survival of ∼12 months with only 3–5% of patients surviving for more than 3 years.1
Surgical resection and radiation therapy, together with adjuvant chemotherapy (e.g.,
temozolomide (TMZ)), is currently used to treat GBMs clinically with magnetic resonance
imaging (MRI) playing a central role in initial diagnosis and treatment monitoring. Although
TMZ prolongs survival, chemoresistance and recurrence are common.18 Temozolomide is an
alkylating agent that directly damages DNA and results in cell cycle arrest and apoptosis;19
however resistance to temozolomide arises by the presence of O6-methylguanine DNA
methyltransferase that is able to repair DNA methylation damage. Despite temozolomide
being the only approved chemotherapeutic agent to show a survival benefit, anti-angiogenic
agents including both the anti-VEGF monoclonal antibody bevacizumab and a variety of
small molecule tyrosine kinase inhibitors (TKIs) have shown some promise. While
bevacizumab has shown a benefit in progression-free survival, anti-angiogenic agents induce
changes in tumor vasculature that alters appearance on MRI despite little change in tumor
architecture leading to a pseudoresponse.192
Thus, having reliable markers and methods to assess therapeutic response is of
extreme importance for seeking alternative treatment routes. In this context, imaging
extracellular pH (pHe) has gained importance. A shared trait among cancers is the metabolic
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shift from oxidative phosphorylation to glycolysis (Warburg effect), which leads to increased
acidification of the extracellular milieu as tumor cells extrude H+ and lactate, produced as a
result of increased glycolysis.193 Since TMZ induces apoptosis and given the cancer-induced
metabolic shift, we posit decreased aerobic glycolysis of treated tumor cells can be reflected
as increased intratumoral pHe.
Biosensor Imaging of Redundant Deviation in Shifts (BIRDS) is a 3D chemical shift
imaging (CSI) platform where paramagnetically-shifted non-exchangeable protons on (DOTA) based macrocyclic complexes are directly detected. The proton shifts provide a
readout of the physicochemical environment and the signal does not depend on diffusion or
blood flow.133,136,141 Here we use BIRDS, which is an attractive alternative MR method for
molecular imaging, to evaluate therapeutic efficacy in U251 and U87 human-derived glioma
models. First, we evaluate effects of TMZ in U251 gliomas by measuring pHe inside and
outside the tumor boundary after TMZ treatment. Second, we show the effects of a TKI
(sorafenib) on the longitudinal progression of both tumor vasculature and pHe (before and
after treatment) in U87 tumors.

5.3 Materials and methods
Experiments were performed according to NIH guidelines. Yale University’s animal
care and use committee (IACUC) approved the protocol. U251 scans were conducted on an
Agilent (Santa Clara, CA) 11.7T horizontal-bore spectrometer, using a 1H surface radiofrequency (RF) coil (1.4 cm diameter). U87 scans were conducted on the same system but
operating Bruker (Billerica, MA) software and using a transmit/receive coil in addition to
the

same

surface

coil.

TmDOTP5-
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(1,4,7,10-tetraazacyclododecane-1,4,7,10-

tetrakis(methylene phosphonate) complexed with thulium) was purchased from
Macrocyclics (Dallas, TX, USA), Gadobutrol was obtained from Bayer (Whippany, NJ, USA),
TMZ was obtained from Sigma-Aldrich (St. Louis, MO, USA) and sorafenib was obtained from
AK Scientific (Union City, CA). U87 and U251 cells were purchased from American Type
Culture Collections (Manassas, VA, USA).

5.3.1 Preparation and treatment of rats bearing U251 or U87 tumors
U251 and U87 cells were grown and prepared as described in Chapters 3. In brief,
cells were maintained in standard culture and harvested at high confluence. Adult, female
athymic nude rats (200-250 g; n =19), maintained according to approved animal care
protocols, were anesthetized with isoflurane (2-3%) and positioned in a stereotaxic
instrument. Cells were washed and suspended in serum-free media and a 5 µL volume of the
cell suspension (100,000 cells/µL for U251, 40,000 cells/µL for U87) was injected
intrathalamically (U251, n=11; U87, n=8). For U251 tumors, starting at twelve to fourteen
days post injection, TMZ (40 mg/kg) was orally administered daily in 5 rats, in 2 cycles of 4
days each with a gap of 2 days in between the cycles. In both treated (n = 5) and untreated
(n = 6) U251 tumors, the glioma volume was measured by contrast-enhanced MRI. At the
end of chemotherapy (22-24 days post injection), pHe was measured using BIRDS. In U87
tumors, baseline imaging was performed 10 days after tumor cell inoculation. Animals were
randomized into treated (n=4) or control (n=4) groups. Starting at day 11, sorafenib (100
mg/kg) was administered via oral gavage daily until terminal imaging. MR imaging was
repeated at day 15 and day 19, providing for two additional timepoints after the start of
therapy. At all time points, tumor volume was measured using T2-weighted and contrast-
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enhanced T1-weighted imaging and pHe was measured using BIRDS. Since sorafenib targets
tumor vascularity, additional imaging was performed to measure parameters of tumor
vascularity using dynamic contrast enhanced (DCE) MRI.

5.3.2 U251 Tumor volume and acidity measurements by MRI
Tumor volume was measured with Gadobutrol and TmDOTP5- inducing longitudinal
(T1) and transverse (T2) relaxation enhancements, respectively, by MRI. Spin-echo images
with 128×128 in-plane resolution, 1 mm slice thickness and field of view (FOV) of 25×25
mm2, recycle time (TR) of 4 s, and echo time (TE) of 7 ms. These parameters give an in-plane
resolution of 0.195×0.195 mm2 and voxel size of 0.038 mm3, i.e., parameters which are
sufficient for defining tumors of 1 mm3. Although we used T1 and T2 agents (i.e., Gd3+ and
Tm3+, respectively) in our study to assess tumor sizes, previous work has shown that Gd3+
and Dy3+ extravasation in the same subject identify the same tumor boundary.88 The tumor
volume was calculated from the difference in the MR image intensity in all MR slices before
and after contrast agent (either Gadobutrol or TmDOTP5-) injection. The absolute intensity
difference before and after contrast agent was divided by the image intensity before contrast
agent injection to obtain a relative change in the intensity. The volume of the tumor was
assumed to be equal to the volume of the region where the relative intensity change is larger
than a threshold value, established by comparison with the relative intensity change
measured in the contralateral (left) hemisphere.
At 12-14 days after tumor inoculation (~2 weeks), an infusion line was established in
the lateral tail vein of the rat. A 30G needle was inserted into PE10 (Braintree Scientific, LLC)
line and filled with heparinized saline. The needle was inserted into the lateral tail vein of
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the rat and checked for backflow to ensure correct placement within the vein, prior to being
anchored to the tail with tape. Each rat underwent bolus injection of Gadobutrol (~0.4
mmol/kg) to estimate the tumor volume from increased MRI signal (T1 contrast) due to
Gadobutrol extravasation.
At 22-24 days after tumor inoculation (~3 weeks) each rat underwent infusion of
TmDOTP5- (~0.4 mmol/kg) for pHe imaging and the tumor volume was estimated from
decreased MRI signal (T2 contrast) due to TmDOTP5- extravasation.141 The anesthetized rats
were prepared as described earlier with renal ligation to maintain a high concentration of
TmDOTP5- (slowly infused at 0.5-0.7 mL/hr using a syringe pump) during BIRDS
experiments.194,195 Ventilation was adjusted to maintain normal physiology. Body
temperature was measured with a rectal probe and no further adjustments in the waterheated pad were made for the entire duration of the experiment (~2 hrs).
Tumor acidity was measured using the BIRDS technique described previously.
133,134,141

In short, chemical shift imaging (CSI) for BIRDS was performed to measure the

chemical shifts of the pHe-dependent proton resonances of TmDOTP5- to calculate pHe within
each voxel at an isotropic resolution of 1mm3. A 205 μs dual-banded Shinnar-Le Reux pulse
with a bandwidth of 40kHz was used for excitation of the H2, H3, and H6 resonances of
TmDOTP5-. pHe was calculated in each voxel using BIRDS as previously described.141

5.3.3 Histopathological study of effect of TMZ therapy
Post experiment, rats were perfuse-fixed with 4% paraformaldehyde and embedded
in paraffin. Brain tissue sections (6 µm) were immunohistochemically stained for Ki-67 and
cleaved Caspase-3 as previously described.196 Primary antibody diluted in 1% BSA/PBS was
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applied overnight at 4 °C for Ki-67 (1:25, Abcam, ab66155) and Caspase-3 (1:25, Cell
Signaling Technology, #9661). The sections were incubated with a goat anti-rabbit
secondary antibody (1:500, Pierce, #31460) for 60 minutes followed by incubation with
metal enhanced 3,3-diaminobenzidine (DAB; Life technologies, #34065) for 10 min.
Expression of immunohistochemical markers was quantified by evaluating the presence of
DAB staining and visually quantifying positive staining.

5.3.4 U87 Tumor volume, vascular, and acidity measurements by MRI
Quantitative T2 mapping was performed by acquiring T2-weighted images with 10 TE
10-100ms, TR of 6 s, slice thickness 1 mm, 25 × 25 mm FOV, 128 × 128 matrix. Diffusionweighted imaging was performed using an EPI sequence with 6 b values (0-3000 s/mm2) in
a single direction and acquired with slice thickness 1 mm, 25 × 25 mm FOV, 64 × 64 matrix.
Quantitative T1 mapping consisted of T1-weighted images acquired using a RARE sequence
with TE 10ms, 5 TR (400-8000ms), slice thickness 0.7mm with 0.3mm gap, 25 × 25 mm FOV,
128 × 128 matrix. The T1 sequence was then repeated after 0.25 mmol/kg gadoterate
meglumine (Dotarem) administration to serve as a post-contrast image which was used,
along with T2 images, to delineate tumor boundaries. A contrast enhanced T1-weighted 3D
FLASH was also acquired with TE 5ms, TR 30ms, and 0.33mm isotropic resolution for highresolution coverage of the entire tumor for coregistration.
DCE-MRI was acquired using a dual-echo spoiled gradient echo acquisition (TR/TE:
39ms/2.5-5ms) every 5 seconds over 22 min. At 2 min into the dynamic scan, a bolus IV
injection of 0.25mmol/kg Dotarem, a clinically available macrocyclic gadolinium agent, was
injected and then flushed with heparinized saline. Other imaging parameters included a flip
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angle of 15o and one average for a temporal resolution of 5 s. Three central slices of the tumor
were chosen with the exact same positioning, FOV (25 × 25 mm), and matrix (128 × 128) to
be co-registered to the T1 data. Measurements from pre-contrast T1-weighted images were
used to transform the signal time-intensity curves into time-concentration curves (TCCs).
The arterial input function (AIF) was measured by collecting arterial blood samples at
discrete time points post-injection in a representative animal. A hematocrit of 0.45 was
assumed for deriving the contrast agent concentration in the blood. The raw AIF was fit to a
bi-exponential curve and applied to the analysis for all datasets. A region of interest (ROI)
was placed in the tumor, which was the area used for all analyses. To measure vascular
parameters [Ktrans (volume transfer coefficient, min-1), Fp (plasma flow rate, min-1), ve
(extracellular volume fraction, unitless), vp (plasma volume fraction, unitless)], a twocompartment exchange model (2XCM) was used to fit the DCE data. The parameters were
estimated by fitting each voxel using least squares regression using prior software.185
Prior to the start of pH mapping, the animal was removed from the magnet bore and
transferred to a 1.5 cm single loop surface coil. For BIRDS pHe measurements, 100 mg/kg
probenecid was administered over 10 min and followed after 20 min by a coinfusion of 100
mg/kg probenecid and 1 mmol/kg TmDOTP5-. Probenecid was used to increase the plasma
concentration of the circulating contrast agent and reduce its rate of renal clearance. All
infusions were performed using a syringe pump at a rate of 15 µL/min for a total infusion
time of 100 min. Chemical shift imaging began 45 min after the start of the infusion. All
acquisition parameters were the same as those used for U251 tumors. Quantitative T2
mapping was performed for tumor localization as described earlier.
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5.3.5 Statistics
T1, T2, and ADC parameters were generated by fitting voxel-level data to a
monoexponential function in Matlab. All DCE vascular parameters and pHe by BIRDS were
quantified on a voxel by voxel basis and spatially plotted in Matlab overlaid on T2-weigheted
images. All parameters were averaged across the tumor ROI. All staining, tumor size and pHe
results were expressed as mean ± SD and comparisons between groups were assessed by
Student’s t-test with two tails where p<0.05 was considered significant.

5.4 Results
5.4.1 Effect of TMZ on tumor size, apoptosis, and proliferation
Tumor size was measured by MRI contrasts generated from water proton
longitudinal (T1) and transverse (T2) relaxation enhancements. The effect of TMZ on U251
tumor growth was assessed by measuring the tumor volume at ~2 weeks (i.e., 12-14 days
using T1-enhanced contrast by Gadobutrol) and ~3 weeks (i.e., 22-24 days using T2enhanced contrast by TmDOTP5-) post tumor inoculation (Figure 5.1A). In the treated
group, the rats were imaged at 12.6±0.5 and 22.8±0.7 days, whereas in the untreated group
the rats were imaged at 12.4±2.2 and 22.0±3.3 days. Recent experiments indicate that tumor
volumes measured with a T1 agent (e.g. Gadobutrol) are nearly identical with those
measured using a T2 agent (e.g. TmDOTP5-) in the same rat.88 Ambiguity exists in delineating
tumors in clinical images with ill-defined tumor boundaries. However, U251 tumors in
rodents have a tumor mass with fairly well-defined boundary. Thus, ambiguity in tumor
boundaries has minimal effect on the tumor volume measurements compared to clinical
scans. The volume of untreated tumors at 2 weeks post tumor inoculation was 5.9±2.7 µL,
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which increased to 25.3±13.9 µL at 3 weeks. Treated tumors had similar volumes at 2 weeks
(5.2±1.2 µL) and 3 weeks (3.9±0.9 µL) (Figures 5.1A and 5.1B). Thus, tumor sizes were
significantly different in treated vs. untreated animals at later stages of tumor growth
(p<0.01) and there was no further tumor growth with therapy.
Expression of Ki-67 and cleaved Caspase-3, shown in Figure 5.1C-E, was investigated
in treated and untreated rats. Quantitative analysis revealed that the average Ki-67 labeling
before TMZ treatment was 67.5%, which reduced to 10.5% following TMZ treatment
(p<0.03) indicative of reduced proliferation. Cleaved Caspase-3 staining before TMZ
treatment was 2.5%, which increased to 15.5% following TMZ treatment (p<0.001)
suggesting apoptosis initiation. Expression of MCT-4 was analyzed in a representative
sample of untreated and treated tumors and high MCT-4 expression was observed in
untreated tumors (Figure 5.1F).
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Figure 5.1. Effect of TMZ treatment on U251 tumor morphology, apoptosis, and
proliferation. (A) T1- and T2-weighted MRI at ~2 and ~3 weeks post tumor implantation,
respectively, depicting tumor sizes in untreated and TMZ treated U251 tumors. (B) Tumor
volume in treated and untreated U251 bearing rats at ~2 and ~3 weeks post tumor
implantation, where the difference between treated and untreated groups were significant
at later stages (*, p=0.01). (C) Ki-67 and cleaved caspase-3 staining in untreated and TMZ
treated U251 tumor bearing rats. Arrows point to brown colored positive DAB staining. (D)
Percentage of cells showing positive staining for Ki-67 and Cleaved Caspase-3. In treated vs.
untreated tumors, Ki-67 shows a significant decrease in proliferative index (*, p=0.025) and
cleaved caspase-3 shows a significant increase in apoptotic index (#, p=0.001). (E) High
magnification Ki-67 staining of untreated U251 tumors. The arrows point to positive DAB
staining for Ki-67 where co-localization with hematoxylin (blue) is clearly visible. (F) MCT4 staining of treated and untreated U251 tumors with arrow marks pointing to positive DAB
staining for MCT-4.
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5.4.2 Effect of TMZ on intratumoral and peritumoral acidity
Representative BIRDS data from untreated and treated rats are shown in Figure 5.2.
The tumors were localized by T2 contrast as a result of TmDOTP5- extravasation from
immature tumor vasculature.133,135 Treated tumors appeared smaller in size compared to
untreated tumors (Figures 5.2A (i) and 5.2B (i); see also Figures 5.1A and 5.1B). The
proton resonances of TmDOTP5- in the corresponding imaging slice are shown in Figures
5.2A(ii) and 5.2B (ii). As the permeability and clearance rates of TmDOTP5- vary in different
tissues, the peak intensities vary across the different regions in the image. As reported
previously,141 BIRDS can distinguish pHe maps for tumors of different sizes, and both the
intratumoral pHe (inside tumor boundary) and peritumoral pHe (outside tumor boundary)
can be measured simultaneously. The intratumoral pHe values for the untreated and treated
tumors were ~6.8 and ~7.1, respectively (Figures 5.2A (iii) and 5.2B (iii)). However, the
peritumoral pHe values quite distal from the tumor boundary for the untreated and treated
tumors were approaching neutral values (i.e., ~7.2 and ~7.3, respectively in Figures 5.2A
(iii) and 5.2B (iii)). It should be noted, however, that acidic peritumoral pHe values were
observed immediately adjacent to the tumor boundary in untreated tumors. This is
supported by greater Ki-67 expression in untreated rats when compared to treated rats
(Figures 5.1C and 5.1D). This trend of acidic peritumoral pHe immediately adjacent to the
tumor boundary has been observed for other aggressive gliomas.135,141
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Figure 5.2. Representative pHe maps from BIRDS in untreated and TMZ treated rats bearing
U251 tumors. (i) The T2-weighted images identify the tumor boundary (tumor = blue outline;
brain = orange outline) in untreated (A) and temozolomide treated (B) U251 tumors. (ii) CSI
data for corresponding slice in (i) shows varying TmDOTP5- levels throughout the brain. (iii)
Quantitative pHe maps were obtained using multiple TmDOTP5- peaks and the intratumoral
and peritumoral pHe average values and their standard deviations are indicated. In
untreated rats, the tumor is larger, the intratumoral pHe is acidic and spreads beyond the
tumor boundary. In treated rats, the tumor is smaller, the intratumoral pHe is near neutral
with lower pHe localized within the tumor boundary.
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Because the spatial resolution of pHe maps was lower than that of MR images, we took
precautions to report the intratumoral and peritumoral pHe values accurately. In small
tumors, where many voxels intersect the tumor boundary defined by MRI, partial
contribution from the non-tumor area can confound the results. Thus, voxels that contained
more than 50% tumor tissue were considered tumor voxels resulting in at least 2 tumor
voxels in the smallest tumors detected.
The intratumoral and peritumoral pHe values for untreated and treated tumors are
represented in histograms in Figure 5.3A and 5.3B, respectively. The histograms were fitted
to a Gaussian distribution to obtain the most probable pHe and the full width at half
maximum (FWHM) of these histograms. The most probable intratumoral pHe values were
higher in treated when compared to untreated tumors. The FWHM values of untreated
tumors (~0.4) were higher than treated tumors (~0.3), indicating heterogeneous pHe in
untreated rats, which is normalized by TMZ in treated rats. Figure 5.3C shows the average
values of intratumoral and peritumoral pHe in treated and untreated rats. Average
intratumoral pHe was significantly (p<0.01) lower in untreated rats compared to treated
rats, whereas in peritumoral regions no significant difference (p>0.05) was observed
between the two groups.
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Figure 5.3. Distribution of pHe values in untreated and temozolomide treated tumors.
Intratumoral (gray bars) and peritumoral (black bars) regions are shown for untreated (A)
and TMZ treated (B) U251 tumors. Average pHe values (±SD) for intratumoral and
peritumoral regions in untreated and TMZ treated U251 tumors (C) show that the average
pHe value for intratumoral voxels is significantly lower in untreated tumors compared to
treated tumors (*, p=0.001).
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To investigate how pHe is affected in voxels positioned at different distances relative
to the center of mass of the tumor, the brain was separated into regions of interest (ROIs)
starting from the center of the tumor and progressing outwards in concentric 1 mm circles
(Figure 5.4A). The boundaries between the intratumoral and the peritumoral regions
(shown with white and black arrows for the treated and untreated groups, respectively, in
Figure 5.4B) were calculated from the average tumor volume obtained from the anatomical
MR images (Figure 5.1B), assuming a spherical tumor shape. Lower pHe values were
observed in the intratumoral regions (ROIs 1 and 2) in the untreated group (Figure 5.4B).
In the treated group, the pHe values in the intratumoral regions (ROI 1) were partially
normalized by TMZ treatment. The lower pHe value measured in ROI 3 in the untreated
group (7.13 ± 0.10) reflects the increased acidity of the tissue surrounding the tumor, as can
also be observed in Figure 5.2. The treated group, in comparison, has pHe values of the tissue
surrounding the tumor (ROI 2) closer to normal values (7.21 ± 0.04). However, the lower
average pHe value observed for the untreated group in regions surrounding the tumor (ROI
3) might be due to contributions from larger tumors (with lower pHe). For regions distant
from the tumor center (ROIs 4 to 10) the pHe values are not significantly different between
the treated and the untreated groups (p>0.05). In addition, heterogeneous pHe distributions
in the untreated rats were suggested by larger SDs in each ROI compared to treated rats,
except ROI 1. The larger standard deviation for ROI 1 is most likely due to variations in the
temozolomide effect on intratumoral pHe across different animals. Note that most of the
intratumoral regions for the treated group is restricted to ROI 1, based on the tumor
boundary estimation described above. The SD for the rest of the ROIs (ROIs 2 to 10) is
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smaller in the treated group because those ROIs contain mostly normal brain tissue whose
pHe is minimally affected by the temozolomide treatment.
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Figure 5.4. Average pHe values across all animals in various ROIs positioned at increasing
distance from the center of mass of the tumor. The T2 map was used to mask the tumor and
determine its center of mass. The brain was then segmented into ROIs (A) defined by the
distance from the corresponding voxel to the center of mass of the tumor. Each ROI was
defined as the area bounded by two circles of radius n-1 mm to n mm from the center of mass
of the tumor (n=1 to 10). The average pHe value for each animal was calculated from the pHe
values from all the voxels inside each ROI. Then, the average pHe values and the
corresponding standard deviations (indicated as the error bar) across animals were
calculated for each ROI (B). The boundaries between the intratumoral and the peritumoral
regions (shown with white and black arrows for the treated and untreated groups,
respectively) were calculated from the average tumor volume obtained from the anatomical
MR images (Figure 5.1B), assuming a spherical tumor shape.
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5.4.3 Effect of sorafenib on U87 tumor size, MR relaxation, and diffusion
All U87 animals (n=8) had baseline imaging performed at Day 10 after tumor cell
inoculation. Sorafenib (n=4) or DMSO control (n=4) was administered starting on Day 11.
However, all animals did not complete the full imaging protocol as there were losses during
scanning and fast tumor progression in control animals. Control (n=4) and treated (n=3)
animals were imaged at a first follow-up (Day 15). Control (n=3) and treated (n=3) animals
were imaged again at a second follow-up (Day 19); however, two control animals died at the
beginning of imaging and only completed tumor volume measurements. Finally, two treated
animals survived and were imaged at Day 26.
Tumor volume was measured by manually outlining tumor boundaries on T2weighted and contrast-enhanced T1-weighted MRI across multiple slices allowing for
complete coverage over the entire tumor volume. Representative T2-weighted images are
shown in Figure 5.5A before and at multiple time points after therapy in both sorafenib
treated and control tumors. Quantitative tumor volumes were similar in treated and control
tumors at baseline (15.1±10.2 mm3 vs. 17.2±10.7 mm3). However, tumor volumes were
lower in treated tumors versus controls at day 15 (35.0±20.8 mm3 vs. 78.9±66.7 mm3) and
day 19 (58.1±40.1 mm3 vs. 145.1±91.7 mm3). Since tumor volume was variable at baseline
as seen by large standard deviations resulting in divergent tumor progression, tumor
volumes were normalized to the tumor volume at day 10 and are shown in Figure 5.5B.
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Figure 5.5. Effect of sorafenib treatment on U87 tumor volume and morphology. (A) T2weighted MRI at baseline (Day 10), 4 days after start of sorafenib therapy or DMSO control
(Day 15), and 8 days after start of sorafenib therapy or DMSO control (Day 19). All
timepoints were acquired longitudinally in the same animal and depicted the tumor size in
untreated and sorafenib-treated U87 tumors. (B) Normalized tumor volume in treated and
untreated U87 bearing rats at baseline and two time points after start of sorafenib therapy
or DMSO control, where the difference between treated and untreated groups were
significant at the final time point (*, p=0.014).
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Quantitative T1 mapping was performed before and after the administration of a
gadolinium contrast agent (Dotarem). Representative T1-weighted images and quantitative
T1 maps before and after contrast administration are shown in Figure 5.6A for both
sorafenib and DMSO treated animals. For comparison purposes, only baseline (Day 10) and
4 days post-treatment (Day 15) data are shown in grouped analyses. The intrinsic T1 was not
different between the DMSO and sorafenib groups at baseline (2.33±0.13 s vs. 2.28±0.17 s)
or four days after treatment (2.49±0.09 s vs. 2.48±0.13 s); however, the intrinsic T1 did
increase as the tumor grew larger in both groups (Figure 5.6B). After administration of the
contrast agent, the T1 decreased in both DMSO and sorafenib groups. At baseline, T1
decreases were not different between DMSO vs. sorafenib animals (1.46±0.18 s vs. 1.35±0.19
s). However, after four days of treatment initiation, the post-contrast T1 in DMSO animals
was significantly lower (1.24±0.26 s) compared to sorafenib treated animals (1.63±0.06 s)
(p=0.05) (Figure 5.6C). Additionally, the post contrast T1 values in sorafenib animals
continued to increase at later time points, reaching 1.55±0.17 s at eight days post-treatment
and 2.02±0.04 s at fifteen days post-treatment; however, T1 values for DMSO controls are not
available for comparison at these later time points since control animals reached their
survival endpoints earlier. The increase in T1 in sorafenib treated rats reflects a decrease in
delivery of the contrast agent to the tumor as illustrated by the reduction in contrast in T1weighted imaging (Figure 5.6A).
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Figure 5.6. Sorafenib reduces the delivery of contrast agents to the tumor and effects T1
relaxation. (A) Representative T1-weighted images (TR/TE: 1000/10 ms) are shown at
baseline (Day 10) and four days after sorafenib therapy or DMSO control (Day 15).
Additionally, quantitative T1 mapping for the same tumors are shown before (intrinsic) and
after (contrast-enhanced) administration of 0.25 mmol/kg of a gadolinium-based contrast
agent (Dotarem). In all images the brain is outlined in white and the tumor is outlined in
black. (B) Average intrinsic T1 values for each time point across all tumors. (C) Average
contrast-enhanced T1 values for each time point across all tumors. All values are shown as
average ± standard deviation.
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DCE-MRI was used to study the vascularity of sorafenib treated U87 tumors. The
dynamic data was fit to a two-compartment exchange model that allowed for four vascular
parameters to be quantified and spatially mapped across the tumor at multiple time points
(Figure 5.7A). Due to the limited number of animals and the highly variable parameter
values between tumors, no changes were found to reach statistical significance. The Ktrans
was not different between the DMSO and sorafenib groups at baseline (2.33±0.13 s vs.
2.28±0.17 s) or four days after treatment (10.2±2.2 10-3/min vs. 13.8±7.4 10-3/min) (Figure
5.7B). At baseline, Fp was more variable between tumors as shown by values for DMSO vs.
sorafenib animals (34.8±18.5 10-3/min vs. 53.3±47.5 10-3/min). However, after four days of
treatment the Fp in sorafenib animals decreased to 20.7±11.0 10-3/min, whereas it slightly
increased in DMSO animals to 57.9±6.3 10-3/min (Figure 5.7C). Additionally, the Ktrans and
Fp continued to decrease at later time points; in the sorafenib group the Ktrans was 3.92±2.43
10-3min-1 at eight days post-treatment and 1.60±0.44 10-3min-1 at fifteen days posttreatment and Fp was 4.06±2.47 10-3min-1 at eight days post-treatment and 2.00±0.42 103min-1 at fifteen days post-treatment. Similarly, in the sorafenib group the v and v were also
e
p

heterogeneous and variable between tumors. There was little change in ve between baseline
and four days after sorafenib treatment (0.17±0.05 vs. 0.10±0.03) (Figure 5.7D), which was
similarly seen in vp (0.012±0.012 vs. 0.017±0.007) (Figure 5.7E). However, at later
timepoints, ve and vp increased, respectively, to 0.35±0.10 and 0.045±0.008 at eight days
post-treatment and continued to increase to 0.81±0.16 and 0.104±0.004 at fifteen days posttreatment. However, the parameter values based on the two-compartment exchange model
are likely biased by the restricted extravasation of the contrast agent into the extracellular
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space as tumor appearance and architecture on imaging do not suggest a loss of cellularity
that would support such a large increase in the extracellular volume fraction.

Figure 5.7. Sorafenib effects on tumor vascularity as measured using DCE-MRI. (A)
Representative Ktrans, Fp, ve and vp parametric maps are shown at baseline (Day 10) and four
days after sorafenib therapy or DMSO control (Day 15). All parametric maps were quantified
over the tumor ROI and overlaid on T2-weighted images (TE/TR: 30/6000 ms) of the entire
brain. The two time points were acquired in the same animal. Average Ktrans (B), Fp (C), ve (D)
and vp (E) for each time point across all tumors. All values are shown as average ± standard
deviation.
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Finally, pHe was measured longitudinally using BIRDS after sorafenib therapy. BIRDS
has been precluded from repeated measures of pHe in the same tumor due to the need for
surgical interventions to increase the circulating concentration of the contrast agent
(TmDOTP5-) as was performed for the TMZ studies in U251 tumors. However, using
probenecid, an organic anion transporter inhibitor, sufficient agent is able to extravasate
into the tumor to allow for quantitative pHe mapping and demonstrating the first time that
BIRDS has been used to monitor pHe changes in a tumor in the context of a therapeutic study.
Representative longitudinal pHe maps in sorafenib treated and DMSO control animals are
shown in Figure 5.8A. The pHe was not different between DMSO and sorafenib groups at
baseline (Day 10) (6.53±0.04 vs. 6.53±0.08, respectively). However, at four days posttreatment, the pHe in sorafenib treated tumors increased to 6.77±0.05, while in DMSO
control tumors the pHe remained unchanged (6.58±0.06) (Figure 5.8B). The statistically
significant (p=0.01) increase in pHe represented a trend towards normalization of the
intratumoral pHe as normal brain pHe is ~7.1-7.3. Notably, this increase in pHe began within
the first days of treatment, before the pronounced vascular changes expected with TKIs
developed. However, due to the vascular effects of sorafenib, as reflected in the reduction in
contrast enhancement on T1-weighted imaging, TmDOTP5- was not delivered to the tumor in
sufficient amounts to allow for pHe mapping at later time points in treated tumors as can be
seen in CSI datasets where sharp signals are seen from TmDOTP5- within the tumor at Day
10 (baseline) and Day 15 (4 days post-treatment), but are absent at later time points (Figure
5.8C).
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Figure 5.8. Effects of sorafenib on extracellular pH. (A) Representative pHe maps are shown
at baseline (Day 10) and four days after sorafenib therapy or DMSO control (Day 15). pHe
was quantified over the tumor ROI and overlaid on T2-weighted images (TE/TR: 30/6000
ms) of the entire brain. The two time points were acquired in the same animal. (B) Average
pHe for each time point across all tumors. All values are shown as average ± standard
deviation where *p=0.01. (C) Representative CSI datasets for a sorafenib-treated tumor
acquired at baseline (Day 10) as well as 4, 8, and 15 days after the start of sorafenib therapy.
The contrast agent (TmDOTP5-) is detectable at baseline as well as four days post-treatment;
however, at later time points, the agent is not delivered to the tumor in sufficient amounts to
make pHe mapping possible.
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5.5 Discussion
Assessment of therapeutic response in GBMs is usually achieved by T1- and T2dependent MRI contrasts. However, these methods can be confounded by pseudoprogresson
and pseudoresponse. Thus, alternative methods for monitoring therapeutic response are
needed.
Various MRS and MRI techniques for pHe mapping have been previously reported.
Gallagher et al. imaged pHe in mouse lymphoma using hyperpolarized

13C

bicarbonate

measurements.109 pHe-sensitive contrast was measured in C6 glioma rats using GdDOTA4Amp5-, a pH sensitive T1 agent.88 MRI methods based on chemical exchange saturation
transfer (CEST), using either diamagnetic or paramagnetic agents have been used to
generate pHe-sensitive maps such as CEST imaging of the amine protons on glutamine.
Amide proton transfer (APT) and amine CEST have been used in both preclinical and clinical
settings.130,197
BIRDS is a different technique, which has been used to image the intratumoralperitumoral pHe gradient in gliomas.141,198 Because the molecular readout from the
TmDOTP5- protons is chemical shift-dependent, the method is independent of field strength
and agent concentration. We reported previously that the error in pH determination
depends on the error in chemical shift measurement, which in turn depends on the signalto-noise ratio (SNR) for each proton resonance.134 Typical in vivo SNR values for H2, H3 and
H6 protons is in the range of 5 to 20, which corresponds to an error in pH measurement in
the range of 0.01 to 0.03. While a limitation of BIRDS is the spatial resolution compared to
conventional MRI, the pHe readout even at a course spatial resolution provides valuable
insights into the tumor microenvironment in relation to its neighboring tissue.
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It was observed by Estrella et al. (2013) that regions of highest tumor invasion
corresponded to regions of lowest pHe.5 So, it is hypothesized that acidic pHe mediates local
invasive growth and metastasis. Recently, we showed that extensive acidic pHe in the
periphery of the tumor is correlated with increased invasiveness. This is associated with
increased presence of Ki-67 positive cells in the tumor boundary of invasive models.141
Similarly, in untreated tumors we observed lower pHe in the tumor boundary and increased
presence of Ki-67 positive cells indicative of increased proliferation and invasive growth.
TMZ treatment in U87 rat gliomas has shown alterations in the lactate to pyruvate ratio in
comparison with untreated rats due to reduced pyruvate kinase M2 activity.199,200 In
addition, reduced metabolic output in response to reduced tumor burden suggests altered
pHe in intratumoral and peritumoral regions in response to TMZ. We observed an inhibition
of tumor growth with TMZ treatment, similar to several previous reports.200-203 Also in
agreement with previous studies, we observed apoptosis induction and reduced
proliferation with TMZ treatment.199,203
In a recent report by Huang et al., we present an alternative method for achieving a
transient increase in the circulatory concentration of BIRDS agents (TmDOTP5-) by using
probenecid.135 Probenecid is an organic anion transporter inhibitor that is used to decrease
the renal excretion rate of antibiotics and certain other drugs and thus achieve increased
drug concentration. Co-infusion of probenecid along with TmDOTP5- showed that
intratumoral peritumoral pHe gradient was unaffected by co-infusion. This allowed for
longitudinal studies to be performed in a cohort of U87 tumors treated with sorafenib.
Here we demonstrate longitudinal pHe mapping with BIRDS for the first time in the
context of treatments (sorafenib). The pHe increased significantly after four days of
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treatment with the TKI sorafenib. This suggests that although the morphologic appearance
of the tumor is unchanged, the vascular and metabolic features of the tumor
microenvironment are impacted early in the treatment course. While we did observe the
reduction in contrast enhancement after administration of gadolinium contrast agents
(Dotarem) expected with sorafenib therapy, these changes were very modest at the earliest
time points after therapy. Additionally, DCE-MRI is frequently used to study the vascular
features of the tumor microenvironment. However, in the setting of anti-angiogenic
therapies such as sorafenib, where the extravasation of the contrast agent into the
extracellular space is greatly reduced, the dynamic modeling can lead to results that are not
in agreement with the morphology of the tumor. For example, although there are significant
increases in the extracellular and plasma volume fractions quantified from DCE-MRI, there
are no corresponding changes in the tumor appearance on imaging that would suggest that
the tumor is becoming less cellular (decreased extracellular volume fraction, ve). Additional
support for this finding comes from measures of the apparent diffusion coefficient (ADC)
that has been correlated with tumor cellularity, such that reductions in ADC represent more
highly cellular tumors.80 However, changes in tumor ADC in U87 tumors is not observed.
Therefore, the reductions in pHe early during the course of therapy can represent a novel
way to differentiate a therapeutic response.
In conclusion, mapping pHe in intratumoral and peritumoral regions using BIRDS
could serve as a biomarker in evaluating therapeutic response in gliomas which in turn could
be potentially applied in evaluating response to a wide range of therapies beyond
temozolomide and sorafenib.
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Chapter 6: Conclusion and Ongoing/Future Directions
6.1 Summary
In the work presented in this dissertation, we have used a variety of magnetic
resonance imaging (MRI) and spectroscopic imaging (MRSI) methods to study the tumor
microenvironment in human-derived preclinical models of glioblastoma. In particular, we
have further developed Biosensor Imaging of Redundant Deviation in Shifts (BIRDS) as a
quantitative tool for studying tumor metabolism as reflected by an acidic extracellular pH
(pHe). In prior work, BIRDS pHe mapping has been used to measure the intratumoral–
peritumoral pHe gradient in 9L and RG2 rodent models of gliomas and to correlate the
extensive acidic pHe in regions surrounding the tumor with tumor cell invasion.141 Here, we
have expanded BIRDS to image the acidic pHe in several human-derived models of
glioblastoma (U87 and U251).
While prior work using BIRDS has relied on renal intervention to reduce contrast
agent clearance, a BIRDS protocol was developed using pharmacologic inhibition of renal
clearance that allowed for longitudinal, repeated pHe mapping (Chapter 3). We then
exploited the corresponding temperature readout from BIRDS in a hypothermia model to
verify the quantitative ability of the method. The cerebral temperature was manipulated and
the corresponding temperature changes were measured by BIRDS.204 Due to the redundant
nature of the measurement, BIRDS provides simultaneous quantitative measures of both pH
and temperature that are calculated based on the same calibration.
Further, the longitudinal BIRDS protocol allowed for measuring the acidic
microenvironment throughout tumor progression (Chapter 4). We combined BIRDS with
other MRI techniques, including diffusion-weighted imaging and dynamic contrast enhanced
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imaging to provide imaging markers of tumor cellularity and vascularity, allowing for a
thorough characterization of the vascular and metabolic features of the tumor
microenvironment. We made simultaneous and longitudinal measurements of tumor
perfusion (Fp), permeability (Ktrans), and volume fractions of interstitial (ve) and plasma (vp)
spaces from dynamic contrast enhanced (DCE) MRI, cellularity from apparent diffusion
coefficient (ADC) MRI, and extracellular pH (pHe) from BIRDS. Spatiotemporal patterns of
these parameters during tumorigenesis were unique for each tumor and both U251 and U87
tumors became acidic (pHe 6.1-6.8) early during tumor formation and remained acidic
throughout tumor progression. While there was no correlation between tumor size and pHe,
U251 tumors were more acidic, suggesting lower aerobic glycolysis than in U87 tumors.
Finally, we provided further evidence supporting the role of pHe as a potential
biomarker of therapeutic response (Chapter 5). Rats bearing U251 gliomas treated with
temozolomide (40 mg/kg) had a lower intratumoral–peritumoral pHe gradient and a
reduced tumor volume with increased proliferation and induction of apoptosis when
compared to untreated rats.142 Additionally, rats bearing U87 gliomas had an increased
intratumoral pHe with sorafenib (100 mg/kg) therapy. BIRDS was shown to be able to be
used to map the pHe in gliomas and provide a physiological readout of the therapeutic
response on the tumor microenvironment.
Using imaging methods sensitive to the cellular, vascular and metabolic features of
the tumor allows for a more comprehensive characterization of the tumor
microenvironment that may shed insights into changes reflective of the treatment response.
The development of pHe mapping imaging may serve as a biomarker of disease progression
and response to therapy. Based on these results, ongoing work as described in this chapter
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has expanded BIRDS beyond common glioma models. One critique of cell line models is that
they are not representative of clinical disease. To address this concern, we sought to
implement BIRDS-based pHe mapping in a patient-derived xenograft model of metastatic
melanoma. We also sought to expand the applicability of BIRDS by implementing the method
on clinical MRI scanners and in tumors in different parts of the body. Finally, in the context
of glioblastoma, we sought to gain further insight into the role of central necrosis and
peritumoral edema through histological comparisons and their potential impact on antitumor immunity in glioblastoma. Taken together, this ongoing work provides the basis for
future studies on applications for pHe mapping in assessing different therapies in a multitude
of different cancers, as well as technical improvements that can lead to improved imaging
times and spatial resolution in BIRDS pHe mapping.

6.2 Application of BIRDS to patient-derived xenograft models of metastatic
melanoma
While glioblastoma is the most common primary malignant tumor in the brain, brain
metastases are the most common malignancy in the CNS in adults with melanoma having a
high propensity to spread to the brain.205 Brain metastases, particularly from melanoma,
present a challenge in diagnosis and therapeutic monitoring. The presentation of metastatic
disease is highly heterogeneous based on location and number of tumors, as well as the
tissue in which it grows being different from the tissue from which the tumor was derived.
Recent therapeutic advances have made significant progress in the treatment of
metastatic melanoma to the brain using surgery, radiation, and novel immunotherapies,
including the checkpoint inhibitors.206 Particularly, perilesional edema indicates tissue
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involvement beyond anatomically-defined tumor boundaries and has been associated with
a worse outcome in patients with metastatic melanoma. Vasogenic edema is extravasation
of fluid and intravascular proteins into the cerebral parenchyma and is induced by tumor
and immune secreted factors. Edema can provide a route for tumor spread and impacts
therapeutic efficacy, with edema being a contradiction to immune therapies.207 Additionally,
an acidic pHe has also been associated with increased migration and invasion in
melanoma.123,208,209 However, there are limited preclinical models available to reliably study
this.
One limitation of standard rodent cell line models is that they are not reflective of
clinical disease, where cell lines are chosen that exhibit some particular features of tumors.
To overcome some of these limitations, patient-derived xenograft (PDX) models have been
developed that involve harvesting tumor cells from a clinical tumor and then injecting those
cells, either directly or after short term cell culture, into immunosuppressed rodents. In
particular for imaging characterization, no PDX model of metastatic melanoma in rats has
been reported previously. It has been shown that acidosis develops in melanoma;210
however, the effect of maintaining an acidic extracellular pH (pHe) and how it contributes to
tumor invasiveness, proliferation, and inhibited therapeutic response in patient-derived
tumors is unknown. The objective of this work was to use the multimodal MRI/MRSI
protocol to characterize the acidic microenvironment and peritumoral edema in PDX models
of metastatic melanoma.
In this work, two metastatic melanoma cell lines were used. A375BR is based on the
commercially available cell line A375 which has undergone rounds of selection to promote
the formation of brain metastases. YUMETRO is a PDX cell line created at Yale University by

192

isolating tumor cells from a cerebellar metastatic melanoma lesion and growing the cells in
short-term cell culture. Each cell line was labeled using a lentiviral reporter containing genes
for tdTomato and luciferase (Addgene, plasmid #72486) to allow for fluorescence detection,
as well as luminescence detection after administration of luciferin. Cells were infected with
the reporter and then sorted for high expression of tdTomato by FACS.
Cells were maintained in culture and harvested at high confluence. After intracranial
injection into the brain of athymic/nude rats (80,000 cells in 5 µL), tumors were allowed to
grow and checked every 7 days for luminescence with an in vivo imaging system (Perkin
Elmer) after intravenous administration of luciferin (150 mg/kg). Once tumors reached their
growth endpoint, the MRI/MRS protocol for quantitative relaxation (T1, T2) and diffusion
(ADC) measurements were used to characterize tumor size, structure and cellularity and
quantitative pHe measurements were made using BIRDS. All imaging data were acquired at
11.7T. Quantitative T2 (TE/TR: 10-100/6000ms), T1 (TE/TR: 10ms/0.4-5s, before and after
0.25 mmol/kg gadoterate meglumine) and apparent diffusion coefficient (ADC, b: 0-3000
s/mm2) maps were acquired. For BIRDS pHe measurements, a coinfusion of 100 mg/kg
probenecid and 1 mmol/kg TmDOTP5- was administered and CSI was used to measure the
chemical shifts of the pHe-dependent proton resonances to calculate pHe within each voxel
at an isotropic resolution of 1mm3 as previously described.6,7
A PDX model of metastatic melanoma (YUMETRO) was successfully grown in the
brain of athymic/nude rats (Figure 6.1). T2 imaging at 11.7T showed peritumoral edema
that extended into the grey matter of the ipsilateral hemisphere and contrast-enhanced T1
weighted imaging showed heterogenous contrast enhancement within the tumor, features
that were also exhibited in the clinical MRI prior to creation of the PDX model.
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A benefit of using labeled cells was that tumor growth could be tracked using
luminescence imaging, rather than MRI (Figure 6.2). The level of luminescence, while not
perfect, is reflective of the size of the tumor. Once significant levels of luminescence were
present, the tumor was then imaged using MRI. As with other tumor models, there was
significant variability in the growth rates of individual tumors with YUMETRO tumors
reaching their terminal sizes after 40-120 days.
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Figure 6.1. Creation of a patient-derived xenograft (PDX) model of metastatic melanoma. On
the left are MRI of the patient tumor from which the YUMETRO cell line was derived, which
was taken from a phase II clinical trial at Yale Cancer Center for the treatment of metastatic
melanoma with pembrolizumab.207,211,212 The clinical imaging protocol consisted of T2
FLAIR, diffusion-weighted (DWI), susceptibility weighted (SWI) and contrast enhanced T1weighted (MP-RAGE) imaging. After isolating tumor cells and expanding in short term cell
culture, the cells were intracranially injected into the brain of athymic rats and allowed to
grow. Corresponding T2, contrast enhanced T1 and diffusion weighted imaging was
performed and showed that peritumoral edema as well as many of the heterogenous features
of the tumor were exhibited in the PDX model.
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Figure 6.2. Luminescence imaging of tumor growth in YUMETRO PDX model of metastatic
melanoma. Imaging was performed using an in vivo imaging system after intravenous
administration of luciferin. All images are acquired from the same animal at different time
points after intracranial injection of tumor cells. Luminescence increased with increasing
tumor size.
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Figure 6.3. Comparison of A375BR and YUMETRO PDX models of metastatic melanoma.
Anatomical T2-weighted MRI is shown along with corresponding quantitative T2 maps.
Additionally, contrast-enhanced T1, ADC and pHe maps from BIRDS are also shown. All
different contrasts are acquired from the same tumor. The tumor is outlined in black and the
brain is outlined in white.
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The YUMETRO PDX model was compared against the A375BR cell line, which is a
commercially available melanoma model (Figure 6.3). MRI and MRSI was performed on
both cell lines at 11.7T. A375BR tumors were much more homogenous in their growth,
lacked peritumoral edema, and grew to much larger sizes at earlier times points in
comparison to YUMETRO tumors. Both A375BR and YUMETRO tumors were acidic as
measured by BIRDS with pHe values of 6.3-6.7, although A375BR was slightly more acidic
indicating higher rates of glycolytic metabolism. Regions of peritumoral edema in YUMETRO
tumors exhibited higher T2 and ADC values; however, no edema was evident in A375BR
tumors. Finally, intratumoral regions of increased T2 and ADC developed in YUMETRO
tumors that were not evident in A375BR and may represent regions of necrosis.
PDX models of metastatic melanoma in rats provide a new platform for evaluating the
development of acidosis in tumors. This preliminary work highlights the differences in
structural appearance and edema formation in PDX models that are more reflective of
clinical tumors. The peritumoral edema that forms is vasogenic in nature due to disruption
of the blood-brain barrier and an increase in vascular permeability. In many respects, the
growth pattern and appearance of A3675BR tumors were more similar to the U87 models of
glioblastoma used previously, while the PDX models had more similarities to U251 tumors.
Imaging of PDX tumors can be used in future work for evaluating the therapeutic response
to a variety of different immunotherapies that are being tested in metastatic melanoma.
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6.3 Applications of BIRDS to other tumor types
Although BIRDS has been utilized to measure the pHe in rodent models of
glioblastoma, all prior work was performed by imaging the brain on high-field preclinical
scanners.135,141,142,178 However, to expand the applicability and translatability of BIRDS, the
development and implementation of BIRDS for pHe mapping on a clinical MRI scanner using
a large animal model is desirable. The VX2 tumor model is an orthotopic liver tumor in
rabbits that exhibits growth patterns characteristic of hepatocellular carcinoma and has
been previously used for translational studies involving intra-arterial therapies for liver
cancer treatment.213,214 To demonstrate the feasibility of BIRDS on a lower-field clinical
scanner (3T), we used this rabbit model for liver cancer, where we measured the
intratumoral–peritumoral pHe differences in livers implanted with highly vascularized and
hyper-glycolytic VX2 tumors.213,215-218 All work presented has been recently published.181
All experiments were conducted under approved Animal Care and Use Committee
protocols. Nine male New Zealand White rabbits (2.5-4 kg; Charles River Laboratories, MA,
Boston) underwent implantation of VX2 tumors in the left lobe of the liver as previously
described.216,219,220 Tumors were allowed to grow for 14 days until a solitary tumor (1–2 cm
in diameter) became visible on MRI.221,222 All MR data was obtained on a 3T Prisma scanner
(Siemens Healthcare, Erlangen, Germany) using a 15-channel radio frequency (RF) knee coil.
T1 VIBE images were obtained for localization purposes using a field-of-view (FOV) of
20x20cm2, 384x384 matrix, 60 slices of 2.5mm thickness, TR/TE= 5.2/2.5ms.
In vivo BIRDS was performed using 15ml of TmDOTP5- infused at a rate of 0.5 ml/min
for 30 min for a total dose of 0.5mmol/kg. Probenecid, a drug used with BIRDS to increase
agent perfusion by temporarily blocking renal clearance, was not necessary in these
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experiments, as the contrast agent was easily able to perfuse the liver. Selective excitation of
H2, H3 and H6 protons of TmDOTP5- was achieved using a dual-band 640µs Shinnar-Le Roux
(SLR) RF pulse with 10.4kHz bandwidth and 18.9kHz separation with an offset of -4930Hz
relative to the water frequency to ensure the full excitation of TmDOTP5- protons. Other
parameters used for the 3D-CSI acquisition were a flip angle of 900 for the SLR pulse, a FOV
of 20x20x25cm3, 20 averages, 13x13x13 rectangular encoding steps, and a total acquisition
time of 6 minutes. The CSI dataset was reconstructed to 25x25x25 matrix, with a voxel size
of 8x8x10mm3. The pHe was calculated in each CSI voxel from the chemical shifts of H2, H3
and H6 TmDOTP5- protons, respectively, as described in Chapter 3 and in previous
work.134,194
Tumor growth was successful in all animals (n=9). Examples of pHe mapping using
BIRDS with TmDOTP5- in a rabbit liver with VX2 tumors are shown in Figure 6.4. The VX2
tumors (red contour) were localized as a hypointensity in the T1-weighted VIBE images
(Figure 6.4A) within the whole liver (blue contour) and the rabbit abdomen (orange
contour) for referencing and localization purposes. CSI slices (Figure 6.4C and 6.4D)
corresponding to the T1-weighted images are shown. High SNR signals were visible for the
H2, H3 and H6 TmDOTP5- protons inside the VX2 tumors but also in neighboring liver regions
and in other well-perfused regions of the body (e.g. blood vessels, muscles) where TmDOTP5diffused or accumulated during infusion. Examples of H2, H3 and H6 signals from two voxels,
one localized inside the VX2 tumor and the other in the normal liver, are shown in Figure
6.4E and Figure 6.4F, respectively. The pHe in these voxels were 6.80 and 7.23, respectively.
For the two CSI slices shown in Figure 6.4C and Figure 6.4D, the corresponding pHe maps
were also generated (Figure 6.4G and 6.4H). The average pHe calculations indicate a lower
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pHe inside the VX2 tumor (6.77±0.03) and also in the tumor’s adjacent regions (6.89±0.09),
relative to the average pHe value measured in the normal liver (7.22±0.04).
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Figure 6.4. In vivo pHe mapping using BIRDS in VX2 tumors in rabbit liver at 3T. T1 VIBE MR
images (A and B) were used to localize the VX2 tumor (red outline) within the liver (blue
outline) and the abdomen (orange outline). Two different CSI slices from the same animal
were used to show the H2, H3 and H6 MR signals of TmDOTP5- in each voxel (C and D). 1H
NMR spectra from a voxel containing tumor (E) and normal liver (F) indicate a high SNR in
these voxels (>10), allowing accurate pHe determination. The pHe maps corresponding to the
two CSI slices (C and D) are shown (G and H, respectively). The measurements indicate lower
average pHe values inside the tumor (6.77±0.03) and in the immediate vicinity of the tumor
(6.89±0.09), compared to those for the normal liver (7.22±0.04). Reproduced with
permission.181
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A similar trend was observed in all rabbits investigated. The lowest pHe was
measured inside the VX2 tumors, a slightly higher pHe in the regions adjacent to the tumors,
and the highest pHe in the liver regions further removed from the tumor (Figure 6.5). To
better understand and compare the pHe distributions in these three liver regions, a pHe voxel
fraction was calculated for each of these regions by counting the number of voxels with pHe
values within every 0.02 pH interval from 6 to 8, relative to the total number of voxels
(Figure 6.5A). A fit of the pHe voxel fraction to a Gaussian distribution provided the mean
and standard deviation of the pHe distribution. The pHe values inside the tumor, at tumor
edge, and in normal liver were 6.79±0.08, 6.88±0.09, and 7.19±0.04, respectively (Figure
6.5B). The pHe values inside the tumor and at tumor’s edge were significantly lower (p<109 for tumor, p<10-7 for tumor’s edge) than in normal liver. Moreover, the pH value inside the
e

tumor was also significantly lower than that at tumor’s edge, although the calculated p-value
of 0.045 is only moderately significant.
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Figure 6.5. pHe value distributions in VX2 tumors in the rabbit liver. Intervals of 0.02 pHe
values were used to display the voxel fractions corresponding to each pHe range (A).
Intratumoral regions of VX2 tumors (red), the tumor margin (orange) and normal liver
(blue) are shown. From these distributions, the mean pHe and standard deviation were
calculated (B). Significantly lower pHe values were measured inside the tumor (6.79±0.08;
p<10-9) and at tumor edge (6.88±0.09; p<10-7), compared to the pHe values measured in the
normal liver (7.19±0.04). The pHe values inside the tumor are also significantly lower than
those in the immediate vicinity of the tumor (p<0.05). Reproduced with permission.181
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In this work, we report the mapping of pHe with BIRDS in an orthotopic tumor model
for liver cancer on clinical MRI scanners. Implementation of BIRDS on a clinical scanner
(Siemens) at lower magnetic field (3T) opens up the possibility of conducting a multitude of
novel MRI/MRS experiments with direct clinical relevance.
High signal-to-noise ratios (SNR) values were measured in most liver areas, including
the tumor, due to excellent blood perfusion in the liver. The linewidths of the TmDOTP5resonances in vivo suggest a heterogeneity in the pHe distribution inside each voxel.
However, a limitation of this work is the relatively large voxel size (8x8x10mm3). Thus, the
tumor CSI voxels are not entirely defined within the anatomically-defined tumor boundaries
and there is volume averaging in voxels located near the tumor margin. Although there is
variability in the size and appearance of individual tumors, the standard deviation of average
tumor pHe values is very small (0.08) underscoring the reproducibility of the pHe
measurements with BIRDS.
The significantly lower pHe (p<10-9) in VX2 tumors (6.79±0.08) compared to normal
liver (7.19±0.04) is consistent with pHe measurements in rat glioblastoma tumor models.141
There was also a reduced pHe (6.88±0.09; p<10-7) in voxels adjacent to the tumor margin,
suggesting that acidosis may spread into surrounding tissue. A similar result has been
observed in rat glioblastoma models where aggressive RG2 tumors have acidic spread
beyond the anatomically defined tumor margins than less aggressive 9L tumors.141 VX2 are
also aggressive tumors and the areas of low pHe observed outside the margins of the tumor
is consistent with tumor infiltration. Further, there is evidence that the anti-tumor immune
response in the peritumoral region is affected by the acidic pH.223,224 Thus, a more thorough
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investigation of these regions is necessary, which involves the development of CSI
methodologies that will allow pH mapping at even higher spatial resolution.
In conclusion, BIRDS was further developed as a non-invasive CSI method for pHe
mapping on clinical scanners (Siemens). BIRDS was implemented to scan a location outside
of the brain by using a rabbit model of liver cancer and was able to successfully compare pHe
measurements from tumor regions with those from normal liver. pHe measurements with
BIRDS may serve as a functional biomarker of metabolic activity that can reflect response to
therapy and allow for further tumor characterization.

6.4 Multiparametric MRI to assess necrosis and peritumoral edema in glioblastoma
Glioblastoma exhibits a highly heterogenous tumor microenvironment characterized
by central necrosis and peritumoral edema. Necrosis forms where regions of hypoxia
develop, leading to tumor cell migration and a pseudopalisading pattern.225 In vitro work has
shown that necrotic cells can promote tumor infiltration.226 Further, the presence of edema
is associated with a poor clinical outcome.227 The presence of edema involves additional
clinical management with corticosteroids (such as dexamethasone) that also may contribute
to worse outcomes. There has been increased interest in understanding the role of edema in
both tumor infiltration as well as its contribution to the immunosuppressive state of
glioblastomas. While immune responses are present in the brain, the immune-environment
is unique due to its presence behind the protective blood-brain barrier, which prevents the
accumulation of many immune cell subtypes. Given the promise of immunotherapies in other
cancer types, clinical trials have not yet shown a survival benefit in glioblastoma; however,
a variety of different immunotherapy strategies have been attempted.228 However, the
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microenvironment is immunosuppressive which limits the ability of standard antiprogrammed cell death protein-1 (anti-PD1) immunotherapy. Recent evidence suggests
tumor-associated macrophages drive the production of edema in glioblastoma.229 The
infiltrative pattern may also be related to tumor vascularity as regions of reduced perfusion
may have greater tumor cell infiltration.230
Multiparametric MRI coupled with comparisons to histological features provides an
opportunity to study these patterns in glioblastoma. Volumetric analysis using MRI has
shown hyperintensity on T2-weighted FLAIR images in the peritumoral region
corresponding to edema, as well as a contrast enhancing rim surrounding a non-contrast
enhancing core corresponding with necrosis.231,232 Although edema can be identified on
standard T2-weighted MRI, edema can also be detected as an increase in the apparent
diffusion coefficient (ADC) in diffusion weighted imaging due to a reduction in diffusion
restriction with the increase in free water. Further, dynamic contrast enhanced (DCE) MRI
has been used to study the vascular parameters where regions of reduced perfusion can lead
to hypoxic regions and the development of necrosis. On contrast-enhanced imaging, this can
either lead to no enhancement or accumulation of contrast agent that does not clear from
the tumor.
Using a subset of U87 and U251 tumors analyzed for longitudinal studies (Chapter 4),
we looked to further assess necrosis and peritumoral edema that develops at later stages of
tumor growth. Imaging data were acquired using an 11.7 T Bruker horizontal-bore
spectrometer. All imaging was performed once the animals reached their terminal endpoint
so that histological comparisons could be made with corresponding MRI. The imaging
protocol included T2-weighted, diffusion-weighted, and contrast-enhanced T1-weighted
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imaging along with DCE-MRI for vascular measurements and BIRDS for pHe mapping using
the same imaging acquisition parameters as described previously. At the end of the imaging
experiment, animals were perfused and the brain was extracted and fixed in 4%
paraformaldehyde prior to slicing into 3 mm coronal slabs. The tissue was paraffin
embedded

and

sectioned

into

10

µm

slices.

Tissue

sections

underwent

immunohistochemistry (IHC) for proliferating cell nuclear antigen (PCNA) and cluster of
differentiation 68 (CD68) with hematoxylin as a counterstain. In brief, sections were
deparaffinized and rehydrated prior to antigen retrieval and peroxidase blocking. Sections
were incubated with primary antibodies (PCNA, CD68) followed by incubation with a
biotinylated secondary antibody and 3,3-diaminobenzidine (DAB). All stained sections were
mounted on glass slides and microscopy was performed (4x, 10x) for digitization and
visualization using an automated high-resolution microscope with stitching capabilities
(Keyence).
Peritumoral edema was much more evident in U251 tumors with most U87 tumors
displaying little to no peritumoral edema (Figure 6.6). Edema appeared as a brighter signal
on T2-weighted images in U251 tumors, which was reflected as higher T2 values in
edematous regions (47.2±6.6 ms) compared to contralateral normal grey matter (40.8±1.7
ms). Additionally, the ADC was higher in edematous regions (1.03±0.26 mm2/s) compared
to normal tissue (0.73±0.06 mm2/s) in the same regions of interest (ROIs) in U251 tumors.
Taken together, an increased T2 and ADC can be used to identify edematous regions.
Using an ROI analysis, different regions of the tumor could be identified including an
intratumoral region as well as regions of necrosis, peritumoral edema and a contrastenhancing rim (Figure 6.6). Contrast agent accumulation and clearance is evident in
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dynamic signal enhancement curves from DCE-MRI, where the increase in the signal
intensity is due to a contrast-induced reduction in T1 values. Similar dynamics and amount
of contrast agent uptake were seen in the intratumoral region of both U87 and U251 tumors
suggestive of viable tumor tissue. However, necrotic regions in U251 tumors had a faster and
much greater accumulation of contrast agent, represented as a higher signal intensity. U87
tumors did not exhibit this characteristic enhancement pattern. The contrast-enhancing rim
is more pronounced in U251 tumors with a slower dynamic uptake of contrast agent
compared to intratumoral regions. Edematous regions are initially non-contrast enhancing
and are much more pronounced in U251 tumors; however, at later times during the dynamic
acquisition, edematous regions did exhibit slight increases in signal that may allow
differentiation of edematous regions from normal appearing brain. Based on patterns of
contrast uptake, these tumor regions can be uniquely identified with contrast-enhanced T1weighted imaging and the dynamics of contrast uptake provide additional metrics of
characterizing vascular features.
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Figure 6.6. Region of interest (ROI) analysis for U87 and U251 tumors. T2-weighted and
contrast-enhanced T1-weighted imaging are shown for U87 (A) and U251 (B) tumors. ROIs
were defined for the intratumoral region (green), contrast enhancing rim (yellow), necrosis
(red), edema (light blue) and contralateral hemisphere (dark blue). Dynamic signal
enhancement during contrast agent administration from DCE-MRI are shown for each
identified tumor region in U87 (C) and U251 (D) tumors showing distinct contrast agent
uptake patterns.
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To further evaluate the changes occurring in regions of peritumoral edema,
immunohistochemistry was performed for proliferating cell nuclear antigen (PCNA) and
cluster of differentiation 68 (CD68). PCNA is a proliferation marker that is upregulated in
dividing cells. CD68 is a universal marker for macrophages that also tends to stain glial cells.
We found increased immunohistochemical staining for both CD68 and PCNA in regions that
corresponded to peritumoral edema identified by T2-weighted MRI (Figure 6.7).
These data provide evidence that edematous regions are not just regions of increased
water content, but that there are fundamental changes to the cellular components that make
up this tissue. CD68 is a non-specific marker, but tends to stain both resident glial cells as
well as tumor-associated macrophages which appear to be present to a much greater extent
in edematous regions. Future work will seek to further characterize the edematous region in
terms of acidic pHe and immune responses which are likely modulated by the presence of
infiltrating tumor cells in edematous regions.
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Figure 6.7. MRI and immunohistochemical evaluation of peritumoral edema in U87 and
U251 tumors. T2-weighted and contrast-enhanced (CE) T1-weighted imaging for U87 (top
row) and U251 (bottom row) tumors are used to highlight peritumoral edema and central
necrosis in U251 tumors, respectively. Hematoxylin and eosin (H&E) staining provided
histological comparisons of tumor architecture. Immunohistochemistry for proliferating cell
nuclear antigen (PCNA) and cluster of differentiation 68 (CD68) showed regions of enhanced
glial cell and macrophage proliferation in edematous regions of U251 tumors.
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6.5 Conclusion
The tumor microenvironment in glioblastoma is unique due to the distinctive
features of brain tissue in which these tumors form. This environment creates a favorable
space for tumor cells to survive and thrive. Further, the environment is adaptable with
immature and permeable vasculature and significant acidosis that develops early during
tumor progression and promotes tumor infiltration into surrounding tissue. Given these
changes, there is significant benefit to developing imaging methods that allow for
characterizing more than just the morphological appearance of the tumor. Vascular and
metabolic readouts have been studied using molecular imaging technologies with the goal of
providing quantifiable biomarkers that can be used for predicting prognosis or assessing
therapy efficacy and deciding whether treatment course should be changed.
In glioblastoma, a challenge is the early identification of tumor response to therapy
as progression is defined entirely by radiological means (primarily MRI) that can be unclear
leading to the phenomenon of pseudoprogression and pseudoresponse. Further,
glioblastoma is difficult to biopsy and while tumor tissue is available at time of tumor
resection for molecular analysis, multiple surgeries or subsequent biopsy are not always
performed. Advanced MRI/MRS methods could be added to already existing imaging
protocols to provide additional information about the state of the tumor (metabolic,
vascular, immune, etc.). Vascular and metabolic characteristics could be readily identified on
imaging and their changes studied with tumor progression and during therapeutic response.
These changes become especially important when studying therapies that directly alter the
vasculature or immune response. Metabolism, while not directly targeted by many therapies,
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provides an indirect readout and may be decreased with a reduction in the cellular burden
of the tumor.
The goal of this work was to demonstrate methods available for quantifying
metabolic and vascular features of the tumor microenvironment to complement the
morphologic features that are currently in use for clinical diagnosis. Hopefully,
advancements in imaging protocols and tumor characterization will lead to improvements
in clinical diagnosis, monitoring tumor progression, and assessing the therapeutic response.
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